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Abstract 
 
Muscular dystrophies (MDs) are inherited disorders characterised by muscle 
weakness and atrophy. One of the most severe forms is Duchenne muscular 
dystrophy (DMD) which together with the milder allelic form Becker muscular 
dystrophy (BMD) are known as the dystrophinopathies and result from defects 
in the X-linked gene encoding dystrophin. Dystrophin is a structural protein of 
the muscle that connects the internal cytoskeleton of muscle fibres to the 
extracellular matrix. DMD is also amongst the most common forms of muscular 
dystrophy, affecting ~1 in 4000 live male birth and manifests as rapidly 
progressive muscle degeneration leading to loss of ambulation and death in the 
second or third decade from respiratory or cardiac failure. Currently, there is no 
cure for this devastating disease. Clinical management of symptoms and 
complications is limited to stabilising the condition, slowing deterioration over 
time and palliative care. Since discovery of the DMD gene in 1986, researchers 
have dedicated substantial effort into vector technologies, facilitating the use of 
gene therapy to reintroduce a functional copy of the dystrophin gene into 
muscle fibres, a potential approach to treat DMD patients. However, this 
approach poses additional challenges relative to many gene therapy 
approaches since the full-length dystrophin cDNA is ~14 kb, exceeding the 
packaging capacity of most viral vectors. A number of large internal in-frame 
dystrophin deletions have been identified in patients that produce a relatively 
mild phenotype with later age of onset and a slower rate of disease progression 
than classical DMD. This observation has inspired the construction of internally 
truncated, but largely functional versions of dystrophin suitable for gene transfer 
using viral vectors. So far the most widely used miniaturised dystrophin 
transgenes have been tested in AAV-mediated gene delivery which has 
identified several limitations indicating the use of more favourable transgenes 
that have smaller deletions, yet carrying more functional parts of dystrophin. In 
this study human mini-dystrophin constructs of 4.3-7.7 kb in size were designed 
that retain key functional elements of dystrophin molecule and their relative 
functionality investigated in mdx mice. The ultimate aim of this study is the 
characterisation and optimisation of these mini-dystrophin constructs for gene 
delivery studies via viral vectors as a therapeutic tool for treatment of Duchenne 
muscular dystrophy.
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Chapter 1 Introduction 
 
1.1 Skeletal muscle structure and function 
 
There are three types of muscle, skeletal muscle (striated), smooth muscle and 
cardiac muscle, that all are responsible for contraction but vary in origin, 
development, structure and function. Cardiac and smooth muscle cells are 
responsible for involuntary movement, while skeletal muscle cells react to 
conscious and voluntary control. In an adult human skeletal muscle, cells 
(muscle fibres) can be 2-3 cm long and 100 µm in diameter (Alberts et al., 
2008). Muscle is enclosed by a strong sheath of extracellular matrix (ECM) 
known as epimysium. Whole muscle consists of many subunits called fascicles. 
Each fascicle is surrounded by connective tissue called perimysium. Fascicles 
are composed of bundles of highly differentiated and elongated muscle fibres 
with a cytoplasm containing an organised filament system based on the 
contractile proteins actin and myosin which are enveloped by a sheath called 
the endomysium. Approximately 10-50 muscle fibres are joined together in a 
bundle which are attached at both ends to tendons or connective tissue and 
have multiple nuclei that are generally located peripherally within the fibre 
(Hagen et al., 1998). The number of nuclei is approximately 50 -100 per 
millimetre of muscle fibre length (Ishikawa, 1983).  
 
Muscle fibres consist of bundles of parallel-oriented myofibrils and these form 
myofilaments. Myofibrils count for 75-85 percent of the fibre volume. Myofibrils 
consist of regularly consecutive 2-3 µm long sections and parallel overlapping 
thick and thin filaments known as sarcomeres (Bagshow, 1982) which are the 
basic units of force generation (Loeb, 1986). Organelles such as mitochondria 
and sarcoplasmic reticulum (SR) are found in the muscle fibre cytoplasm 
(sarcoplasm). The sarcoplasmic reticulum is essential for storage of calcium 
that is released after stimulation of muscle and triggers contraction. The typical 
red colour of muscle is caused by the muscle pigment myoglobin, an iron- and 
oxygen-binding protein that is responsible for storage and transfer of oxygen 
(Schiebler et al., 1999). Thick and thin filaments are responsible for force 
generation and are predominantly composed of the proteins myosin and actin 
respectively. The myosin molecule consists of two heavy chains and four light 
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chains while thin filaments are composed of actin, tropomyosin and troponin. 
Globular actin molecules polymerise to build actin filaments  (Bagshow, 1982). 
A myofibril volume contains 55% myosin and 25% actin. Using specific dyes, 
some regions of a muscle fibre appear darker than other areas, because dense 
protein bands are stained stronger. These bands are known as A-bands and the 
weaker areas with less protein density are labelled as I-bands. Within the I-band 
there is a dense protein zone known as Z-line or Z-disk (Eisenberg, 1985). 
Within the A-band is a dense protein area called the H-zone. In the middle of 
the H-zone is an area known as the M-line. The M-line consists of a network of 
proteins that binds the thick filaments and the Z-disk, and is composed of a 
protein complex that binds to the thin filaments. Thin filaments are attached at 
the Z-disk but are free at the other end to interlock to the thick filaments. During 
muscle contraction the sarcomere I-band and H-zone become shorter while the 
A-band length remains constant (Bagshow, 1982).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Structural organisation of a muscle fibre and the sarcomere 
The muscle fibre is surrounded by a plasma membrane (sarcolemma) and 
is composed of many fibrils packaged into parallel-organised units. The 
muscle fibre contains two membrane systems within the myofibrils, the 
transverse tubule system and the sarcoplasmic reticulum. Myofibrils consist 
of parallel overlapping thick (myosin) and thin filaments (actin) organised 
into sarcomeres. Thin filaments are attached at the Z-disk but are free at the 
other end to interdigitate with the thick filaments. The A-band contains thick 
filaments which during contraction remains relatively constant in length. The 
I-band, rich in thin filaments changes its length along with the sarcomere.  
Alberts et al., 2008 
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The muscle fibre contains two specialised membrane systems within the 
myofibrils. One is the transverse tubule system and the other the sarcoplasmic 
reticulum, both separate from each other but responsible for conveying the 
external stimulus provided by the motor neuron to the centre of the fibre 
(Peachey, 1985). There are two different types of skeletal muscle fibres based 
on functional, histological and morphological differences which relate to the 
proportion of myofibrils to sarcoplasm and mitochondria. Type I fibres, the so-
called slow-twitch fibres, are red in appearance due to the higher content of 
oxygen-binding protein myoglobin. They are thin and contain a high number of 
mitochondria and sarcoplasm and are specialised to generate slow and 
sustained contraction. Type II fibres are known as fast-twitch fibres or white 
fibres due to their lower myoglobin content. They are thicker and contain 
relatively small number of mitochondria, have a high number of myofibrils and 
pronounced sarcoplasmic reticulum. These fibres are characterised by the 
ability for strong but short-term performance (Schiebler et al., 1999). Muscle 
fibres have a complex membrane network.  
 
The muscle fibre is entirely enclosed by the plasma membrane which is known 
as the sarcolemma. The sarcolemma is divided into three layers, the plasma 
membrane (plasmalemma) which is a lipid bilayer, basal lamina and thin 
collagen fibrils. The sarcolemma is tightly attached to the basal lamina, which 
consists of extracellular matrix (ECM) proteins (Voermans et al., 2008). 
Disruptions of this connection are the cause of numerous forms of muscular 
dystrophy (Rahimov and Kunkel, 2013a). 
 
Satellite cells, the adult muscle stem cells, are usually located between the 
basal lamina and the plasma membrane (Moyle and Zammit, 2014). These cells 
are involved in forming new fibres after muscle injury. The precursors of skeletal 
muscle fibres are called myoblasts. Myoblast development depends on two 
different regulatory pathways, embryonic specification by the paired box genes 
Pax3 and Pax7, and the MyoD cascade of transcription factors which regulate 
the expression of genes that are involved in myoblast maturation. Nuclei are 
initially in the centre of myotubes, however they move to periphery later 
following fusion and the maturation of myofibres (Folker and Baylies, 2013). 
After a period of proliferation, the myoblasts stop dividing and start to express 
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muscle specific genes that are required for their final differentiation. In this 
process they fuse and form differentiated, highly specialised and multinucleated 
muscle fibres. After differentiation muscle fibres grow and mature, the nuclei do 
not replicate their DNA and the fibre never divides again (Charge and Rudnicki, 
2004). In adult life, new skeletal muscle fibres are not generated, however the 
existing muscle fibres have the ability to grow if renewal is required. This 
process can be initiated after stimulation or exercise-induced injury and is 
regulated by activation of quiescent mononuclear satellite cells lying within the 
basal lamina (Ceafalan et al., 2014). Upon activation, satellite cells can 
proliferate, differentiate and fuse to the existing muscle fibres. Satellite cells 
divide asymmetrically, producing myoblasts and replenishing the pool of stem 
cells (Kuang et al., 2007). This self-renewal capability of satellite cells becomes 
limited in some forms of muscular dystrophy. For instance, in Duchenne 
muscular dystrophy, differentiated muscle fibres are progressively damaged 
due to loss of dystrophin. Satellite cells are activated to repair the damaged 
fibres. This regenerative process is exhausted over time leading to loss of 
capability to repair and eventually fibres are irreversibly replaced by connective 
tissue and fat (Sacco et al., 2010). 
 
1.2 The dystrophin-associated glycoprotein complex (DGC) 
 
The DGC is a protein network which links the actin cytoskeleton to the 
extracellular matrix (ECM) surrounding the muscle fibre (Poon et al., 2002) and 
stabilises the sarcolemma, protecting the muscle from contraction-induced 
damage and necrosis (Straub et al., 1997; Culligan et al., 1998; Hoffman and 
Dressman, 2001). The DGC comprises at least ten different proteins. This 
complex may also be involved in transmembrane signal transfer (Rando, 2001). 
The DGC consists of cytoplasmic, transmembrane and extracellular proteins 
including dystrophin, sarcoglycans, dystroglycan, caveolin-3, syntrophins, 
dystrobrevins, sarcospan and neuronal nitric oxide synthase (Lapidos et al., 
2004). Dystrophin binds F-actin intracellularly which directly connects the DGC 
with the contractile elements of the muscle (Rybakova et al., 1996). In the 
absence of dystrophin, the entire DGC is destabilised at the sarcolemma 
(Thomas et al., 1998). Studies have implicated components of this complex in a 
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wide range of muscular dystrophies. Furthermore, disruption of the DGC is also 
involved in many forms of acquired diseases (Townsend, 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3 Muscular dystrophy 
 
Muscular dystrophies (MDs) are a heterogeneous group of over 40 inherited 
diseases characterised by progressive muscle atrophy and weakness (Emery, 
2002b; Muir and Chamberlain, 2009). These conditions arise as a consequence 
of muscle fibre degeneration leading to irreversible fatty infiltration and fibrosis 
(Kornegay et al., 2012). Although muscular dystrophies show similarities in 
dystrophic changes on muscle biopsy, their underlying genetic causes vary 
widely with different forms of the disease affecting different muscle groups 
(Mercuri and Muntoni, 2013). The various forms of muscular dystrophy differ in 
their mode of inheritance, the underlying genetic causation, the affected muscle 
groups, age of onset and the disease course (Emery, 2002b). A number of 
muscular dystrophies can affect cardiac and respiratory function and result in 
premature death (Rando, 2001; Heydemann and McNally, 2007). In rare forms 
of muscular dystrophies other organs or tissues are involved such as skin, eye, 
Fairclough et al., 2013 
Figure 1.2 Dystrophin-associated glycoprotein complex 
The DGC connects the actin-based cytoskeleton to the extracelluar 
matrix. Transmembrane components of the DGC include sarcoglycans, 
beta-dystroglycan (β-DG) and sarcospan. Alpha-dystroglycan (α-DG) 
provides a direct link between dystrophin and the extracellular proteins. 
The cytoplasmic components of the complex include alpha-dystrobrevin, 
syntrophins and dystrophin that binds to actin filaments. The signalling 
molecule neuronal nitric oxide synthase (nNOS) is anchored to 
dystrophin via the dystrophin rod domain and syntrophin.  
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brain and inner ear. Muscular dystrophy is classified into different forms, based 
on underlying molecular and cellular mechanisms (Rahimov and Kunkel, 2013a). 
Several muscular dystrophies result from mutations leading to disruption of the 
dystrophin-associated glycoprotein complex (DGC) (Ibraghimov-Beskrovnaya et 
al., 1992).  
 
Duchenne muscular dystrophy is caused by frame-shifting mutations resulting in 
complete loss of dystrophin protein in muscle fibres, whereas mutations causing 
BMD are mainly in-frame and produce reduced levels and partially functional 
dystrophin. Both forms result in disruption of cytoskeletal and ECM connection 
(Koenig et al., 1988; Monaco, 1989). 
 
The sarcoglycan complex in muscle consists of four transmembrane proteins, α-, 
β-, γ- and δ-sarcoglycans and mutations in this complex are associated with 
autosomal recessive limb-girdle muscular dystrophies (LGMDs) which generally 
present as childhood forms of LGMD (Lim and Campbell, 1998; Nigro, 2003; 
Sandona and Betto, 2009). Defects in any of the sarcoglycan subunits generally 
result in reduction or absence of the entire protein complex and destabilisation 
of the sarcolemma (Rahimov and Kunkel, 2013a). 
 
The dystroglycan complex is the core element between cytoskeleton and ECM 
(Moore and Winder, 2010). The dystroglycan complex is encoded by a single 
gene DAG1 and consists of α- and β-dystroglycan, both produced from a single 
transcript through post-translational proteolytic cleavage and subsequently 
forming a stable complex. Dystrophin binds to β-dystroglycan on the 
cytoplasmic side of the cell. By contrast, α-dystroglycan is localised on the 
extracellular side and binds laminin in the ECM (Ibraghimov-Beskrovnaya et al., 
1992).  
 
A large number of muscle and brain disorders result from mutations in genes 
that are involved in glycosylation of α-dystroglycan, one of the major 
mechanisms leading to LGMDs and congenital muscular dystrophy (CMDs) 
(Johnson et al., 2013). Hypoglycosylation of α-dystroglycan results in reduced 
binding capacity to laminin in the ECM (Zhang et al., 2011). There is also 
secondary loss of laminin-α2 which is caused by mutations in other genes 
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(Brockington et al., 2001). The main CMD subtypes are classified by gene 
involved and clinical phenotype including severe forms such as muscle-eye-
brain disease (MEB), Walker-Warburg syndrome (WWS) and Fukuyama CMD 
which are known as dystroglycanopathy type A (MDDGA) (Moore et al., 2002) 
and are caused by mutations in POMT1, POMT2, FKTN, FKRP, LARGE, 
POMGNT1, ISPD, the LMNA-related CMD and  the SEPN1-related CMD 
(Muntoni and Voit, 2004). There are two other forms including a less severe 
form called as MDDGB and the mildest form known as MDDGC (Rahimov and 
Kunkel, 2013a). These disorders are known as secondary dystroglycanopathies 
because they are caused by insufficient glycosylation of α-dystroglycan, and not 
by mutations in the dystroglycan gene itself (Rahimov and Kunkel, 2013a). 
 
The ECM is a network of extracellular glycoproteins that provides structural 
support to myofibres. Mutations in these proteins generally cause congenital 
muscular dystrophy (CMD) (Rahimov and Kunkel, 2013b). The most common 
form is caused by the deficiency of laminin-α2 (LAMA2) and is known as 
merosin-deficient or type 1A (MDC1A) (Helbling-Leclerc et al., 1995). There are 
many other forms of muscular dystrophies with different underlying defects and 
clinical manifestation (Mercuri and Muntoni, 2013). 
 
1.3.1 Dystrophinopathies 
 
Duchenne muscular dystrophy (DMD; OMIM 310200) is the most common 
childhood form of muscular dystrophy with an incidence of ~1 in 4000 newborn 
males (Mendell et al., 2012; van Ruiten et al., 2014). The first reported clinical 
observations are from the 19th century by Edward Meryon (1852) and some 
years later by Guillaume Duchenne de Boulogne (1861) who described clinical 
manifestations and muscle histology of the disease in detail (Becker and Kiener, 
1955; Kunkel et al., 1989). Becker and Kiener described the less frequent and 
milder allelic form Becker muscular dystrophy (BMD; OMIM 300376) with an 
incidence of ~1 in 17000 (Becker and Kiener, 1955). DMD and BMD are both X-
linked, inherited disorders of muscle caused by mutations in the DMD gene, the 
largest known human gene which encodes dystrophin (Kingston et al., 1984). 
Mutations in the DMD gene lead to absence (in DMD) or alteration in protein 
structure and reduced expression (in BMD) of the dystrophin protein, resulting 
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in muscle degeneration (Hoffman et al., 1987b). In about two thirds of cases 
inherit the mutation from their mother who is a carrier of the defective gene. De 
novo mutations occur in one third of cases (Lane et al., 1983). The onset of 
Duchenne muscular dystrophy is in infancy (Manzur et al., 2008; van Ruiten et 
al., 2014). Affected individuals are clinically normal at birth, although creatine 
kinase levels in serum may be elevated if checked. Motor delay may be the first 
symptom of DMD between 2-5 years of age, and then patients present 
difficulties in running and climbing stairs (Dubowitz, 1978; Emery, 2002a), 
followed by rapid disease progression and loss of ambulation by 13 years of 
age (Bushby et al., 2010b). About 20% of affected boys have mental 
impairment with an IQ of less than 70 (Bushby et al., 1995). Most affected 
individuals develop respiratory complications due to diaphragmatic and 
intercostal muscle weakness and die in their twenties or early thirties from 
respiratory failure unless mechanically ventilated (Bushby et al., 2010a). 
Cardiac dysfunction and cardiomyopathy are also part of the dystrophinopathy 
phenotype and can also result in early death (Emery, 1993). Becker muscular 
dystrophy is similar to Duchenne muscular dystrophy in the distribution of 
muscle wasting but the course of the disease is milder, the onset of symptoms 
later and the rate of progression slower (Romitti et al., 2009). The age of onset 
is very variable and some individuals have no symptoms until adult life. Loss of 
ambulation may occur, but later than in DMD. Life expectancy is higher than in 
DMD and mortality is often associated with cardiac symptoms. Differing disease 
severity of these forms depends on the type of mutation and the resulting 
dystrophin expression. BMD patients also display dilated cardiomyopathy and 
respiratory and skeletal muscle weakness (Monaco et al., 1988; Bushby et al., 
2010a). Most patients are diagnosed based on a combination of phenotypical 
manifestation and genetic analysis (Annexstad et al., 2014). Independent of 
family history, DMD diagnosis is made by observation of aberrant muscle 
function in male infants (Bushby et al., 2010a). DMD is generally diagnosed 
when the child is around 5 years old but due to delayed developmental 
milestones the diagnosis might be much earlier. Clinical symptoms include 
delay in walking and speaking, waddling gait, toe walking, difficulty with running 
or climbing stairs and frequent falls. Gower’s sign (a characteristic manoeuvre 
for standing from a prone position) in a male infant usually leads to diagnostic 
investigations (Bushby et al., 2010a). Alongside the clinical presentation, testing 
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for a DMD mutation in a blood sample is essential, since the results are 
required for prenatal diagnosis and feasibility of currently available mutation-
specific clinical trials (Bushby et al., 2010a). Genetic tests include multiplex 
PCR (Prior and Bridgeman, 2005) multiplex ligation-dependent probe 
amplification (Lalic et al., 2005) multiplex amplifiable probe hybridisation (Dent 
et al., 2005) and single-condition amplification/deletion (Flanigan et al., 2003). 
No further testing is required if one of these tests leads to the confirmation of a 
DMD mutation. If a DMD mutation has not been identified in genetic testing, 
signs or symptoms consistent with DMD are present and CK level is persistently 
elevated, full sequencing of the dystrophin gene and/or a muscle biopsy may be 
necessary. Depending on availability of genetic testing, a muscle biopsy could 
be considered for determination of the level of dystrophin expression to 
distinguish DMD from the milder BMD (Bushby et al., 2010a). Two reviews from 
an international group of experts in DMD management provide multidisciplinary 
guidelines for DMD diagnosis and comprehensive recommendations for 
pharmacological and psychosocial management and optimal care (Bushby et al., 
2010a; Bushby et al., 2010b). 
 
1.4 Dystrophin gene (DMD) and protein 
 
1.4.1 Chromosomal organisation, protein isoforms and tissue 
distribution of dystrophin 
  
The X-linked dystrophin gene is the largest gene in human genome (van Essen 
et al., 1992). The genomic sequence covers more than 2.5 million base pairs, 
representing approximately 0.1% of the entire human genome. The coding 
sequence of 79 exons comprises 1% of the genomic locus, while 99% of the 
gene consists of intronic sequences (Lander et al., 2001). The complete ~14 kb 
messenger RNA of full-length dystrophin encodes 3685 amino acids and is 
primarily expressed in skeletal and cardiac muscle and at lower levels in the 
brain (Lambert et al., 1993). There are three full-length isoforms, Dp427b (brain), 
Dp427m (muscle) and Dp427p (Purkinje), and several smaller isoforms 
(Sadoulet-Puccio and Kunkel, 1996; Muntoni et al., 2003) (Figure 1.3). The 
three full-length isoforms have the same number of exons, but differ in their 
respective promoters and unique first exons (Muntoni et al., 2003). The brain 
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Figure 1.3 Genomic organisation of the dystrophin gene 
The black vertical lines represent the 79 exons of the dystrophin gene 
distributed over about 2.5 million bases. The arrows indicate the 
promoters of the various isoforms: brain (Dp427b), muscle (Dp427m) 
and Purkinje (Dp427p) promoters; R represents the retinal isoform 
promoter (Dp260), B3 the brain isoform promoter (Dp140 ), S the 
Schwann cells isoform promoter (Dp116) and G the ubiquitous (Dp71). 
(B) The domain composition of the various dystrophin proteins is 
indicated.  
Muntoni et al., 2003 
promoter drives expression in the hippocampus of the brain and in cortical 
neurons (Lederfein et al., 1992), the Purkinje promoter in Purkinje cells and the 
muscle promoter in skeletal muscle and cardiomyocytes (Bies et al., 1992). Due 
to alternative internal promoters and splicing, a range of shorter dystrophin 
isoforms are generated producing the protein products Dp260 in retina, Dp140 
in brain, retina and kidney, Dp116 in Schwann cells and Dp71 with ubiquitous 
expression in most non-muscle tissues (Muntoni et al., 2003). This splice 
variant is also detected in cardiac but not in skeletal muscle (Tennyson et al., 
1996). 
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1.4.2 Protein structure and domain composition of muscle specific 
dystrophin protein (Dp427m) 
 
The muscle specific dystrophin transcript encodes Dp427m, a 427 kDa protein 
(Figure 1.4) which is a member of the beta-spectrin and alpha-actinin family 
(Blake et al., 2002). Dystrophin is a cytoplasmic protein and located at the inner 
surface of the muscle fibre membrane (sarcolemma). It is a vital part of the 
dystrophin-associated glycoprotein complex (DGC) which connects the 
cytoskeleton of muscle fibres to the surrounding extracellular matrix through the 
sarcolemma. The lack of this structural protein results in sarcolemmal instability 
and reduces the resistance of the muscle fibres to contraction-induced injury 
(Durbeej and Campbell, 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
The dystrophin molecule contains a number of distinct protein domains. The N-
terminal actin-binding domain (ABD), containing two calponin homology motifs, 
a central coil-coiled, triple-helical rod domain which is characterised by 24 
spectrin-like repeats separated into three subregions by 4 hinges and including 
a second ABD and the binding site for neuronal nitric oxide synthase (nNOS), a 
cysteine-rich region responsible for binding to β-dystroglycan (composed of a 
WW domain, two EF hands and a zinc-finger domain). The C-terminus binds to 
α- and β-syntrophin and dystrobrevin (Koenig et al., 1988). Although the 
elements of the dystrophin molecule have been identified and studies in 
transgenic mdx mice have explored the importance of a number of these 
structural domains, the functional requirement for many parts of the protein 
Figure 1.4 Dystrophin protein (Dp427m) and its domains 
(ABD) actin binding domain; (N-Ter) N-terminus; (CH) calponin homology; 
(H) hinge region; (nNOS) neuronal nitric oxide synthase-binding site; (cys-
rich) cysteine-rich domain; (WW) domain that contains two conserved 
tryptophans and binds proline-rich proteins; (EF) intracellular calcium- 
binding motif; (ZZ) zinc finger domain; (C-Ter) C-terminus; (DgBD) 
dystroglycan-binding domain; (DbBD) dystrobrevin-binding domain; (Syn) 
syntrophin binding domain. The molecular structure is derived from NCBI 
Nucleotide accession NM_004006 and associated annotations.  
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remains unclear (van der Plas et al., 2006). The N-terminal domain is one of the 
regions in the gene with a high rate of deletions. Mutations in this region 
encoding ABD1 have shown to be associated with reduced dystrophin resulting 
in a severe BMD phenotype. In contrast a deletion of ABD2 domain but 
maintaining ABD1 leads to a mild phenotype in transgenic mdx muscle (Banks 
et al., 2007). The loss of the C-terminus which contains the cysteine-rich 
domain and is associated with the other proteins of DGC complex leads to 
disruption of the whole complex (Sweeney and Barton, 2000).  
 
1.4.3 Mutations in muscle specific dystrophin Dp427m 
 
The dystrophin gene has a high mutation rate relative to other human genes. 
This is due to the large size and the internally repetitive structure of the gene 
which makes it vulnerable to non-homologous recombination events (Lapidos et 
al., 2004). Deletions and duplications account for more than two thirds of the 
mutations that cause DMD or BMD (Den Dunnen et al., 1989; Koenig et al., 
1989a). Approximately 65% of mutations in both diseases are intragenic 
deletions of one or more exons. There is no direct relationship between the 
location and extent of the deletion and the severity of the clinical presentation. 
The phenotype depends more directly on the effect that these mutations have 
on the translational reading frame (Muntoni et al., 2003). Frame-shifting 
deletions of a single exon or nonsense mutations can lead to the severe clinical 
phenotype of DMD, whereas in-frame deletions of up to 50% of the dystrophin 
coding sequence can lead to a mild BMD phenotype, with a shorter but partially 
functional dystrophin and a reduced expression level (England et al., 1990; 
Love et al., 1991b). However there are exceptions to this reading frame rule 
with DMD patients carrying in-frame deletions or duplications and patients with 
frame-shift mutations presenting with a BMD phenotype (Muntoni et al., 2003). 
Deletions can occur anywhere in the dystrophin gene but there are two regions 
with a high incidence: the most commonly mutated region is between exons 45-
55 and there is a minor 5’ end hot-spot including exons 2-19 (Koenig et al., 
1989b). 5-10% of DMD and BMD mutations are duplications in the dystrophin 
gene (Love et al., 1991b; Muntoni et al., 2003). Another form of DMD mutation 
is point mutation which accounts for 20% to 35% of cases and most of the point 
mutations identified in DMD patients are nonsense mutations (Roberts et al., 
 13 
1994). DMD/BMD phenotypes and their corresponding mutations are 
catalogued in the Leiden muscular dystrophy database (http://www.dmd.nl/).  
 
1.5 Animal models of DMD 
 
There are two naturally occurring animal models for DMD with defects in 
dystrophin: X-linked muscular dystrophy mice (mdx) (Bulfield et al., 1984), and 
X-linked muscular dystrophy dogs (cxmd) (Valentine et al., 1988). The mdx 
mouse was identified in 1984 on the C57BL/10 strain while screening for 
biochemical variants in CK and carries a nonsense point mutation in exon 23 of 
dystrophin gene (Bulfield et al., 1984). The mouse is the most widely used 
animal model for DMD due to the ease of breeding and relatively low cost of 
housing (Sicinski et al., 1989). Although DMD patients and mdx mice are both 
dystrophin deficient, the muscle pathology of mdx mice progresses more slowly, 
displaying a milder phenotype compared to DMD patients. Mdx mice show only 
a 20% reduction in life span (Chamberlain et al., 2007). There are other alleles 
at the mouse DMD locus including exon 52 knockout mice (mdx52) (Araki et al., 
1997) and mdx3cv which both have a more severe phenotype. Other 
researchers have described the double knockout mice (dko) lacking both 
dystrophin and utrophin which develop a disease with a much more severe 
pathology than mice missing dystrophin alone (Deconinck et al., 1997) and 
display a more severe dystrophic phenotype than DMD patients. Although there 
are genetic and phenotypic differences between dko mice and humans, these 
mouse models, provide a valuable experimental model to monitor the efficacy of 
therapeutic interventions (Isaac et al., 2013). 
 
Dystrophin-deficient dog models (cxmd) for DMD were first identified in 1988 in 
the dystrophic golden retriever (Valentine et al., 1988) which may be the most 
promising animal model for testing therapeutic interventions due to closer 
clinical similarity with human DMD in terms of disease severity compared to 
dystrophic mouse models (Shimatsu et al., 2003). However the high cost for 
maintenance, daily care and difficult breeding of dystrophic dogs has limited 
their use for experimental and preclinical testing (Grounds et al., 2008). 
Furthermore the most widely used golden retriever model (GRMD) shows a 
wide variability in the phenotype making the functional assessment difficult 
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(Brinkmeyer-Langford and Kornegay, 2013). It has been reported that 
dystrophic dogs treated with corticosteroids displayed impairment of some 
measures of muscle function showing a larger number of necrotic fibres which 
is in contrast to the beneficial effects of steroid use in human patients (Hollinger 
et al., 2014). Other breeds include Rottweiler (Collins and Morgan, 2003) and 
German shorthaired pointers (Schatzberg et al., 1999). A Beagle model has 
also been produced  by crossing beagles with dystrophic golden retriever 
(Shimatsu et al., 2003).  
 
Hypertrophic Feline Muscular Dystrophy (FHMD) is a feline model for 
dystrophin deficiency (Vos et al., 1986). The characteristic features of these 
dystrophic cats are their distinct hypertrophic muscles but the disease 
symptoms and progression are different from human DMD or other mammalian 
models. Therefore they have not been used due to the pathological 
dissimilarities with DMD (Nakamura and Takeda, 2011). 
 
Recently, pig models have been described as being more similar to humans in 
terms of genetics and physiology. A DMD pig model with a deletion in exon 52 
may have potential for use in experimental studies, in particular exon skipping 
research, since exon 52 is a frequent deletion in DMD patients (Klymiuk et al., 
2013). This model exhibits progressive and dystrophic features in skeletal 
muscle, including cycles of degeneration-regeneration, inflammation, fibrosis, 
impaired ambulation, elevated creatine kinase and muscle weakness with a 
short life expectancy of 3 months due to respiratory failure (Klymiuk et al., 2013). 
A pig model has also been identified as a novel animal model for BMD. 
Dystrophin insufficiency causes selective muscle histopathology and loss of 
dystrophin-glycoprotein complex assembly in pig skeletal muscle (Hollinger et 
al., 2014). Currently, pig models are being used in experimental studies in a 
variety of human diseases including cancer, diabetes, cystic fibrosis, 
Huntington’s disease, kidney disease and cardiovascular disease (Flisikowska 
et al., 2014). 
 
The homozygous dystrophin-deficient zebrafish (dmdta222ta/ta222ta) shows 
similarities with many aspects of the human disease including fibrosis, 
inflammation and dystrophic histopathology in muscle sections and has been 
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suggested as a model system for analysis of muscle fibre loss and in vivo drug 
screening (Berger et al., 2010). 
 
1.6 Therapeutic approaches for DMD 
 
Currently, the only available therapies for DMD are conventional, such as use of 
glucocorticoids, respiratory support through mechanical ventilation, cardiac 
support using beta-blockers and ACE inhibitors, and orthopaedic or surgical 
interventions (Bushby et al., 2010a). However, there have been promising 
experimental approaches developed in mammalian models for therapeutic 
applications, leading to human clinical trials (Bushby et al., 2010a). Since the 
discovery of the genetic defect in DMD (Monaco et al., 1986), various molecular 
strategies have been proposed to either replace the defective dystrophin gene 
through introduction of a functional copy or restore the translational reading 
frame (Chamberlain, 2002). Although recent advances in transgene engineering, 
AAV serotype analysis and vector delivery to muscle have shown promising 
results in animal models of DMD, there are still hurdles that limit attempts for a 
successful gene transfer strategy. Major obstacles associated with viral vectors 
include limited packaging capacity, loss of therapeutic gene expression and 
immune response (Dunant et al., 2003). Alternative therapeutic approaches are 
exon skipping, readthrough of stop codons, transplantation of muscle stem cells 
or other stem cells, utrophin upregulation, the use of surrogate genes to 
increase muscle mass such as follistatin and combined cell- and gene 
approaches (Cossu and Sampaolesi, 2007).  
 
1.6.1 Non-viral gene transfer 
 
Plasmid DNA containing a dystrophin insert can be engineered and amplified in 
large amounts and injected into skeletal muscle of mdx mice (Park and Oh, 
2010). Researchers have observed dystrophin expression in up to 10% of the 
muscle fibres as a result of naked plasmid injection into mdx mouse muscle and 
a decrease in internally nucleated fibres without development of an immune 
response (Acsadi et al., 1991). However preclinical studies have not shown this 
method to be efficient enough to be considered as a treatment for DMD (Muir 
and Chamberlain, 2009). This approach in combination with electroporation is a 
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useful tool for measuring local effects of transgenes in animal models but not for 
systemic transgene delivery which would be required to achieve whole body 
muscle targeting in patients (Wells et al., 2003). 
 
1.6.2 Upregulation of a dystrophin-related protein or other genes 
 
A possible alternative therapy is to compensate for the missing dystrophin using 
dystrophin-related proteins such as utrophin, a protein with a high degree of 
structural and functional similarity to dystrophin (Tinsley et al., 1992). Utrophin 
can also associate with dystrophin-associated proteins and act as a link 
between F-actin and extracellular matrix (Khurana et al., 1991). Although 
utrophin is primarily expressed at the neuromuscular junctions in adult muscle, 
a number of studies have demonstrated that utrophin overexpression can lead 
to an amelioration of the dystrophic phenotype (Tinsley et al., 1996). Using this 
method could also avoid the negative effect of the immune response against 
exogenous dystrophin, since utrophin is normally expressed in mdx and DMD 
muscles (Chakkalakal et al., 2005). However utrophin binds actin only via the N-
terminal domain and lacks sequence corresponding to spectrin-like repeats 15-
19 of dystrophin and therefore cannot stabilise nNOS at the membrane (Lai et 
al., 2013). In addition to utrophin, the rAAV-mediated gene delivery of other 
genes such as the muscle-building follistatin in combination with a micro-
dystrophin has shown improved resistance to eccentric contraction-induced 
injury and force restoration in mdx mice (Rodino-Klapac et al., 2013). 
 
1.6.3 Cell-based therapy 
 
Another potential therapeutic option is cellular therapy aiming to reconstitute the 
satellite cell niche. The transplanted cells must possess the ability to fuse with 
existing myofibres and express the missing dystrophin (Muir and Chamberlain, 
2009). There are two different cell transplantation options: allogeneic (donor-
derived) and autologous (patient-derived). Autologous grafts are less prone to 
immunological rejection, but require genetic manipulation to restore the genetic 
defect before cells can be reintroduced into skeletal muscle, whereas cell 
transplantation from a donor involves the risk of immune rejection (Price et al., 
2007). Allogeneic satellite cells from a wild type donor have been widely used 
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as stem cells for a cell-based therapy option. The drawback of this method is 
the limited distribution of cells, massive cell death after injection and immune 
rejection (Skuk et al., 2007). Autologous transplantation of isolated satellite cells 
could circumvent the immunological response, however the limited  amount of 
isolated myogenic progenitors and reduced myogenicity following their 
expansion in culture reduces their transplantation capacity (Webster and Blau, 
1990). Other cell types suggested for a cell-based therapy include  
bone marrow-derived progenitors capable of being expanded quickly in vitro 
and migration and engraftment in muscle (Ferrari et al., 1998), and muscle-
derived progenitor cells, isolated based on expression of specific markers such 
as CD133 and CD34. Autologous transplantation of muscle-derived CD133+ 
cells (Torrente et al., 2007) and mesoangioblasts derived from pericytes 
(Dellavalle et al., 2007; Meng et al., 2012) have also been suggested as 
candidates with regenerative capacity in skeletal muscle. Alternative 
prospective cell types are embryonic stem cells (ESCs) and patient-specific 
induced pluripotent stem cells (iPSCs) which can be reprogrammed from patient 
fibroblasts and expanded in culture (Perlingeiro et al., 2008; Dick et al., 2011). 
Use of patient-derived iPSCs may overcome many limitations of cell therapy 
such as immune rejection of the transplanted cells and expansion of the cells to 
a therapeutically useful number. However, significant problems remain, such as 
targeted differentiation of the cells into a myogenic lineage without resort to viral 
vectors expressing myogenic factors (Yoshida and Yamanaka, 2010). 
 
1.6.4 Stop codon readthrough (small molecule therapy) 
 
Approximately 10% of DMD mutations are nonsense mutations introducing a 
premature termination codon into the dystrophin mRNA resulting in termination 
of protein translation and absence of dystrophin at the cell membrane 
(Wilschanski et al., 2011). Aminoglycoside antibiotics such as gentamicin can 
cause the translational apparatus to ignore stop codons (Malik et al., 2010). 
Treatment of cultured mdx cells with gentamicin has shown the presence of 
dystrophin in the sarcolemma and functional protection against muscle injury 
(Barton-Davis et al., 1999). However, high toxicity in clinical trials precluded the 
use of this agent in patients (Welch et al., 2007). The identification that PTC124 
(ataluren) had more efficacy in premature stop codon readthrough than 
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gentamicin has led to a phase I preclinical safety trial using ataluren 
administration. Phase II trials involved 5-20 year old DMD and BMD patients 
over 48 weeks. Patients receiving a low dose treatment showed slower disease 
progression, whereas treatment with high dose ataluren demonstrated a similar 
outcome as in placebo group. A phase III study using ataluren was started in 
March 2013 to determine the efficacy of low-dose ataluren (Seto et al., 2014). 
The encouraging results from this study suggest ataluren as an important 
advance in treatment of nonsense mutations in dystrophinopathies in terms of 
safety and efficacy (Bushby et al., 2014).  
 
1.6.5 Exon skipping 
 
Exon skipping provides an alternative approach to restore the reading frame of 
the dystrophin transcript by modulating the splicing machinery with antisense 
oligonucleotides (AON), skipping mutated exon(s) and resulting in production of 
a truncated but partially functional dystrophin protein (Yin et al., 2008). AONs 
are synthetic single-strand nucleic acids which bind to a complementary 
sequence at the mRNA level (Mann et al., 2001). One of the limitations of exon 
skipping is that due to the genetic heterogeneity of DMD, only small cohorts 
with specific mutations may benefit from any given AON drug (Mitrpant et al., 
2009). However, since the majority of deletions occur between exon 43 and 53, 
skipping of a subset of exons could be applicable to a substantial cohort of 
affected individuals. For example a treatment targeted at skipping exon 51 
could be effective in 13% of DMD patients (Aartsma-Rus et al., 2006). Two 
different compounds, drisapersen (2-O-methylAONs-Pro051-GSK-2402968) 
developed by Prosensa and GSK, and eteplirsen (morpholino AON-AVI4658) 
by Sarepta Therapeutics have been tested in clinical trials to skip exon 51 in 
dystrophin pre-mRNA and restore the mRNA reading frame. Drisapersen is 
composed of a 2-O-methyl phosphorothioate backbone (Flanigan et al., 2014). 
Eteplirsen is composed of a phosphorodiamidate morpholino backbone 
(Mendell et al., 2013). Both compounds have been used in clinical trials in 
patients with confirmed mutations for DMD. However after treatment the primary 
outcome measure (6-minute walk test) in the largest trial did not show any 
significant improvement over placebo. Several side effects including low platelet 
19 
 
counts and kidney toxicity was reported in some patients with higher drug doses 
(Flanigan et al., 2014). 
 
1.6.6 Viral vector-mediated gene therapy 
 
Gene delivery of dystrophin using viral vectors requires truncated versions of 
dystrophin, since the full-length dystrophin cDNA (~14 kb) is too large to be 
accommodated into most conventional viral vectors (Wang et al., 2000). The 
idea for generation of mini- and micro-dystrophin constructs has arisen following 
observation of some BMD patients carrying large intragenic dystrophin deletions 
but displaying a mild phenotype (England et al., 1990; Love et al., 1991a). For 
example, large in-frame deletions involving almost 66% of the coding region 
have been reported in patients with mild BMD (Passos-Bueno et al., 1994). 
These findings suggested that it would be possible to convert a severe DMD 
caused by a frame-shift mutation into a milder, BMD-like form by expressing an 
internally truncated dystrophin gene (Wang et al., 2009).  
 
Over recent years, several viral vectors have been used in preclinical studies to 
facilitate gene therapy for DMD. Adenovirus (Ad), recombinant adeno-
associated virus (rAAV) and retroviruses carrying dystrophin constructs have 
been widely used and have shown improvement in disease pathology in animal 
models of DMD (Gregorevic et al., 2004). Adenoviral vectors have a large 
cloning capacity and are able to transduce dividing and non-dividing cells. 
These vectors have high transduction level in regenerating muscles and a large 
cloning capacity, capable of expressing a full-length dystrophin protein in the 
patient cells. However, use of adenoviral vectors remains problematic due to 
the limited persistence of transgene expression and immunological reactions 
against viral products in animal models (Ghosh et al., 2006). 
 
Adeno-associated viral vectors have shown encouraging results in a number of 
genetic disorders including muscular dystrophies and gene transfer of mini- and 
micro-dystrophins (Warrington and Herzog, 2006). Wild type AAV is a non-
pathogenic virus in humans (Carter, 2005), has high transduction efficiency and 
displays long-term stable expression of the transgene in mdx muscle 
(Goyenvalle et al., 2011). AAV has a major drawback which is the limited 
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packaging capacity of approximately 5 kb and is therefore unable to transfer the 
full-length dystrophin to skeletal muscle (Blankinship et al., 2006). However the 
development of mini- and micro-dystrophins has to some extent overcome 
these constraints (Muir and Chamberlain, 2009). 
 
Retroviral vectors derived from lentivirus such as HIV are one of the most 
promising viral vectors for gene transfer strategies, due to their ability to 
integrate into host chromosomes of dividing and non-dividing cells leading to 
long-term integration in the host genome (Naldini et al., 1996). They have up to 
~11 kb insert capacity and display low toxicity (Sinn et al., 2005). A major 
concern of using these vectors is the risk of activation of nearby genes and 
insertional mutagenesis which might be carcinogenic (Wang et al., 2009). 
 
1.6.7 Mini- and micro-dystrophin functional domains 
 
Gene replacement studies have shown that dystrophin expression can be 
restored to the sarcolemma by introducing mini- or micro-dystrophin where the 
C-terminal region and part of the internal rod domain had been removed, 
provided the essential dystroglycan-binding domain and parts of N-terminal  
actin-binding regions remain unaffected (Banks et al., 2007). Chamberlain and 
colleagues at the University of Washington-Seattle and other groups have 
conducted extensive work on mini- and micro-dystrophins in gene therapy 
experiments leading to improvement of dystrophic muscle in mdx mice (Harper 
et al., 2002; Scott et al., 2002; Friedrich et al., 2004; Banks et al., 2007; Park 
and Oh, 2010; Nakamura and Takeda, 2011). 
 
Studies in transgenic mice have also shown that expression of truncated 
dystrophin molecules missing large sequences of the dystrophin rod domain 
prevented a wide range of functional characteristics of dystrophic pathology 
(Harper et al., 2002). Research has shown that dystrophin lacking the middle 
portion of the protein can correct underlying pathology as long as the N-terminal 
actin-binding domain and C-terminal domain are intact (Banks et al., 2007). 
Other studies have postulated that cysteine-rich and C-terminal domains are 
crucial for stabilising the DGC and are required for a fully functional dystrophin 
protein due to binding properties of this regions to other integral proteins (Bies 
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et al., 1992) and the absence of the C-terminus in dystrophin of mdx has been 
suggested to lead to loss of DGC as a whole (Sweeney and Barton, 2000). 
While the cysteine-rich domain which binds to the dystroglycan-sarcoglycan 
complex has been reported to be critical for function (Corrado et al., 1996; 
Rafael et al., 1996) and disruptions in this region result in a severe phenotype in 
patients (Suzuki et al., 1992; Ervasti, 2007), the C-terminal domain has been 
suggested to be at least partially redundant and can be removed without 
severely compromising dystrophin function (Harper et al., 2002; Yatsenko et al., 
2009).  
 
For identification of the minimal regions of the rod domain required for a 
functional protein, smaller constructs retaining one to six repeats in dystrophin 
were generated (Harper et al., 2002; Jorgensen et al., 2009). Although some of 
these micro-dystrophin constructs showed efficacy in preventing progressive 
muscle damage, the treated mdx muscles were slightly weaker than controls 
suggesting that gene therapy using micro-dystrophins might prevent 
development of dystrophy, but do not fully restore muscle strength (Blankinship 
et al., 2006).  
 
A biophysical scan of the rod domain targeting 24 individual spectrin-like 
repeats assessed thermodynamic stability and resistance to proteolysis of 
repeats found that individual repeats considerably vary in their behaviour, 
suggesting that the architecture of the rod domain and its biological function is 
more complex than a repetitive structure (Mirza et al., 2010). These data 
suggest that individual repeats are not simply interchangeable and therefore 
care should be taken when designing mini-dystrophin constructs (Banks et al., 
2010). 
 
Reviewing the literature, much attention has been paid to the role of the rod 
domain in binding to signalling molecules including nNOS. nNOS restoration 
should be considered as a criterion for selecting a truncated version of 
dystrophin molecule for DMD gene therapy (Akbar et al., 2003; Lai et al., 2009; 
Thomas et al., 2009; Li et al., 2010b; Jarmin et al., 2014). In skeletal muscle, 
nNOS is produced by endothelial cells and by muscle fibres and expressed at 
the sarcolemma (Thomas et al., 2003). The muscle-specific isoform of neuronal 
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nitric oxide synthase (nNOS) has been identified as a component of the DGC 
(Chang et al., 1996), is expressed in skeletal muscles of all mammals (Akbar et 
al., 2003) and has been reported to have a significant impact on many 
processes in skeletal muscle including regulation of the blood flow, force 
production, glucose uptake and  myotube differentiation (Thomas et al., 2003). 
Therefore the absence of nNOS may negatively influence clinical features of 
dystrophinopathies (Stamler and Meissner, 2001). In normal skeletal muscle, 
nNOS is located at the cytosolic surface of the sarcolemma and is activated 
during contraction to transport nitric oxide (NO) to the muscle vasculature, 
causing the dilation of blood vessels that is needed for the increased 
metabolism of contracting muscle (Sander et al., 2000). Incorrect nNOS 
localisation impairs dilation of blood vessels during muscle contraction leading 
to muscle ischemia and necrosis (Thomas et al., 1998). Although nNOS 
function depends on its location in the muscle fibre membrane (Nawrotzki et al., 
1998), the nNOS knockout mouse displays no muscle pathology (Huang et al., 
1993; Chao et al., 1998) and removing nNOS from mdx mouse does not lead to 
a more severe phenotype (Crosbie et al., 1998). However, in dystrophin-
deficient muscle, the sarcolemmal nNOS is reduced and incorrectly localised to 
the cytosol (Brenman et al., 1995; Li et al., 2011b). 
 
Initial studies indicated that nNOS indirectly anchors to the C-terminal domain of 
dystrophin via syntrophin (Brenman et al., 1995; Chang et al., 1996). 
Systematic research on the rod domain nNOS-binding site has shown that the 
presence of repeats 16 and 17 is required for binding nNOS at the sarcolemma 
and that the presence of syntrophin alone does not result in sarcolemmal nNOS 
expression. Based on this model, it was suggested that localisation of nNOS 
depends on two distinct interactions, one between the syntrophin and nNOS 
PDZ domains and the other between spectrin-like repeats 16 and 17 in the 
dystrophin rod region and the nNOS PDZ domain (Lai et al., 2009). According 
to these findings utrophin that lacks both repeats 16 and 17 and some of the 
dystrophin mini-genes will not localise nNOS to the sarcolemma (Lai et al., 
2013). These observations suggest that mini-dystrophin design could 
significantly impact nNOS restoration to the sarcolemma in order to reduce the 
disease pathology.  
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Recently the same group has reported that only the expression of naturally 
phased repeats 16 and 17 is sufficient to restore nNOS to the sarcolemma in 
mouse muscle, since the presence of α2 and α3 helices of dystrophin repeats 
16 and 17 form a domain in the α1 helix of dystrophin repeat 17 that is 
responsible for nNOS binding to dystrophin (Lai et al., 2013). However, despite 
extensive research in the last decade, the mechanism of dystrophin and nNOS 
interaction is not completely understood and requires further research (Li et al., 
2011a). 
 
Several studies have explored the correlation between deletion of different 
hinges with disease severity (Carsana et al., 2005; Banks et al., 2010). The 
presence of hinge 2 or hinge 3 affects flexibility of the rod domain (Banks et al., 
2010). Hinges separate the nested spectrin-like repeats, allowing more flexibility 
in the rod domain. Experiments using several mini- and micro-dystrophins have 
shown that replacing hinge 2 with hinge 3 led to improvement in the dystrophic 
phenotype of the mdx mouse. The inclusion of the polyproline site in hinge 2 
with a large deletion in the hinge 3 region led to ringed and small myofibres, 
disruption of myotendinous and abnormal neuromuscular junctions in mdx 
gastrocnemius muscles. In contrast, replacing hinge 2 (exon17) with hinge 3 
significantly prevented muscle degeneration and improved muscle function 
(Harper et al., 2002). Both hinges contain six prolines which disrupt the alpha-
helical structures. Prolines in hinge 3 are evenly spaced but five of the six 
prolines in hinge 2 are grouped together. It has been proposed that the location 
of this polyproline sequence within the truncated rod domain is associated with 
a severe structural disruption affecting the connection between F-actin and β-
dystroglycan. In contrast, the presence of hinge 2 in full-length dystrophin, 
containing a larger number of spectrin-like repeats between the hinge and the 
β-dystroglycan binding domain, allows greater flexibility in the dystrophin 
structure. This led to the suggestion that the rigid alpha-helical structure of the 
polyproline site significantly reduces the flexibility of truncated dystrophins 
which is required for connection between the cytoskeleton and extracellular 
matrix (Banks et al., 2010). These data suggest that the polyproline site is not a 
necessary component of dystrophin and that the consequences of removing or 
retaining hinges might also depend on the size of deletions and the number of 
spectrin-like repeats.  
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The phasing of the repeats and hinges are another important factor for a 
functional dystrophin (Harper et al., 2002). Constructs which had repeats and 
hinges joined in ways that did not significantly differ from the natural pattern of 
these units in dystrophin have proved to be more functional. A construct 
(∆H2−R19) carrying precisely eight sequential rod domain repeats displayed 
significant functional improvement in mdx mouse compared to a similar 
construct (∆exon 17-48) containing 1 partial and 8 repeats as a result of 
deletion of the relevant exons (Harper et al., 2002). 
 
To sum up, large in-frame deletions in the rod domain do not severely disrupt 
the muscle function as long as the reading frame is preserved. However, the 
rod domain cannot be completely deleted or their domains replaced by 
homologous domains from other proteins and the precise order and phasing of 
the retained domains is crucial (Harper et al., 2002; Carsana et al., 2005).
 
1.6.8 Clinical trials and current status of DMD gene transfer therapy 
 
Although efficient gene transfer of truncated versions of dystrophin has been 
reported in various mouse models, there are still several issues that need to be 
addressed when using viral vectors in larger animal models or patients. One of 
the major hurdles in viral vector-mediated gene therapy remains the host 
immune response (Odom et al., 2007). The only human trial with rAAV 
mediated mini-dystrophin gene delivery resulted in transgene-specific T-cell 
immune reaction. Six boys with frame-shifting deletions participated in this study 
which started in March 2006 and completed in April 2009. The AAV used for 
this trial was produced by Asklepios Biopharmaceutical (Mendell et al., 2010). 
rAAV-mediated micro-dystrophin ∆D3990 was injected into patient’s biceps. 
Some of patients displayed increased T-cell immune response against the viral 
vector. At least one patient showed mini-dystrophin specific T-cell immune 
response 15 days post treatment. None of the treated patients showed 
significant dystrophin levels. The T-cell reaction against the transgene was 
thought to be as a result of a low level of dystrophin expression in revertant 
fibres that are found in DMD patients (Mendell et al., 2010). A recent study 
involving 70 DMD patients has shown anti-dystrophin T-cell immune response 
in ~28% of patients (Flanigan et al., 2013). In a different study, it has been 
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shown that transient immunosuppression prevented T-cell activity in the 
dystrophic dog model (Gregorevic et al., 2009).  
 
A major issue for a gene replacement therapy is that a successful transgene 
delivery depends on the disease progression, the degree of fibrotic tissue and 
the level of intact dystrophin fibres. A combination of gene replacement therapy 
with cell therapy may have more efficacy for patients in later stages of the 
disease (Seto et al., 2014).    
 
1.7 Statement of aims 
 
Design and production of truncated miniaturised versions of dystrophin 
encoding specific domains to investigate the structural and functional benefits 
gained from these domains, whilst maintaining a size capable of being 
packaged into lentiviral vectors. 
 
In vivo gene transfer of the mini-dystrophins in mdx mouse muscle using 
intramuscular injection and electroporation; evaluation of the expression and 
subcellular localisation of mini-dystrophins. 
 
Analysis of the level of dystrophin expression and the number of transfected 
fibres; evaluation of morphological changes including internal nuclei and 
myofibre size distribution. 
 
Investigating the ability of mini-dystrophins to restore DGC proteins such as the 
sarcoglycan complex and nNOS. 
 
Determination of the overall suitability of different constructs for preclinical 
studies including cloning into lentiviral vectors for stem cell transduction into 
dystrophin-deficient skeletal muscle. 
 
Identification of key elements of the dystrophin molecule required for optimal 
functionality following gene transfer.
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Chapter 2 Materials and Methods 
 
2.1 Standard molecular biology techniques 
  
2.1.1 Polymerase chain reaction (PCR) 
 
PCR amplification was conducted using a thermal cycler (SensoQuest, 
Labcycler 48). The amplification parameters depended on the template and 
primers. Primer sets used in this project are listed in appendix A and B. Usually 
the PCR reaction was prepared in a 50 µl reaction mixture as listed below: 
 
 
 
 
 
 
 
 
PCR reactions were run using the following program: 
 
1. Initial denaturation: 94 °C for 5 minutes  
2. Denaturation: 94 °C for 30 seconds 
3. Annealing: 60 °C for 30 seconds 
4. Extension: 72 °C for (30 seconds-3 minutes, depending on the fragment size)  
5. Last extension: 72 °C for 5 minutes 
30-35 cycles for steps 2-4. Hold at 4 °C  
 
2.1.2 Agarose gel electrophoresis 
 
0.8-1.5 % agarose gels (Lonza) were prepared (Table 2.1). 1-5 µl of samples 
and 1-2 µl of 6x Loading Dye (New England BioLabs) were loaded and gels run 
at 5 V/cm in 1x TAE buffer for 60-90 minutes until optimal migration was 
obtained. DNA was visualised under UV light, using GelDoc-it 310 Imaging 
System (UVP). Size of DNA fragments were determined relative to 1 kb DNA 
Component Volume (50 µl) 
5x Phusion Buffer 10    µl 
dNTPs (10 mM) 1      µl 
Forward primer (5 µM) 2      µl 
Reverse primer (5 µM) 2      µl 
DNA (50 ng/µl)                             2      µl 
Phusion DNA Polymerase          0.5   µl 
Nuclease-Free Water 32.5 µl 
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Ladder (New England BioLabs) 100 bp DNA Ladder (New England BioLabs) or 
Lambda DNA HindIII Digest (New England BioLabs). 
  
2.1.3 DNA purification by gel extraction 
 
For the isolation and purification of a single DNA band, the desired product was 
excised, extracted and purified from the agarose gel using QIAquick Gel 
Extraction Kit (Qiagen) according to manufacturer’s recommendations. 
 
2.1.4 Digestion of DNA using restriction endonucleases 
 
Reactions were prepared by pipetting DNA, buffer and water together, vortexing 
the mixture and adding the enzymes. Samples were incubated according to 
manufacturer’s recommendations under optimal conditions for the enzyme. 
Digested products were run on an agarose gel for quantification or isolation of 
particular bands. In the case of double or triple digestion, simultaneous 
digestion was performed according to manufacturer’s instructions. 
 
2.1.5 DNA measurement 
 
DNA concentrations were determined using NanoDrop spectrophotometer 
(Thermo Scientific, NanoDrop 2000).  
 
2.1.6 PCR or restriction digest purification 
 
PCR fragments or digestion products were purified with the QIAquick PCR 
Purification Kit (Qiagen). The procedure was performed using a microcentrifuge 
(Eppendorf 5417R), according to manufacturer’s recommendations. 
 
2.1.7 DNA sequencing 
 
Sequencing was carried out by sequencing service MWG Biotech in Ebersberg, 
Germany. 15 µl of purified plasmid DNA or PCR products at a concentration of 
50 ng/µl were sent with 15 µl of the appropriate primer at 5 pmol/µl. 
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2.2 Splicing by overlap extension polymerase chain reaction (SOE-PCR) 
 
SOE-PCR was used to create defined deletions in cDNA clones which included 
two different PCR steps. Primers were designed for two gene fragments 
flanking the region to be deleted. The reverse primer of the left fragment 
contained an overhang sequence complementary to the forward primer of the 
right fragment. The forward primer of the left fragment and the reverse primer of 
the right fragment contained an endogenous or engineered unique restriction 
enzyme site. In the first PCR reaction the fragments were amplified using the 
standard PCR protocol. Upon a successful PCR at the expected sizes for each 
of the two PCR products, the resulting products were purified using QIAquick 
PCR Purification Kit (Qiagen) and 5 µl of each template was added to a PCR 
tube. If one PCR product was judged to be in a lesser amount, the reaction was 
compensated by adding another 1-5 µl of it. No primers were added in this step 
as the templates primed each other. 15 PCR cycles were used for amplification. 
The products were run on an agarose gel to isolate the combined product of the 
individual fragments and the new products were gel extracted using QIAquick 
Gel Extraction Kit (Qiagen) and digested for cloning. The principle of the SOE-
PCR is illustrated in figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic of SOE-PCR principle 
Two fragments were produced in the first PCR step, using 
the full-length dystrophin as template.  
 
Dystrophin 
full-length 
1 
ATG NotI TAG 
11058 
SaII 
Step 2: 
PCR with products of the step 1 as template 
NotI 
SalI 
NotI 
PCR PCR 
NotI 
SalI 
Step 1:  
2 PCRs of the left and right fragments; 
primers at the connection site are overlapping 
ATG 
1 
SalI 
TAG 
11058 
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2.3 Cloning 
 
2.3.1 Ligation 
 
The concentration of vector and insert DNA were determined either using the 
NanoDrop spectrophotometer or by agarose gel against a known amount of 
standard marker. DNA ligation reactions were prepared using T4 DNA Ligase 
and T4 DNA Ligase Buffer (New England BioLabs). The reactions were 
incubated in a total reaction volume of 20 µl at room temperature for 10 minutes 
and heat inactivated at 65 °C for a further 10 minutes. The reaction mixture was 
used directly for bacterial transformation without further purification. 
 
2.3.2 Transformation into chemically competent E. coli cells 
 
XL10-Gold Chemically Ultracompetent Cells (Stratagene), or Methyltransferase 
Deficient Chemically Competent C2925 E. coli Cells (New England BioLabs) 
suitable for growth of plasmids free of Dam and Dcm methylation, were used for 
transformation of plasmids. The competent cells were thawed on ice. 
100 pg - 1 ng of plasmid or ligation mixture was mixed with the cells. After a 
short incubation on ice for 15-30 minutes, heat shock was carried out at 42 °C 
for 45 seconds and samples were immediately placed back on ice for 2 minutes. 
SOC medium (Table 2.1) was added and the transformed cells were shaken 
horizontally at 37 °C in a rotating incubator at 200 rpm for 1 hour. Cells were 
plated out on prewarmed selective medium containing LB medium and Agar 
(Table 2.1), and 50 µg/ml Ampicillin (Sigma) or Kanamycin (Sigma). Plates were 
incubated at 37 °C overnight. 
 
2.3.3 Purification of plasmid DNA  
 
For clean-up of plasmid DNA, single colonies of transformed bacteria were 
inoculated in 5 ml of LB medium containing selective antibiotic (Ampicillin or 
Kanamycin at 50 µg/ml), incubated at  37 °C in a shaking incubator for 12-16 
hours overnight. The cells were harvested and plasmid DNA was prepared, 
using QIAprep Spin Miniprep Kit (Qiagen). For larger scale plasmid preparation 
50-500 ml of bacterial culture was grown and plasmid extracted with either 
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EndoFree Plasmid Maxi Kit (Qiagen) or EndoFree Plasmid Mega Kit (Qiagen) 
following the manufacturer’s instructions.  
 
2.4 Cell culture 
 
2.4.1 Cells 
 
Cell culture work carried out for this study varied for each specific cell type 
including HeLa cells, HEK-293T, C2C12, mdx-immorto and C57BL/10-immorto 
myoblasts (Jat et al., 1991) (all provided by Morten Ritso, Institute of Genetic 
Medicine, Newcastle University) and human myoblasts (MRC-CNMD Biobank).  
In order to keep adherent cells healthy and actively growing it was necessary to 
subculture them at regular intervals. Apart from C57BL/10-immorto and mdx-
immorto lines (incubated and grown at 33 °C), cells were grown at 37 °C and 
5% CO2, fed every other day and passaged when they reached a seeding 
density of ∼70% and until consistent growth rate and appropriate yield was 
achieved.   
 
2.4.2 Cell expansion 
 
Generally when cells attained ∼70% confluence, they were split into 5x 10 cm2 
petri dishes. To do this the supernatant was removed and the cells washed with 
5 ml of sterile 1x PBS (Dulbecco’s Phosphate Buffer Saline, Sigma). For 
splitting, 1 ml of 0.05% Trypsin-EDTA 1x (Life Technologies) was used and 
incubated for 2-3 minutes at 37 °C and 4 ml of growth medium was added to 
inactivate the Trypsin-EDTA. The cell suspension was transferred into a 15 ml 
tube and centrifuged at 450 g for 5 minutes. The supernatant was discarded 
and cells resuspended in 5 ml growth medium. 1 ml of the cell suspension was 
dispensed into each of the 10 cm2 petri dishes and 9 ml of growth medium was 
added to each petri dish and returned to the incubator. When the cells reached 
∼70% confluence, cells were ready for freezing and storage. 
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2.4.3 Standard cell culture conditions for immorto myoblasts 
 
The most used cell lines for this study were mouse mdx-immorto and mouse 
C57BL/10-immorto myoblasts (Jat et al., 1991). Both cell lines were derived 
from mdx and C57BL/10 mice that were crossed with transgenic immorto 
mouse CBA; B10-Tg (H-2Kb-tsA58) carrying the Simian Virus 40 (SV40) 
thermo-labile large tumor antigen (Jat et al., 1991), a conditional immortalising 
gene, under the control of the mouse H-2Kb gene promoter. The tsA58TAg 
gene product is expressed in the presence of IFNγ and temperature of 33°C. 
Cells were grown in 75 cm2 collagen-coated flasks at 33 °C in 5% CO2 using 
immorto growth medium (Table 2.2) supplemented with mouse recombinant 
IFNγ (Life Technologies) and allowed to reach ∼70% confluence. Cells were 
detached using trypsin and split as previously described.  
 
2.4.4 Immorto myoblast differentiation into myotubes 
 
After several passaging steps, immorto myoblasts were seeded into  
collagen-coated flasks or 6-well plates, depending on the experiment. Myotube 
formation was induced by reducing the serum concentration to 5%. Cells were 
allowed to grow in immorto growth medium at 33 °C in 5% CO2 until they 
reached ∼70% density. From this point on medium was replaced by 
differentiation medium supplemented with 2% Horse Serum (Life Technologies) 
and temperature was raised from 33 °C to 37 °C to induce myotube formation. 
The differentiation medium was replenished every other day until cells were 
fused into myotubes over a period of 2-8 days. 
 
2.4.5 Thawing and recovery of frozen cells 
 
This process was performed very quickly to minimise cell death. Prewarmed 
medium was prepared in advance. Frozen cryovials were taken from liquid 
nitrogen and immediately placed in a water bath at 37 °C. The vial was 
disinfected with 70% ethanol as soon as the ice became detached from the wall 
of the tube. The content was poured into a 10 cm2 petri dish containing 8 ml of 
appropriate growth medium. The plate was shaken and placed in the incubator. 
After 3-4 hours incubation and cell attachment the medium was changed with 8 
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ml fresh medium to remove freezing solution and any DMSO residue from the 
culture. 
 
2.4.6 Freezing of living cells for long-term storage 
 
Ideally cells were frozen from cultures at low passage number. When cells 
reached the appropriate density, medium was removed from the flasks/dishes, 
washed and cells detached using trypsin as described previously. Once cells 
were detached, 5-10 ml washing medium (Table 2.2) was added to each 
flask/dish, the cell suspensions were then collected and transferred into a 50 ml 
centrifuge tube and centrifuged at 350 g and 4 °C for 5 minutes. After 
centrifugation the supernatant was aspirated with a sterile glass pipette, the 
pellet resuspended in 5 ml of cold freezing medium (Table 2.2) and quickly 
dispensed in 5 aliquots into cryotubes placed on ice. The cryotubes were placed 
in a box and stored at -80 °C for a minimum of 48 hours, before they were 
transferred to liquid nitrogen for long-term storage. 
 
2.4.7 Cell counting 
 
When cell number was required, cells were counted using a hemocytometer. 
Cells were trypsinised as described previously and a uniform cell suspension 
was obtained and placed in a conical centrifuge tube. The cell suspension was 
pipetted up and down in the tube 7-10 times. 100 µl of the cell suspension was 
placed into a new Eppendorf tube and 100 µl Trypan Blue (Sigma) was added 
and mixed gently. Four corner squares of the hemocytometer were selected 
and using a hand tally counter, the number of cells in this area of 16 squares 
was counted and the average was calculated. The total number of cells was 
determined using the 10x objective of the microscope Motic AE20. The live cells 
(unstained by Trypan Blue) were counted and dead cells (stained blue) could be 
counted separately for estimating viability. The number of cells per ml was 
calculated following this formula: Cells/ml = number of cells counted/number of 
squares counted x 104 x dilution factor. Total cells = cells/ml x vol. of original 
suspension. The percentage of viable cells was calculated as: % viability = 
(number of viable cells counted/total number of cells counted) x 100. 
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2.4.8 E6E7 expressing retrovirus supernatant production 
 
This work and all other viral work was performed at containment level 2, 
according to the institutional guidelines (Newcastle University, BioCOSHH 
regulations for Microbiological Hazards and Genetic Modification, GM Ref.: 
28/10a). A vial of E6E7 virus producing cells was provided by Dr Rolf Stucka 
(Friedrich Baur Institute, Munich, Germany). Cells were thawed in a 25 cm2 
flask in virus culture medium (DMEM supplemented with 10% FBS) with 0.2 
mg/ml G418 Selection Marker (Geneticin, Life Technologies) and cultured for at 
least two passages, so that the cells proliferated well after thawing and reached 
∼70% confluence. At this time the medium was replaced with antibiotic-free 
medium. The supernatant was collected after 24 hours and filtered through a 
0.45 µm filter. Aliquots were prepared and stored at -80 °C for long-term 
storage. For cell transduction including immortalisation 500 µl of the 
supernatant was used along with medium containing 4 µg/ml Hexadimethrine 
bromide (Polybrene, Sigma) to infect cells. 
 
2.4.9 Establishment of an immortalised human DMD cell line 
 
A muscle biopsy with informed consent was obtained in the course of a clinical 
trial from a Duchenne muscular dystrophy patient (aged 10 years at biopsy) with 
a deletion in exon 52 which was processed in the MRC-CNMD Biobank. 
Immortalisation was performed according to the procedure described in the 
published protocol (Lochmuller et al., 1999). The isolated myoblasts were 
infected with a retrovirus expressing the E6E7 gene region from human 
papillomavirus type 16 and the integration of the virus was confirmed by 
selection of G418-resistant cells for 14 days. Cells were grown in standard 
skeletal muscle growth medium (Table 2.2) and allowed to reach ∼30-50% 
confluence.  
 
2.4.10 Enrichment of myoblasts in culture 
 
During the first several passages of the primary cultures, myoblast growth was 
enhanced by preplating in order to eliminate fibroblasts from the culture. During 
each subculturing step, the cell suspension was incubated for 20 minutes which 
34 
 
allowed the fibroblasts to settle onto the plastic surface. The supernatant 
containing a cell population enriched for myoblasts was plated into a new 25 
cm2 flask. At the end of culturing the purity of myoblasts was tested using the 
early myogenesis marker Desmin (Dako) and expression was visualised using 
immunohistochemistry as described elsewhere.  
 
2.4.11 Cell transfection using lipofection 
 
Cells were cultured in the appropriate growth medium for each cell type and 
seeded into 6-well plates 24 hours before transfection to be approximately 70% 
confluent upon transfection. For transfection, growth medium was replaced with 
transfection medium (Table 2.2). Cells were transfected with the mini-dystrophin 
constructs, using the Lipofectamine 2000 Transfection Reagent (Life 
Technologies) as per the manufacturer’s instructions. Cells were incubated for a 
further 24-48 hours before harvesting. For each experiment a GFP control was 
used to evaluate the transfection efficiency and GFP positive cells were 
visualised using an Axioplan M200 inverted microscope (Zeiss). 
 
2.4.12 Cell transfection using electroporation 
 
For difficult-to-transfect cells such as myoblasts, cells were transfected by 
electroporation using Amaxa Nucleofector II (Amaxa Biosystems) and Amaxa 
Cell Line Nucleofector Kit (Lonza). Cells were grown in 6-well plates and 
medium was replaced every other day and passaged at least 3 times before 
electroporation. Cells were seeded at 1.5x105–1x106 viable cells per well. A 
higher confluence was avoided for the optimal transfection efficiency. Cells 
were transfected using transfection medium (Table 2.2) and the cell type 
specific Nucleofector Kit, according to manufacturer’s recommendations and 
analysed 24-48 hours after transfection using light and fluorescence microscopy. 
 
2.4.13 Harvesting cells 
 
The growth medium was removed from the cells and they were washed in 1x 
PBS to remove residual serum. For 6-well plates, cells were washed with 1 ml 
1x PBS and 250 µl of 0.05% Trypsin-EDTA was added to allow removal of the 
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cells from the flasks before harvesting. Alternatively a cell scraper was used to 
detach the cells from the plastic surface. The cell suspension was collected and 
centrifuged at 1300 g for 2 minutes. Cell pellets were washed with 1x PBS, 
centrifuged again, the supernatant removed and frozen at -80 °C. 
 
2.4.14 Stable transfection of mdx-immorto myoblasts 
 
Transfection of mdx-immorto myoblasts with mini-dystrophin constructs using 
Lipofectamine 2000 was performed as previously described. The following day, 
the standard medium was replaced with medium containing 0.2 mg/ml G418. 
The G418 concentration and the optimal cell density was determined using 
titration in 96-well plates as described in the next section. Un- transfected cells 
were used as a negative control in each experiment to ensure that only cells 
expressing neomycin (present in mini-dystrophin plasmids) were able to survive. 
The G418 treatment was continued for 10-12 days and medium changed every 
other day. 24-well plates with 1 ml media in each well were prepared and stable 
transfected cells imaged under an inverted microscope (Motic AE20) to select 
the resistant colonies. A circle was drawn around the positive colonies on the 
underside of the wells. Cells were washed with 1x PBS, a glass cloning cylinder 
(Sigma) was placed on the circle and 20 µl of 0.05% Trypsin-EDTA was added 
on the marked area. A pipette with a sterile tip was lowered to the surface of the 
colony of interest and the cells transferred to a well in the 24-well plate. In 1-2 
days, when cells were confluent, they were split and expanded. Selection of 
G418-resistant cells was continued for at least 14 days and grown until cell 
colonies were ready for long-term storage. Different clones were then screened 
for dystrophin expression by Western blot. 
  
2.4.15 Cells and G418 titration 
 
A combined titration of the cell numbers and the G418 concentration 
determined the plating density and the amount of G418. 100 µl medium was 
preplated into a 96-well plate. 100 µl of cell suspension containing 4000 cells 
per well was added in the first column and 100 µl from the first column was 
carried over to the next well, diluting cells in a ratio of 1:2 for each consecutive 
well (12 wells). 100 µl of the cell suspension in the last well was discarded. The 
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amount of G418 required was determined by titration of a range between 0.2-
1.4 mg/ml by adding 1.4 mg/ml in the first row and decreasing concentrations 
for the following rows in 0.2 µl steps. The last row was used as control without 
G418. Cells were incubated in standard conditions, medium was changed every 
other day and the treatment with G418 continued for 10 days. The G418 
concentration was defined as just above the concentration with complete cell 
death. 
 
2.5 Protein electrophoresis and Western blotting  
 
Cell pellets were lysed in 1% SDS (Sodium Dodecyl Sulfate, Sigma) in 1x PBS. 
The volume of the buffer depended on the size of the pellet. The cells were 
lysed by pipetting up and down and placed in a heat block for 5 minutes. For 
snap-frozen muscle samples and cryostat sections, proteins were prepared in 
lysis buffer (Table 2.1). 40 mg tissue was placed in a 50 ml Falcon tube and 
homogenised in 400 µl lysis buffer using a tissue raptor (Qiagen). Triton X-100 
was added to a final concentration of 1% and the tubes were placed on ice for 
30 minutes. The lysate was centrifuged briefly and transferred to Eppendorf 
tubes and spun at 700 g and 4 °C for 10 minutes. The supernatant was 
transferred into a clean Eppendorf tube and spun down at full speed for 30 
minutes. The resulting pellet containing membrane protein was lysed in 50 µl 
lysis buffer. Protein concentration was measured using the BCA Assay 
(Bicinchoninic Acid Assay, Sigma), according to the manufacturer’s 
recommendations. 25 µg of protein in a final volume of 20 µl was placed in an 
Eppendorf tube. 7.5 µl NuPAGE LDS Sample Buffer 4x (Life Technologies) and 
3 µl NuPAGE Reducing Agent 10x (Life Technologies) were added to the 
sample which was put onto a heat block for denaturation at 95 °C for 5 minutes. 
10 µl SeeBlue Protein Ladder (Life Technologies) and the total volume of 
samples (30 µl) were loaded on Novex NuPAGE 3–8% Tris–Acetate Gels (Life 
Technologies) and the tank (Life Technologies, Novex Mini-Cell) was filled with 
Tris–Acetate running buffer. The gel was run at 150 V for 2 hours. Proteins 
were transferred onto PVDF membranes (GE Healthcare) in a transfer tank 
(Mini Trans-Blot Electrophoresis Transfer Cell, BIO-RAD), containing chilled 1x 
transfer buffer (Table 2.1) and surrounded by ice at 350 mA for 1.5 hours. 
Immediately after transfer the membrane was blocked in 5% milk powder in 1x 
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TBST (Table 2.1) on a shaker for 1 hour. The milk solution was drained and the 
membrane placed in a plastic bag. Primary antibody Anti-Dystrophin Mandra1 
(abcam), 1:1000 or NCL-DYS3 1:125 (Novocastra), diluted in 5% milk in 1x 
TBST solution was added to the membrane and incubated in the sealed bag in 
the cold room on a shaker overnight. The next day primary antibody was 
drained off and membrane rinsed three times in in 1x TBST for 10 minutes. 
Anti-Mouse IgG Horseradish Peroxidase-Conjugated Secondary 
Antibody (Dako, 1:1000), diluted in 5% milk powder in TBST was added to the 
membrane and incubated at room temperature on a shaker for 1 hour. The 
washing steps used for the primary antibody were applied and the protein 
bands were detected in dark room using ECL Prime Western Blotting Detection 
Reagent (GE Healthcare) on photographic film or visualised using a Multi 
Spectral Imaging System (UVP).  
 
2.6 Immunofluorescence and histology 
 
2.6.1 Cryosectioning of muscle tissue 
 
8 µm serial sections of frozen muscles were cut with a cryotome (MICROME 
HM560, Zeiss) and mounted on Superfrost Plus Slides (VWR) along the entire 
TA muscle, separated by intervals of about 100 µm between the sets of serial 
sections. Intervening sections were collected in Eppendorf tubes for protein 
extraction. Slides were stained immediately or wrapped in cling film and stored 
at -80 °C. 
 
2.6.2 Haematoxylin-Eosin (H&E) staining  
 
Slides were air-dried for 30 minutes and stained with Haematoxylin Harris 
(VWR) for 3 minutes. After a wash step in running tap water for 2 minutes they 
were dipped in 1% HCl (Hydrochloric Acid, Fluka; diluted in 70% ethanol) for 5 
seconds and rinsed in tap water for 30 seconds. For staining of the cytoplasm 
Eosin (1% AQUEOUS, VWR) was applied for 30 seconds followed by rinsing 
the slides under running tap water for a further 30 seconds. Slides were dipped 
in an ascending alcohol series of 70%, 90% and 100% for 5 seconds each and 
placed in Histoclear (National Diagnostics) twice for 3 minutes each. The slides 
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were then mounted with DPX Mounting Medium (LAMB) and allowed to dry 
overnight. Images were captured using an Axioplan2 Imaging Microscope 
(Zeiss). 
 
2.6.3 Immunofluorescent labelling of cultured cells 
 
Cells were seeded either onto coated 8-well chamber slides (Lab-Tek) or in 
6-well plates containing cover slips inside the wells and allowed to reach the 
appropriate growth, depending on the cell type. Medium was aspirated, cells 
were washed with 1x PBS and then fixed in 4% PFA (Paraformaldehyde, Sigma) 
at room temperature for 10 minutes before washing in 1x PBS. 0.25% Triton  
X-100 (Sigma) was applied for permeabilisation of cell membranes. The cells 
were then blocked with 4% BSA (Bovine Serum Albumin, Sigma) or 10% Goat 
Serum (abcam) in 1x PBS for 1 hour. Primary antibody was diluted in the same 
blocking solution, added to cells and incubated at room temperature for 1 hour. 
Cells were then washed three times in 1x PBS for 15 minutes and incubated 
with a secondary antibody diluted in blocking buffer at room temperature for 1 
hour and washed as previously described. Slides were mounted and nuclei 
were stained with DAPI Mounting Media Vectashield (Vector Laboratories). 
Cells were visualised with an AxioImager.Z1 (Zeiss). 
 
2.6.4 Immunofluorescence labelling of muscle tissue 
 
Slides were allowed to equilibrate to room temperature. Sections were circled 
with a Water-Repellent Barrier Pen (Vector Laboratories) and washed in 1x 
PBS for 15 minutes. For each experiment secondary-only antibody controls, 
wild type (C57BL/10) tissue sections and dystrophic sections (mdx) were 
included as controls alongside the mini-dystrophin transfected muscle sections. 
Slides were blocked in blocking solution (4% BSA in 1x PBS) for 30 minutes. If 
a secondary goat antibody was used, the samples were blocked in a 20% goat 
serum in 1x PBS. Primary antibodies were diluted in blocking medium. Sections 
were then incubated at room temperature for 1 hour following three washing 
steps in 1x PBS for 10 minutes each. Sections were incubated with secondary 
antibodies (diluted in blocking medium), washed as previously described, 
mounted in Vectashield with DAPI and visualised under an AxioimagerZ.1 
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Microscope (Zeiss). A list of primary antibodies and dilutions used in this project 
is shown in this work (Appendix C). 
  
2.6.5 Direct antibody labelling for immunofluorescence  
  
This method was performed for staining of mouse tissue using mouse 
antibodies. The direct labelling was conducted by Zenon Alexa Fluor 488 
Mouse IgG1 Labelling Kit (Life Technologies). 1 µg of antibody was prepared in 
a maximum volume of 20 µl. 5 µl of component A was added to the antibody 
and incubated for 5 minutes at room temperature followed by addition of 5 µl of 
component B to the mixture and incubation for 5 minutes at room temperature. 
The antibody complex was diluted using standard protocol for the primary 
antibody and applied for staining.   
 
2.6.6 Production of VSV-G lentivirus 
 
Lentivirus with a VSV-G envelope can infect most mammalian cells; therefore 
all work was performed at containment level 2, according to the institutional 
guidelines (Newcastle University, BioCOSHH regulations for Microbiological 
Hazards and Genetic Modification, GM Ref.: 28/10a). Four plasmids including 
the envelope plasmid (pMD2-VSV-G), the core packaging plasmid 
(pMDLg/pRRE), the plasmid expressing REV protein (pRSV-REV) and the 
transfer vector plasmid (pCCL.sin.PPT.prom.EGFP.EWpre), subcloned with 
mini-dystrophins were transfected into the packaging cell line HEK-293T to 
create the infectious viral particles. The transfer constructs carried the mini-
dystrophins C1/∆R3-R13 and C2/∆H2-R19 driven by the desmin promoter or 
GFP under control of the CMV promoter which was used as a control. GFP 
transfected cells were examined using an Axioplan M200 inverted microscope 
(Zeiss). The virus supernatant was collected 20, 30 and 48 hours after 
transfection.  
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2.7 Image analysis 
 
2.7.1 Morphometric parameters 
 
Digital images of the electroporated muscle sections and controls were used to 
analyse the pathology-relevant morphometric parameters including percentage 
of internal nuclei and variability in muscle fibre size. Sections stained for 
dystrophin, laminin and DAPI were imaged using an AxioImager.Z1 at 20x 
magnification and analysed with ImageJ software. For assessment of internal 
nuclei myofibre boundaries were defined. The number of fibres with internal 
nuclei was given as a percentage relative to all fibres. Fibres were measured by 
the software including muscle fibre area, Feret’s diameter and minimal Feret’s 
diameter. The original scale was converted from pixel to µm2 using a user-
defined setting in the software. The corresponding results were saved and 
statistics delivered using GraphPad Prism as described in chapter 5.  
 
2.7.2 Fluorescence intensity quantification 
 
Sections from the electroporated muscles were immunolabelled for dystrophin 
and laminin and images acquired as previously described. Control muscle 
sections, expressing dystrophin at normal levels and mdx, were labelled 
simultaneously. Using ImageJ analysis software the images were split for 
dystrophin and laminin. Subsequently, a threshold was set to create a mask for 
measurement of the region of interest. Each region where intensity values were 
measured covered the entire membrane and background was subtracted from 
the entire image. The channel for dystrophin was measured and the same 
region was selected to measure the intensity of the same region as a 
normalisation value. The ratio of dystrophin and laminin in selected regions was 
calculated by dividing dystrophin and laminin intensity (median intensity of 
green divided by median intensity of red). Values were presented in box plots. 
 
2.8 Image analysis 
 
An AxIoimager.Z1 Microscope (Zeiss) with an AxioCam HRm Camera was used 
to capture images. Wild type sections or cells were used to set exposure times 
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and unstained controls were used to confirm minimal background. A minimum 
of five pictures were taken of each section. Living cells were viewed with a 
Motic AE20 or an Axiovert 200M Inverted Microscope (Zeiss) and the images 
were captured on an AxioCam HRc Digital Camera. An Axioplan2 Imaging 
Microscope (Zeiss) was used for H&E staining. 
 
2.9 In vivo experiments 
 
2.9.1 Animal care and husbandry 
 
Wild type C57BL/10 (BL/10) and C57BL/10ScSn-Dmdmdx (mdx) mice for this 
study were bred in the animal facility at the Institute of Genetic Medicine 
(Elizabeth Greally, Institute of Genetic Medicine, Newcastle University). The 
mdx colony was maintained homozygously. Breeders were housed as pairs of 
one male and one female. Animals were maintained according to the standards 
set by the Functional Genomics Unit (FGU, Institute of Genetic Medicine, 
Newcastle University). All procedures were approved by the Home Office and 
were carried out under Animals Scientific Procedures Act of 1986 under the 
licence number PPL 60/4137.  
 
2.9.2 In vivo electroporation 
 
12 week old mdx mice were weighed and anaesthetised with Isoflurane. Pain 
relief Carprofen or Metacam (at 50 mg/kg or 1 mg/kg respectively; provided by 
FGU) were administered subcutaneously. Both hind legs were completely 
shaved and tibialis anterior (TA) muscles were injected perpendicularly, first 
with Hyaluronidase (0.4 U/µl in 25 µl of normal Saline, Sigma) then with 50 µg 
of plasmid (1 µg/µl – total vol. 50 µl) in the central portion of the muscle (0.5 ml 
insulin needle 3 mm deep). After injecting the second leg, ECG Gel (Camcare 
Gels) was applied to the first leg and electroporated transcutaneously (settings: 
8x 20 ms pulses of 200 V/cm with intervals of 250 ms applied through 2x 1.5 
cm2 stainless steel plate electrodes placed on each side of the leg). 
Electroporation was performed using BTX ECM 830 electroporation device 
firstly on the right, followed by the left leg. The plates were placed in such a 
manner that they did not restrict movement of the leg but were close enough to 
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form a circuit using the gel. Mice were placed into an incubator for recovery. 
Mice were euthanised by cervical dislocation, 14 days post injection at an age 
of 14 weeks and TA muscles were harvested and embedded in 10% Tragant 
(Gum Tragacanth, Sigma) on labelled cork discs and frozen by immersion in 
Isopentane (Sigma) cooled in liquid nitrogen for cryosectioning. 
 
2.10 Computational analysis 
 
2.10.1 Primer design 
 
Primers were designed using Primer3 software, available at http://primer3.ut.ee 
 
2.10.2 Sequence alignments 
 
Sequence alignments were carried out using ClustalW2 at 
http://www.ebi.ac.uk/Tools/msa/clustalw2/, DNAMAN software, Chromas and 
CodonCode Aligner at http://www.codoncode.com/aligner/. 
 
2.10.3 BLAST searches 
 
Searching regions of similarity between sequences were performed using 
BLAST (Basic Local Alignment Search Tool). BLAST is available online at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
 
2.10.4 Cloning analysis using PlasmaDNA 
 
PlasmaDNA program was used for building a visual map of the dystrophin full-
length and mini-dystrophin constructs after sequencing of the entire plasmids. 
This program allows in silico simulation of the cloning experiment. The program 
is freely available for download at http://research.med.helsinki.fi/plasmadna. 
 
2.10.5 Image composite editor 
 
This software was used for creation of the entire muscle cross sections by 
stitching and combining overlapping images to a single image. This software is 
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free available at http://download.cnet.com/Image-Composite-Editor/3000-
2192_4-10973746.html. 
 
2.10.6 ImageJ 
 
Image Analysis Software ImageJ was used for light microscope image 
processing and analysis including muscle fibre cross sectional area, Feret’s 
diameter calculation, assessment of pathological internal nuclei within myofibres 
and pixel value statistics of dystrophin expression density of defined selections. 
ImageJ can be downloaded from http://imagej.nih.gov/ij/download.html. 
 
2.10.7 Statistics 
 
Statistical analyses were carried out using statistical software GraphPad Prism.  
Data were first checked for normality of distribution by the D’Agostino & 
Pearson omnibus normality algorithms, followed by a Bonferroni post-hoc 
analysis of median between groups. For non-normally distributed data a non-
parametric ANOVA (Kruskal-Wallis Analysis of Variance) was performed. 
Adjusted P-values were determined by multiple comparisons using Tukey’s or 
Dunn’s multiple testing. P-Values were given as ****P< 0.0001; ***P< 0.001; 
**P< 0.01; *P< 0.05. The data were summarised showing the median and 
standard deviation for muscle fibre size, percentage of internal nuclei and 
expression intensity for each construct in transfected muscles. The resulting 
data were used to determine a correlation between improvements of transfected 
muscles among different constructs.  
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Reagent Application Recipe Supplier 
Agarose Gel electrophoresis 1x Tris-Acetate-EDTA (see below for details), 0.8%-2% 
agarose and Safe View 
Safe View Nucleic Acid Stain (NBS Biologicals), all 
other components from Sigma 
Agar/LB Transformation/cloning LB broth + 15 g agar/l Agar (Fisher Scientific); See SOC medium 
LB medium Transformation/cloning LB broth (10 g Bacto-Tryptone, 5 g Yeast Extract, 10 g 
NaCl, dissolved in 1 litre distilled or deionised water, and 
sterilised by autoclaving) 
See SOC medium 
 
Lysis buffer Homogenisation of tissue 10 mM tris, protease inhibitor (1 tablet/10 ml) and PMSF (10 
mg/ml in 98% Ethanol; 5 µl/10 ml added just before use) 
Protease inhibitor (Roche), PMSF (Roche) 
Running buffer Western blot 700 ml distilled water and 35 ml 1x  NuPAGE Tris-Acetate 
SDS Running Buffer 20x 
(Life Technologies) 
SOC medium Transformation/cloning 0.5% Yeast Extract, 2% Bacto-Tryptone, 10 mM NaCl, 2.5 
mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM 
Glucose, dissolved in 1 litre distilled or deionised water 
sterilised by autoclaving; 50 µg/ml Ampicillin just before use 
Yeast Extract (Fisher Scientific), Bacto-Tryptone 
(Fisher Scientific), NaCl (Sigma), KCl (Sigma), MgCl2 
(Sigma), MgSO4 (Sigma), Glucose (Sigma), Ampicillin 
(Sigma) 
TAE Gel electrophoresis 1x Tris-Acetate-EDTA (1x TAE= 0.04 M Tris Base, 0.04 M 
Sodium Acetate and 1 mM EDTA) 
All chemicals from Sigma 
TBST Western blot 1x TBST (Tris Buffered Saline with Tween 20, 10x TBST= 
87.66 g/l NaCl, 250 ml/l  of 2 M Tris, pH 7.8,  5 ml/l Tween 
20, in ultrapure water to 1 litre) 
All chemicals from Sigma 
Transfer buffer Western blot 1x transfer buffer (10x transfer buffer= 30.3 g/l Tris Base, 
144 g/l Glycine) 
All chemicals from Sigma 
Table 2.1 Reagents and buffers used in this project 
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Media Applications Recipes Supplier 
Collagen solution Coating culture flasks/plates 179 ml dH2O, 1 ml Ethanoic Acid (EtOOH, 100% 
sterilised by filtering with a 0.2 µm filter, solution 
stored at 4 ºC) 
EtOOH, 100% (Sigma), Collagen (Sigma) 
Differentiation medium Human and mouse 
myoblasts 
Dulbecco's Modified Eagle's medium (DMEM) + 2% 
Horse Serum + 1%  Penicillin/Streptomycin 
(Pen/Strep) 
DMEM (Life Technologies), Horse Serum 
(Life Technologies), Pen/Strep 100x (Life 
Technologies) 
Freezing medium Fibroblasts, HEK293T cells, 
HeLa cells and myoblasts 
70% DMEM, 20% Foetal Bovine Serum (FBS), 10%  
Dimethyl Sulphoxide (DMSO) 
FBS (Sera Laboratories International), DMSO 
(Sigma) 
Immorto growth medium Mouse immorto cells DMEM + 20% FBS + 1% Pen/Strep + 15 µg  IFNγ in 
500 ml DMEM 
IFNγ (Life Technologies)   
Skeletal muscle growth 
medium 
Human myoblasts Skeletal Muscle Growth Medium (SMGM) + 
supplement mix + 10% FBS + 1.5% Glutamax + 0.3 % 
Gentamicin 
SMGM (Promocell),  
Glutamax (Life Technologies), Gentamicin 
(Life Technologies) 
Standard growth medium Fibroblasts, HEK293T cells 
and HeLa cells 
DMEM + 10% FBS + 1% Pen/Strep See above for details 
Transfection medium HEK293T cells, HeLa cells 
and myoblasts 
OptiMEM + 10% FBS, without antibiotics OptiMEM (Life Technologies) 
Virus culture medium Viral transduction, 
immortalisation 
DMEM + 10% FBS + 4 µg/ml Hexadimethrine Bromide 
(Polybrene)  
Polybrene (Sigma)  
Washing medium Fibroblasts, HEK293T cells, 
HeLa cells and myoblasts 
DMEM + 10% FBS + 0.4% Gentamicin or 1% 
Pen/Strep 
See above for details 
Table 2.2 Cell culture media used in this project 
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Chapter 3 Design, construction and characterisation of 
mini-dystrophin constructs 
 
3.1 Introduction 
 
Gene replacement therapy is considered as a promising approach for treatment 
of Duchenne muscular dystrophy. One of the major challenges of this method is 
the large size of the dystrophin cDNA of ~14 kb, exceeding the packaging 
capacity of conventional viral vectors. Therefore smaller versions of the gene 
are needed to facilitate dystrophin gene therapy via viral vectors. The idea of 
generating smaller versions of dystrophin is based on studies in Becker 
muscular dystrophy patients with large in-frame deletions who present with a 
mild phenotype and prolonged life expectancy relative to Duchenne muscular 
dystrophy patients. Reports on transgenic mice expressing mini- and micro-
dystrophins and by deleting coding sequences for different parts in the cDNA 
have identified regions dispensable for dystrophin function (Dickson et al., 2002; 
Harper et al., 2002; Lai et al., 2009a; Lai et al., 2013). These miniaturised genes 
can be introduced into viral vectors including AAV and lentiviral vectors. This 
chapter aims to construct highly functional dystrophin mini-genes following 
consideration of several factors required for rod domain functionality such as 
the number of repeats, presence or absence of internal hinge domains, and 
retention of specific domains such as the nNOS binding site, the second actin-
binding domain and the C-terminus with focus on constructs within the 
packaging capacity of lentiviral vectors with the aim that these could be 
introduced into muscle stem cells. It was hypothesised that engineering smaller 
deletions in the rod domain including various regions to form constructs as 
close to the full-length as possible would lead to functional improvement of the 
mini-genes and might enable us to explore how the deletion of individual repeat 
units or other domains affects the overall gene function. Particularly, it was 
planned to include some constructs capable of restoring nNOS to the 
sarcolemma. In this chapter construction and characterisation of mini-dystrophin 
constructs is demonstrated. 
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3.2 Aims 
 
Rational definition and design of mini-dystrophin constructs that retain key 
functional elements of dystrophin at the protein level.  
 
Provision of a standard method and protocol for construction of truncated mini-
genes that can be applied to introduce deletions in any part of the dystrophin 
molecule. 
 
Characterisation of the mini-dystrophin constructs and verification of the 
translational reading frame. 
 
Investigation of the construct expression after transfection into HeLa cells to 
confirm expression levels and sizes of the expressed mini-dystrophins.  
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3.3 Characterisation of a human full-length dystrophin plasmid as the 
initial clone 
 
3.3.1 Restriction analysis of full-length dystrophin clones 
 
A plasmid containing the entire human coding sequence for the Dp427m 
isoform of dystrophin (the major isoform in muscle) was kindly provided by Rolf 
Stucka, Friedrich-Baur Institute, Munich, Germany. The sequence and a map of 
this plasmid were not available. Therefore a classical plasmid characterisation 
procedure was carried out. The plasmid was transformed into XL1-Blue 
competent cells. Colonies were selected, purified and digested with NotI and 
separated on an agarose gel. The resulting bands and their different sizes 
(Figure 3.1) indicated a mixture of various plasmids in the initial sample. Given 
the expected cDNA size of approximately 14 kb, the plasmid size was expected 
to be larger than 14 kb. Based on these assumptions, clones 2, 4 and 5 (Figure 
3.1) seemed to have the correct size. Clone 5 was selected for further 
characterisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-       + -       + -       + -       + -       + 
Figure 3.1 Restriction analysis of full-length dystrophin clones 
Selected clones (1-5) of the starting full-length dystrophin plasmid were 
digested with NotI. The first lane of each pair is undigested plasmid   
(-). The products larger than 14 kb are potential full-length dystrophin 
clones; lane 1: lambda HindIII marker [kb]; lane 2: ladder [1 kb].  
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3.3.2 Amplification of the complete dystrophin coding sequence 
 
In order to characterise the insert of clone 5, PCR amplification of the entire 
human dystrophin cDNA was performed using 18 overlapping primer pairs 
(primers kindly provided by Ralf Herrmann, Clinic for Paediatrics I, University 
Hospital, Essen, Germany). A table of these primers is attached as appendix A. 
The amplification resulted in 18 fragments of the expected sizes as published 
by Rinninsland et al., 1992, indicating that this clone contained a complete 
dystrophin cDNA sequence (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
B 
 
C 
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Figure 3.2 Amplification of the complete coding sequence of full-
length dystrophin by PCR 
(A) Diagrammatic representation of dystrophin showing the domain 
structure. The N-terminal actin-binding domain is outlined in green 
followed by 24 spectrin-like repeats (red) which are dispersed by 4 
proline-rich hinges (blue). The Cystein-rich domain is shown in yellow 
and the C-terminus in blue. (B) Overlapping PCR fragments numbered 
1.1 to 8.2, covering the entire cDNA of Dp427m. (C) Agarose gel 
showing the PCR products (bp) of expected sizes (lanes 2-19), 
indicating that clone 5 contains the entire dystrophin cDNA sequence; 
lanes 1 and 20: ladder [100 bp].  
969  721 549 503 626 553 704 951 366  849 961 266 959 512 834 883 895 871 
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3.3.3 Primer walking and sequencing of clone 5 
  
Since no detailed sequence information of the dystrophin vector or the multiple 
cloning sites and the adjacent regions of insert and vector were available, a 
complete sequence analysis for the clone 5 was performed to verify its 
properties. Sequencing started from the known sequence of the dystrophin 
insert, using cDNA primer 1.1R for the 5’ and 8.2F for the 3’ regions into the 
vector. The sequencing results were used as templates for the design of the 
next overlapping primers and this procedure was repeated four times until the 
entire vector backbone was sequenced. A contig of the vector was created 
using the sequencing data and the CodonCode Aligner software (Figure 3.3; 
http://www.codoncode.com/). The sequencing results revealed that the 
complete full-length dystrophin plasmid contained 16362 bp consisting of 4314 
bp of vector and 12048 bp of coding and non-coding sequence of dystrophin 
cDNA (Figure 3.4).  
 
 
  
 
  
 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
Figure 3.3 Creation of a full-length dystrophin contig 
The sequence of the vector backbone determined with overlapping 
primers using the CodonCode Aligner software. 
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Multiple cloning site 
 
 HindIII   BglII   NotI          BamHI    KpnI        EcoRI 
…AAGCTTCTAGAGATCTGAGCGGCCGCTCTAGAGGATCCCCGGGTACCGAGCTCGAATTC 
5’-UTR (Dystrophin) 
CGGAGAAAAACGAATAGGAAAAACTGAAGTGTTACTTTTTTTAAAGCTGCTGAAGTTTGTTG
GTTTCTCATTGTTTTTAAGCCTACTGGAGCAATAAAGTTTGAAGAACTTTTACCAGGTTTTT
TTTATCGCTGCCTTGATATACACTTTTCAAAATGCTTTGGTGGGAAGAAGTAGAGGACTGTT
ATGAAAGAGAAGATGTTCAAAAGAAAACATTCACAAAATGGGTAAATGCACAATTTTCT… 
3’-UTR 
…GTCCGACAGCAGTCAGCCTATGCTGCTCCGAGTGGTTGGCAGTCAAACTTCGGACTCCATG
GGTGAGGAAGATCTTCTCAGTCCTCCCCAGGACACAAGCACAGGGTTAGAGGAGGTGATGGA
GCAACTCAACAACTCCTTCCCTAGTTCAAGAGGAAGAAATACCCCTGGAAAGCCAATGAGAG
AGGACACAATGTAGGAAGTCTTTTCCACATGGCAGATGATTTGGGCAGAGCGATGGAGTCCT
TAGTATCAGTCATGACAGATGAAGAAGGAGCAGAATAAATGTTTTACAACTCC 
 
Figure 3.4 Characterisation of the full-length dystrophin (pRSVDysFL) 
(A) Map of the full-length dystrophin (pRSVDysFL) showing the restriction 
enzymes used in this project and the multiple cloning site. The map of the 
full-length dystrophin is annotated using the PlasmaDNA program 
(http://research.med.helsinki.fi/plasmadna). (B) Identification of vector 
elements; the vector backbone and the structural elements were identified 
by BLAST searches and different components defined by the alignment of 
the published sequences to these elements. Abbreviations: SV40-PolyA 
(Simian Virus 40 Polyadenylation Sequence), AmpR (Ampicillin 
Resistance), Ori (Origin of Replication), RSV (Rous Sarcoma Virus 
Promoter). (C) Multiple cloning site and the start codon at the 5’ end and 
the region showing the stop codon. The dystrophin cDNA is cloned via NotI 
at the 5’ end and SalI at the 3’ end (not shown). The untranslated regions 
in this construct are 155 bp at the 5’ and 836 bp at the 3’ ends derived from 
the wild type human sequence. 
 
Bp   Elements 
1–155  Dystrophin 5’-UTR 
156–11213 Dystrophin coding sequence (ATG–TAG) 
11214–12048 Dystrophin 3’-UTR 
12049–16363 Vector 
12666–12900 SV40 polyadenylation signal 
14730–13871 AmpR (counter-clockwise) 
14902–15480 Origin pBR322  
15732–16243 RSV promoter 
16296–16362 MCS 
A 
 
 
 
 
 
B 
 
 
 
 
 
C 
pRSVDysFL 
16362 bp 
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3.4 Construction of mini-dystrophin constructs 
 
3.4.1 Rational definition of mini-dystrophins 
 
Four truncated mini-dystrophin constructs were engineered from the full-length 
human dystrophin cDNA. Individual domains were defined according to the 
reference sequence (accession number NP_003997) obtained from the 
National Centre for Biotechnology Information (NCBI). The dystrophin mini-
genes were of a size to allow them to be packaged within conventional lentiviral 
vectors. Several factors important in the design of mini-dystrophins were 
identified including the preservation of the entire N- and C-terminal regions, 
cysteine-rich domain, four or more spectrin-like repeats and two or more hinge 
regions. Two of these mini-genes maintain repeats 16 and 17 among the 
retained repeats of the rod domain. All constructs contain hinge 1 and hinge 4. 
The construct C9/∆R1-R10 retains the second actin-binding domain (ABD2; 
repeats 11-15) and was generated under my supervision with the technical help 
of Stephanie Carr (undergraduate student, School of Biology, Newcastle 
University), during her bachelor degree in Cellular and Molecular Biology. A 
summary of all constructs is highlighted in this section (Figure 3.5; Table 3.1) 
and detailed descriptions of individual constructs will be given in the relevant 
sections.  
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Full Length Dystrophin 
C1 
C2 
C7 
C9 
~7.4 
~4.3 
~7.7 
~6.0 
Kb Constructs 
Figure 3.5 Summary of mini-dystrophin constructs 
Representation of the mini-dystrophin constructs compared to the full-
length dystrophin. (ABD) actin binding domain; (N-Ter) N-terminus; 
(CH) calponin homology; (H) hinge region; (nNOS) neuronal nitric oxide 
synthase-binding site; (cys-rich) cysteine-rich domain; (WW) domain 
that contains two conserved tryptophans and binds proline-rich proteins; 
(EF) intracellular calcium- binding motif; (ZZ) zinc finger domain; (C-
Ter) C-terminus; (DgBD) dystroglycan-binding domain; (DbBD) 
dystrobrevin-binding domain; (Syn) syntrophin binding domain. The 
sizes of mini-dystrophin constructs are given on the right. Individual 
deletions are outlined in grey and domains highlighted in different 
colours as follows: 
 
N-terminus C-terminus Hinge region Cysteine-rich 
domain 
Repeat 
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3.4.2 Construction of mini-dystrophin C2/∆H2-R19 
  
To illustrate the design, construction and characterisation of mini-dystrophin 
constructs, C2/∆H2-R19 will be used as an example including splicing by 
overlap extension polymerase chain reaction (SOE-PCR), subcloning of the 
construct into an expression vector, overlap-PCR of the entire coding sequence, 
sequencing and confirmation of the reading frame. Construct C2/∆H2-R19 has 
a deletion in the central rod domain relative to wild type dystrophin including 
hinge 2 and repeats 4-19 (16 repeats), resulting in a truncated dystrophin 
protein predicted to be 222 kDa. The correspond 
ing truncation at the transcript level is 5106 bases between nucleotide 1993 and 
7098, connecting glutamine at position 664 directly to glutamic acid at position 
2367 in the protein (Figure 3.6A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Design of the mini-dystrophin construct C2/∆H2-R19  
(A) Sequence of the region of homology between the SOE-PCR primers 
showing the amino acid sequence of the derived construct. (B, C) In-frame 
deletion of 5106 base pairs between nucleotides 1993 and 7098, removing 
16 spectrin-like repeats of the central rod domain and one hinge region.  
...GAAAAGAGTACAGCACAGGAAACTGAAATAGCAGTT... 
   E  K  S  T  A  Q  E  T  E  I  A  V      
                 Q664E2367           
B 
A 
C 
C2/∆H2-R19 ~6.0 kb 
Deletion 5106 bp 
1993-7098 
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3.4.3 SOE-PCR of mini-dystrophin C2/∆H2-R19  
 
The C2/∆H2-R19 construct carries the major functional parts of dystrophin 
including the N-terminal actin-binding domain, cysteine rich domain and C-
terminal region. This construct was generated from the full-length dystrophin 
cDNA using SOE-PCR primers C1/C2-F1-ClaI and C2-R1 to amplify the left 
fragment and C2-F2 and C1/C2-R2-NgoMIV to amplify the right fragment 
(Figure 3.7A), resulting in 378 bp and 1391 bp products (Figure 3.7B). Primers 
C2-R1 and C2-F2 contained mutually homologous sequences on each 3’ end to 
enable the two fragments to be combined in a second PCR step (SOE-PCR), 
creating a 1769 bp product (Figure 3.7C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 PCR amplification of the construct C2/∆H2-R19  
(A) Schematic representation of SOE-PCR relative to the full-length 
dystrophin cDNA. (B) Two fragments are produced in the first PCR 
step, using the full-length dystrophin as a template. For this construct 
the first PCR results in 378 bp (lane 2) and 1391 bp (lane 3) products; 
lane 1: ladder [1 kb]. (C) Fusion of the PCR products from the first PCR 
amplification, generating a 1769 bp construct (lane 2, upper band);  
lane 1: ladder [1 kb].  
 
Deletion 
5105 bp 
1               2                3       1                        2                  
B C 
~380 bp 
~1390 bp 
1 kb 
ladder 
1 kb 
ladder 
← 
C2/∆H2-R19 
~1770 bp 
 
1. PCR 
 
2. PCR 
SOE fragment 
Left fragment 
378 bp 
Right fragment 
1391 bp 
Deletion 
3767 bp 
SOE-PCR 
A 
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3.4.4 Introducing SOE-PCR product into pRSVDysFL  
 
The SOE fragment and the full-length dystrophin were digested with ClaI and 
NgoMIV. Digestion of the full-length dystrophin resulted in three products of 
3200 bp, 3672 bp and 9490 bp (Figure 3.8A). The largest product of 9490 bp 
was gel purified for ligation. The SOE-PCR fragment of 1769 bp was digested 
with the same enzymes, gel purified (Figure 3.8B) and ligated with the 9490 bp 
fragment of the full-length dystrophin. The ligation was used to transform XL10-
Gold ultracompetent cells. The resulting clones were picked, grown up in liquid 
culture overnight and the plasmids purified for characterisation and further 
experiments (sections 2.3.2 and 2.3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 kb  1769 bp 
10 → 
8 → 
6 → 
5 → 
3 → 
4 → 
2 → 
1.5 → 
1 → 
0.5 → 
 
Figure 3.8 Double digest of full-length dystrophin plasmid by ClaI 
and NgoMIV and SOE-PCR fragment 
(A) The full-length dystrophin clone (pRSVDysFL of 16362 bp) is 
predicted to contain two ClaI and one NgoMIV recognition sites. The 
digestion of the full-length plasmid with both enzymes results in three 
products of 3200 bp, 3672 bp and 9490 bp (lanes 2-5); lane 1: ladder  
[1 kb plus]; the largest fragment of 9490 was gel purified. (B) Double 
digest of C2/∆H2-R19 construct by ClaI and NgoMIV after gel purification 
of the SOE-PCR fragment (lane 2); lane 1: ladder [1 kb].  
 
A B 
1         2          3         4         5       1                2          
1 kb plus 
 
9490 bp 
 
 
 
3672 bp 
3200 bp 
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3.5 Characterisation of the mini-dystrophin constructs 
  
3.5.1 Verification of the C2/∆H2-R19 insert and vector by digestion 
 
 First, restriction analysis was performed to test different clones. Plasmids were 
purified and digested with the appropriate restriction enzymes and compared to 
full-length dystrophin. Usually a double digest was performed alongside a single 
digest to compare the insert size with the linearised plasmid. Since the 
dystrophin cDNA was cloned using NotI and SalI, a single digest was usually 
performed with NotI and a double digest with NotI and SalI. The single digest for 
the construct C2/∆H2-R19 resulted in a product of >10 kb, consistent with the 
predicted size of 11095 bp (Figure 3.9A). The vector size after double digest 
was ~4.3 kb, consistent with the predicted 4313 bp and the insert of ~7 kb 
consistent with the predicted 6943 bp (including 5’ and 3’ UTR) (Figure 3.9B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 Digestion of C2/∆H2-R19 compared to the full-length 
dystrophin 
(A) The clones of the full-length dystrophin (lane 2) and C2/∆H2-R19  
(lane 3) were digested with NotI to linearise the plasmids; lane 1: ladder  
[1 kb]. (B) Double digest of full-length dystrophin (lane 2) and C2/∆H2-R19 
(lane 3) with SalI and NotI. The asterisk denotes the vector (~4.3 kb); lane 
1: ladder [1 kb]. 
 
* 
A B 
1 kb        ~16 kb       ~11 kb 
ladder 
1 kb         ~12 kb       ~7 kb 
ladder 
↓ ↓ ↓ ↓ ↓ ↓
10 → 
8 → 
6 → 
5 → 
3 → 
4 → 
1                   2                    3       1                   2                3       
Dys-FL           C2                 Dys-FL          C2                 
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3.5.2 Verification of the deletion in C2/∆H2-R19 by PCR   
 
The second method for verification of the deleted sequence and the insert of the 
mini-dystrophins was PCR amplification using 18 overlapping dystrophin cDNA 
primers showing differences and identities between the amplified sequences 
and the full-length dystrophin PCR products (Figure 3.2). In this example, the 
mini-dystrophin C2/∆H2-R19 deleted for nucleotides 1993-7098 of the wild type 
dystrophin, results in the absence of fragments 2.2-6.2 (Figure 3.10B). cDNA 
amplification offers a fast and sensitive technique for confirmation of the 
engineered deletions in mini-dystrophin constructs prior to complete sequencing 
and further characterisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 PCR amplification of C2/∆H2-R19 dystrophin fragments  
(A) Schematic depiction of the deletion in the dystrophin molecule. 
(B) PCR reactions using 18 overlapping dystrophin cDNA primers (lanes 
2-19). In this construct (C2/∆H2-R19) the fragments between 2.2 and 6.2 
fail to amplify; lanes 1 and 20: ladder [100 bp]. 
A 
 
B 
1      2      3     4      5       6     7       8      9      10    11   12    13     14     15    16    17    18    19     20 
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3.5.3 Verification of the insert C2/∆H2-R19 and sequencing results  
 
In parallel, the mini-dystrophins were sequenced for verification of the inserts 
and reading frame. The sequencing results of individual constructs confirmed 
the absence of the deleted region and a reading frame which connected the 
glutamine at position 664 directly to the glutamic acid at position 2367 as 
predicted. As expected the overhang primer (blue: forward primer of the right 
fragment; green: overhang sequence, complementary to the reverse primer of 
the left fragment) were identified that were designed to join the left and right 
fragments together. The chromatogram below shows that the cDNA fragments 
2.2 and 6.2 were joined, resulting in a truncated mini-dystrophin (Figure 3.11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Sequencing results for C2/∆H2-R19  
The chromatogram shows the nucleotide sequence across the novel 
junction in the construct with the amino acid sequence below. The cDNA 
fragments 2.2 and 6.2 are joined and glutamine at position 664 is directly 
connected to glutamic acid at position 2367, resulting in a truncated mini-
dystrophin of 1983 amino acids. The sequence in green is the overhang 
region of the left forward primer homologous to the distal fragment in the 
SOE-PCR and in blue the corresponding region of the right sequence. 
...GAAAAGAGTACAGCACAGGAAACTGAAATAGCAGTT... 
   E  K  S  T  A  Q  E  T  E  I  A  V      
Q664E2367 
 R4R20 
6.2 
2.2 
C2/∆H2-R19 
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3.5.4 Verification of the reading frame of C2/∆H2-R19 
 
To further confirm that the sequence was as predicted, protein sequences were 
aligned using ClustalW2, validating in-frame deletions relative to specific protein 
domains and the consistency between mini-dystrophin constructs and the full-
length dystrophin. The protein alignment below (Figure 3.12) illustrates two 
predicted parts of dystrophin sequence separated by a deletion in the construct 
C2/∆H2-R19. Individual constructs were generated and characterised by being 
fully sequenced in the same way as described for the construct C2/∆H2-R19. 
The entire coding sequence for this construct can be found as an example in 
appendix D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Protein alignment for C2/∆H2-R19  
Protein sequences of full-lenth dystrophin (Dys-FL) and construct 
C2/∆H2-R19 predicted from the sequencing data and aligned by 
ClustalW2 in order to validate the in-frame deletion and consistency 
between mini-dystrophin constructs and the full-length protein.  
 
Dys-FL          ANICRWTEDRWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSL 600 
C2-1_2.2F       ---------RWVLLQDILLKWQRLTEEQCLFSAWLSEKEDAVNKIHTTGFKDQNEMLSSL 51 
                         *************************************************** 
 
Dys-FL         QKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEK 660 
C2-1_2.2F      QKLAVLKADLEKKKQSMGKLYSLKQDLLSTLKNKSVTQKTEAWLDNFARCWDNLVQKLEK 111 
               ************************************************************ 
 
Dys-FL         STAQISQAVTTTQPSLTQTTVMETVTTVTTREQILVKHAQEELPPPPPQKKRQITVDSEI 720 
C2-1_2.2F      STAQ-------------------------------------------------------- 114 
               ****  
     
 
Dys-FL          LLWLSPIRNQLEIYNQPNQEGPFDVETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVK 2400 
C2-1_2.2F       -------------------------ETEIAVQAKQPDVEEILSKGQHLYKEKPATQPVK 149 
                                         ********************************** 
  Right 
  Left Deletion 
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3.5.5 Subcloning of C2/∆H2-R19 into expression vector pCMV-Tag2 
  
Dystrophin mini-genes were subcloned into the expression vector pCMV-Tag2 
in the NotI and SalI sites (section 2.3.1), removing and replacing the FLAG 
sequence immediately following the CMV promoter with the construct sequence 
(Figure 3.13D). The end of the plasmid including the cloning sites was 
sequenced to confirm the insertion of the constructs into the expression vector. 
This cloning step placed the mini-dystrophin construct under the control of the 
cytomegalovirus (CMV) promoter.  
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1         2          3         4        5      
1                 2                3         
Figure 3.13 Subcloning of mini-dystrophin C2/∆H2-R19 into expression 
vector pCMV-Tag2  
(A) Map of construct C2/∆H2-R19 (~11.1 kb). (B) Map of the expression 
vector pCMV-Tag2 (~4.3 kb), containing the CMV promoter. The restriction 
sites used for subcloning of this construct into the vector are circled. (C) 
Agarose gel of isolated and purified construct C2/∆H2-R19 (lane 2) and the 
pCMV-Tag2 vector (lane 3), prepared for ligation and cloning; lane 1: ladder 
[1 kb]. The construct and the vector were digested with NotI and SalI, the 
original vector removed and the insert cloned into the expression vector 
pCMV-Tag2 digested with the same enzymes. (D) The recloned construct 
(lanes 3 and 5) compared with control construct in the original vector (lanes 
2 and 4) using NotI to confirm the size of the entire construct, and NotI and 
SalI for verification of the sizes of vector and insert. No major differences 
can be seen as both vectors are of similar size (both ~4.3 kb); lane 1: ladder 
[1 kb].  
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ladder pRSV  pCMV  pRSV  pCMV 
 
NotI NotI/SalI 
D 
10 → 
8 → 
6 → 
5 → 
3 → 
4 → 
B 
Expression vector pCMV-Tag2 
A 
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11095 bp 
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3.5.6 Summary of C1/∆R3-R13 construction and characterisation 
 
Construct C1/∆R3-R13 was designed to maintain the most functional parts of 
the dystrophin molecule, while being within the packaging capacity of lentiviral 
vectors. This construct represents a novel mini-dystrophin maintaining the rod 
domain nNOS-binding site (repeats 16 and 17). It was predicted that the 
constructs carrying this part of the protein would lead to nNOS restoration and 
normalise its localisation at the sarcolemma. This construct carries a deletion in 
the rod domain including hinge 2 and repeats 3-13 (11 repeats), resulting in a 
truncated dystrophin protein predicted to be 284 kDa. The corresponding 
truncation on the transcript level is an internal deletion of 3671 bases between 
nucleotide 1619 and 5290, connecting arginine at position 539 to phenylalanine 
at position 1763 (Figure 3.14C). The insert for this construct was generated 
using SOE-PCR primers C1/C2-F1-ClaI and C1-R1 to amplify the left fragment 
and C1-F2 and C1/C2-R2-NgoMIV for the right fragment resulting in 537 bp and 
2572 bp products. In a second PCR step (SOE-PCR) these products were 
fused together generating a 3109 bp construct containing recognition sites for 
ClaI and NgoMIV. The construct was cloned back into the full-length dystrophin 
plasmid by removing the sequence between the same restriction sites and 
replacing it with the synthetic sequence resulting in a final dystrophin coding 
sequence size of 7389 bp. 
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1       2       3     4     5     6     7      8      9      10   11      12    13    14    15   16     17     18   19     20 
Figure 3.14 Summary of construct C1/∆R3-R13 
(A) Schematic of the construct C1/∆R3-R13 indicating the deletion in the 
dystrophin molecule. (B) PCR amplification of dystrophin coding sequence 
from  C1/∆R1-R13 dystrophin fragments. The deleted region is shown using 
18 overlapping dystrophin cDNA primers (lanes 2-19). In this construct the 
cDNA fragments between 2.1 and 5.2 are deleted; lanes 1 and 20: ladder 
[100 bp]. (C) Sequencing chromatogram showing the flanking nucleotides 
and the predicted amino acids at the new junction in the coding sequence. 
The sequence in green is the overhanging homology of the right forward 
primer and in blue the overhanging homology of the left reverse primer. 
5.2 
2.1 
C1/∆R3-R13 
    ...AAGGT ATTGGGAGATCGATTTGCAGCCATTTCACAC... 
       K  V  L  G  D  R  F  A  A  I  S  H 
                      R539F1763 
                        R2R14 
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3.5.7 Summary of C7/∆H2-R23 construction and characterisation 
 
Construct C7/∆H2-R23 carries a large deletion in the rod domain including 
hinge 2 and 3 (2 hinges) and repeats 4-23 (20 repeats) resulting in a truncated 
dystrophin protein of 163 kDa. The corresponding truncation on the transcript 
level is an internal deletion of 6800 bases between nucleotide 1993 and 8793, 
connecting glutamine at position 664 to threonine at position 2951 (Figure 
3.15C). The construct is the smallest dystrophin mini-gene and was derived 
from the C1/∆R3-R13 using SOE-PCR. The primers C7-F1-NotI and C7-R1 
were used to amplify the left PCR product of 1992 bp, and C7-F2 and C7-R2-
ApaI to amplify of the right fragment of 2265 bp. The two fragments were joined 
to form a construct of 4275 bp. Through an unexpected mutation event in the 
bacteria the NotI site was found to be missing one cytosine (GCGGCCGC was 
mutated to GGGCCGC). However the construct remained unaffected since the 
adjacent recognition site SacII could be used for cloning and further 
experiments. Although the SacII site has an internal restriction site in the 
dystrophin cDNA, this was removed from the transcript as part of the internal 
deletion. 
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C 
100 bp   1.1   1.2   2.1    2.2    3.1    3.2    3.3    4.1    5.1    5.2    5.3    6.1     6.2      6.3    7.1    7.2    8.1   8.2   100 bp 
Figure 3.15 Summary of construct C7/∆H2-R23 
(A) Schematic of construct C7/∆H2-R23 illustrating the deletion in the 
dystrophin molecule. (B) PCR amplification of the dystrophin coding 
sequence from C7/∆H2-R23. The deleted region is shown using 18 
overlapping dystrophin cDNA primers (lanes 2-19). In this construct the 
cDNA fragments between 2.2 and 7.2 are deleted; lanes 1 and 20: ladder 
[100 bp]. The fragments 1.1 and 8.2 are missing because the forward 
primer of the 1.1 and the reverse primer of the 8.2 fragments are in UTRs 
which have not been included in this construct. (C) Sequencing 
chromatogram showing the nucleotides and the amino acids at the 
artificially joined sites. The sequence in green is the overhanging region of 
the right forward primer and in blue is the overhanging region of the left 
reverse primer. 
...GAAAAGAGTACAGCACAGACCCTTGAAAGACTCCAG... 
     E  K  S  T  A  Q  T  L  E  R  L  Q 
   Q664T2951 
   R4R24 
 
C7/∆H2-R23 
2.2 
7.2 
1       2      3      4      5       6     7       8      9      10    11   12    13     14     15    16    17    18   19    20 
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3.5.8 Summary of C9/∆R1-R10 construction and characterisation 
 
To further study an additional portion of the rod domain and further optimise our 
constructs, the second actin-binding domain (ABD2) in the rod region (repeats 
11-15) was retained in construct C9/∆R1-R10 (~7.7 kb). This construct 
encompasses a deletion of the rod domain repeats 1-10 and maintains actin-
binding domain of the rod region (ABD2) in addition to N- and C-terminal 
domains, a similar deletion as in construct C1/∆R3-13, hence providing a useful 
comparison. This region of dystrophin interacts with lipid bilayers and binds 
more strongly to the membrane lipids which could stabilise, maintain and 
support the membrane attachment (Sarkis et al., 2011). This construct harbours 
a deletion in the central rod domain including hinge 2 and repeats 1-10 (10 
repeats) resulting in a predicted dystrophin protein of 300 kDa. The internal 
deletion removes 3380 base pairs between nucleotides 1009 and 4389, joining 
glutamic acid at position 336 to proline at position 1464 (Figure 3.16C). Using 
the same technique as previously described, SOE-PCR primers including 
unique restriction sites for this construct (KasI and ClaI) were used to create a 
SOE-PCR fragment of 1780 bp from the full-length dystrophin cDNA. The 
primers C9-F1-KasI and C9-R1 were used to amplify an 874 bp fragment, and 
C9-F2 and C9-R2-ClaI a 906 bp fragment. The SOE-PCR derived construct 
was ligated into the KasI and ClaI sites of full-length dystrophin. The size of this 
mini-dystrophin was 7677 bp. 
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C 
100 bp   1.1   1.2   2.1    2.2    3.1    3.2    3.3    4.1    5.1    5.2    5.3    6.1     6.2      6.3    7.1    7.2    8.1   8.2   100 bp 
 
C9/∆R1-R10 4.1 
1.2 
...TGGCAGTTCATTGATGGAGCCAGCCAATTTTGAGCAG... 
   G  S  S  L  M   E  P  A  N  F  E  Q 
 E336P1464 
 H1R11 
 
Figure 3.16 Summary of construct C9/∆R1-R10 
(A) Schematic of the C9/∆R1-R10 construct showing position of the 
deletion in the dystrophin molecule. (B) PCR amplification using 18 
overlapping dystrophin cDNA primers (lanes 2-19) from C9/∆R1-R10. 
cDNA fragments between 1.2 and 4.1 are deleted; lanes 1 and 20: ladder 
[100 bp]. (C) The chromatogram shows the newly generated construct 
with the predicted amino acid sequences below. Glutamic acid at position 
336 is joined to proline at position 1464 resulting in a truncated mini-
dystrophin protein of 2558 amino acids. The sequence in green is the 
overhanging region of the right forward primer, while the overhanging 
region of the left reverse primer is shown in blue. 
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Table 3.1 Summary of the mini-dystrophin constructs 
Abbreviations: R: repeat; H: hinge; AA: amino acid; bp: base pair; kb: kilo base; kDa: kilo Dalton; ∆: deletion;  
MW: molecular weight. 
 
 
 
 
 
 
 
Construct Vector Cloning 
sites 
Insert size 
ATG-stop 
1. Deletion 
(bp) 
2. Deletion 
(bp) 
Deletion 
(Repeat and Hinge) 
number of 
amino acids 
1. AA 
deletion 
2. AA 
deletion 
MW 
(kDa) 
pRSVDysFL 
 
pRSV-DysFL NotI/SalI 11058 bp 
(~11.1 kb) 
Ø Ø Ø 3686 Ø Ø 427 
C1/∆R3-R13 pCMV2-Tag2A NotI/SalI 7389 bp 
(~7.4 kb) 
1619-5290 
(3671 bp) 
Ø R3-R13 
(11R & 1H) 
2462 539-1763 
 
Ø 284 
C2/∆H2-R19 pCMV2-Tag2A NotI/SalI 5952 bp 
(~6.0 kb) 
1993-7098 
(5106 bp) 
Ø H2-R19 
(16R & 1H) 
1983 
 
664-2367 Ø 222 
C7/∆H2-R23 pCMV2-Tag2A SacII/ApaI 4257 bp 
(~4.3 kb) 
1993-8793 
(6800 bp) 
Ø H2-R23 
(20R & 2H) 
1418 664-2951 Ø 163 
 
C9/∆R1-R10 pCMV2-Tag2A NotI/SalI 7677 bp 
(~7.7 kb) 
1009-4389 
(3380 bp) 
Ø R1-R10 
(10R & 1H) 
2558 336-1464 Ø 300 
C10/∆R3-R13- 
∆CT 
pCMV2-Tag2A NotI/SalI 6942 bp 
(~6.9 kb) 
1619-5290 
(3671 bp) 
10610-11055 
(445 bp) 
R3-R13 
(11R & 1H & CT) 
2314 539-1763 2313-3685 268 
C11/∆R3-R13- 
∆CT-synt 
pCMV2-Tag2A NotI/SalI 6558 bp 
(~6.6 kb) 
1619-5290 
(3671 bp) 
10225-11055 
(830 bp) 
R3-R13 
(11R & 1H & CT) 
2186 539-1763 2185-3685 254 
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3.6 Cell transfection and protein expression of mini-dystrophin 
constructs 
 
3.6.1 Transfection into HeLa cells and Western blotting 
 
To test whether the constructs were able to express the mini-dystrophins in a 
cell culture system, HeLa cells were grown and transfected (section 2.4.11). 
Transfected cell pellets were harvested, lysed with sample buffer and loaded on 
a PAGE gel and the sizes and expression levels of the dystrophin constructs 
determined by Western blot (section 2.5) using a monoclonal antibody specific 
for N-terminus of dystrophin (NCL-DYS3). All constructs expressed mini-
dystrophins (Figure 3.17) and the observed bands correlated with the predicted 
size of the mini-dystrophin proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.17 Illustration of the mini-dystrophin protein expression by 
Western blot 
HeLa cells are transfected with mini-dystrophins and protein expression 
analysed by Western blot using 25 µg of denaturated protein which was 
loaded on a 3–8% Tris–Acetate Gels. (A) mini-dystrophin expression of 
the expected sizes; NCL-DYS3 antibody with an epitope in AA 321-494 
was used to detect the dystrophin N-terminus, a region shared by all 
constructs; lane 1: C1/∆R3-R13 (284 kDa); lane 2: C2/∆H2-R19 (222 
kDa); lane 3: C7/∆H2-R23 (163 kDa); lane 4: C9/∆R1-R10 (300 kDa). (B) 
Actin control. 
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3.7 Discussion  
 
In this chapter a series of 4.3-7.7 kb truncated dystrophin constructs with in-
frame deletions of the dystrophin rod domain have been generated and their 
genetic sequences and reading frame validated. This approach offered the 
opportunity to explore some novel deletions in the dystrophin protein that have 
not been observed in BMD or DMD patients or not generated and tested by 
other research groups.  
 
SOE-PCR is an effective procedure providing spliced DNA for cloning purposes, 
however the technique proved to be challenging for dystrophin construction due 
abundance of restriction sites in the cDNA sequence, since there are only 33 
restriction sites (NM_004006 restriction map) that are absent within the 
dystrophin sequence which could also possibly lead to cleavage of the vector 
during cloning procedure. Moreover, some restriction sites such as ClaI were 
subject to dam methylation which required the regrowth of the cDNA template in 
dam negative bacteria. It was also not always possible to efficiently achieve the 
appropriate conditions for successful amplification of the large fragments. The 
PCR conditions were improved by designing smaller PCR fragments. This 
method has been previously used for generation of micro-dystrophin constructs 
(Clemens et al., 1995; Jorgensen et al., 2009). Although this technique required 
an intermediate cloning step of the constructs into original vectors before 
subcloning into expression vectors, the method proved to be an adequate 
system for generating overlapping sequences and exact location of deleted 
regions in any part of dystrophin cDNA. It was also sometimes difficult to 
amplify the overhang sequence in the second PCR reaction, since residual 
products from the first PCR could compete with the overlap fragments resulting 
in the amplification of undesirable individual fragments making the isolation of 
products difficult. Interestingly, the overlap extension was considerably 
enhanced when only 10-15 cycles were used for amplification. All constructs 
showed in-frame deletions with 100% identity to the full-length dystrophin, 
suggesting that this method is a reliable technique to introduce deletions for 
DMD construct generation.  
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Transient mini-dystrophin expression in HeLa cells was achieved following 
transfection of the plasmids, confirming protein expression and approximate 
size of the mini-dystrophins in live cells. In general, mini-dystrophins with larger 
deletions were associated with higher expression levels in HeLa cells, possibly 
reflecting greater transfection efficiency of smaller constructs. However, this 
finding was not consistent across all experiments, since the expression of 
C9/∆R1-R10 construct was almost as high as the shortest construct in some 
experiments, suggesting that protein expression in vitro is not exclusively 
determined by size of the constructs, or deletions and inclusion of individual 
repeats such as ABD2 in larger C9/∆R1-R10 may have played a role in higher 
expression compared to C1/∆R3-R13. On the other hand, different expression 
levels in HeLa cells could have been random, and as a result of inconsistency in 
transfection efficiency across repeated experiments using the same conditions 
and transfection method. These data suggest that expression level of plasmids 
in cell culture does not necessarily correlate with a higher or less functionality of 
mini-dystrophins and is rather a rapid method to confirm protein expression 
from constructs. 
 
Dystrophin has a large untranslated 3’ sequence which has been suggested to 
contribute to mRNA stability and removal of this region has been shown to lead 
in lower transfection efficiency of truncated dystrophins in C2C12 and COS cells 
(Clemens et al., 1995). However, the construct C7/∆H2-R23 with a complete 
deletion of this region showed dystrophin expression in almost all experiments, 
suggesting that the 3’ deletion does not affect protein expression in this cell 
culture system, and that this portion of the molecule can be removed to provide 
additional space for dystrophin coding sequence. The identification of functional 
portions of the rod domain is required when designing therapeutic dystrophin 
constructs. Further studies are required to assess the novel constructs and 
explore the role of different deletions and whether or not there is a correlation 
between the construct size and function in vivo. It has been proposed that all of 
the spectrin-like repeats might be necessary to withstand and convey the high 
force that is developed in skeletal muscle during contraction (Sweeney and 
Barton, 2000), suggesting that truncated versions carrying a large portion of the 
rod domain may be more beneficial than those with large rod domain deletions. 
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Chapter 4 In vitro characterisation and assessment of 
mini-dystrophin constructs 
 
4.1 Introduction 
 
Cell culture and transfection are useful tools for in vitro study of exogenous 
gene expression and cellular mechanism, enabling functional testing of 
transgene localisation to specific regions in cells. Although cell culture models 
do not necessarily imitate the in vivo environment and cannot replace animal 
models, they allow fast and cost-effective testing of therapeutic strategies prior 
to in vivo studies. Depending on experimental questions, there are several cell 
models that can be used for delivery of engineered truncated dystrophin 
constructs in cell culture. Non-myogenic cell lines such as HeLa- or HEK cells 
are appropriate for transient transfection of constructs into cells, in order to 
observe gene expression, whereas myogenic dystrophin-deficient cell lines are 
required to be able to explore cellular localisation and functionality of 
therapeutic dystrophins. In this work two different types of immortalised 
myoblast lines originating from mouse and human were used. The mdx-
immorto lines carry an immortalising oncogene, the simian virus 40 large 
tumour antigen, allowing infinite proliferation and growth of cells (Jat et al., 1991; 
Morgan et al., 1994). The main drawback of using mdx-immorto myoblasts is 
their low transfection efficiency. For this reason, immortalised DMD-derived 
myoblasts were generated using the E6E7 gene region from human 
papillomavirus, showing extended proliferative life span and potential to 
differentiate (Lochmuller et al., 1999). Furthermore, dystrophic human myoblast 
lines derived from patient biopsies provide the most appropriate cell culture 
model to evaluate therapeutic interventions under their natural genetic 
conditions (Mamchaoui et al., 2011). Lentiviral vectors have been shown to 
enhance transfection efficiency of micro-dystrophins into myoblasts resulting in 
long-term expression and integration of viral genomes into target cells 
(Shunchang et al., 2008; Kimura et al., 2010). In this chapter, the feasibility of 
performing lentiviral transduction as an alternative method to introduce mini-
dystrophins into myoblasts will be explored. 
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4.2 Aims 
 
Transient transfection of mdx-immorto myoblasts to confirm the cellular 
localisation of expressed mini-dystrophins. 
 
Optimisation of transfection and differentiation protocols for mdx-immorto cells. 
 
Investigation of stable transfection of mdx-immorto myoblasts with mini-
dystrophin constructs for further in vitro functional tests. 
 
Identification and establishment of a dystrophin-deficient cell line as a cell 
model system. 
 
Exploration of the ability of lentivirus to transduce dystrophin-deficient 
myoblasts, successfully integrate the viral genome into cells and induce 
dystrophin expression in transduced myoblasts. 
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4.3 Transient transfection of mini-dystrophins and their cellular 
localisation 
 
To investigate protein expression in cultured myoblasts and to examine the 
localisation of the mini-dystrophin constructs, mdx-immorto cells were 
transfected with plasmids carrying mini-dystrophins, followed by 
immunofluorescence microscopy. At day 1, cells were transfected with different 
mini-dystrophin constructs and a GFP plasmid as control. 3 days post 
transfection, myoblasts were fixed and stained with the anti-dystrophin antibody 
Mandra1. Despite repeated attempts only poor transfection efficiency in both 
the GFP as well as mini-dystrophin transfected cells was obtained, indicating 
that the plasmids, including the GFP control, were inefficiently transfected 
(Figure 4.1). The number of transfected cells was insufficient for differentiation 
into myotubes for further functional characterisation experiments such as 
inducing cell damage by osmotic shock. As an alternative to transient 
transfection, stable transfection was undertaken to circumvent this problem.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mini-dystrophin transfection 
Figure 4.1 Transient expression of GFP and mini-dystrophin construct 
C1/∆R3-R13 in mdx-immorto myoblasts  
(A) GFP and mini-dystrophin C1/∆R3-R13 transiently transfected into mdx-
immorto cells and fluorescence microscopy used to visualise the 
transfection efficiency. Only a few cells are transfected with GFP. 10x 
magnification; scale bar 50 µm. (B) Immunofuorescence image of mini-
dystrophin transfected cell (C1/∆R3-13, in this example), using mouse 
antibody Mandra1 and Alexa Fluor 594 goat anti-mouse antibody. 20x 
magnification; scale bar 50 µm. 
GFP transfection 
B A 
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4.3.1 Stable transfection of mdx-immorto myoblasts with mini-dystrophin 
constructs 
 
Using the neomycin resistance of the mini-dystrophin constructs, stably 
transfected mdx-immorto cells were selected after G418 treatment (Figure 4.2A). 
The selection conditions for this cell type, including the optimal cell density and 
the level of G418 to maintain stably transfected clones (section 2.4.15) were 
determined in advance to prevent the growth of untransfected cells. 400 µg/ml 
G418 was used for ~30% confluent cells in 6-well plates and resistant clones 
were selected, expanded and analysed for expression of the mini-dystrophins 
by Western blot (Figure 4.2B). 140 resistant clones were screened, however 
only seven myoblast clones that expressed dystrophin were found, indicating 
inefficient integration of the mini-dystrophin carrying plasmids in the genome of 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Transfected mini-dystrophin clones selected with G418  
(A) Single cell colonies during G418 treatment isolated for expansion and 
further analysis. (B) An example of Western blot on selected clones 
expressing dystrophin using the Mandra1 antibody and 25 µg of 
denaturated protein which was loaded on a 3–8% Tris–Acetate Gels. Only 
3 clones are positive for dystrophin expression on this blot, possibly due to 
loss of mini-dystrophins during cell expansion and proliferation; lane 1: 
differentiated C57BL/10-immorto cell lysate as normal control; lane 2: mdx-
immorto cell lysate; lanes 3-9, stably transfected clones. Protein bands for 
C1/∆R3-R13 transfected clones seem to be smaller than expected size, 
maybe because of unexpected recombination events during replication. 5x 
magnification; scale bar 50 µm.  
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4.3.2 Differentiation ability of stably transfected myoblasts 
 
Differentiation of stably transfected clones into myotubes is required for a 
number of in vitro functional tests and for comparison of the protective effect of 
different mini-dystrophins on membrane stability. C57BL/10-immorto and mdx-
immorto cells were used as wild type and non-transfected dystrophic controls, 
respectively. After 3 days of differentiation, myotube formation was observed in 
the wild type control with complete and unified differentiation after 8 days. 
Similar results were found in mdx-immorto control with a slightly later onset in 
differentiation and lower numbers of fused cells. Differentiation of the stably 
transfected cell lines resulted in some multinucleated, round cells that were not 
able to further differentiate. Despite repeated attempts to achieve an improved 
rate of differentiation, none of the stably transfected clones could be 
differentiated to a comparable state to that observed in control cell lines (Figure 
4.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 3 
C57BL/10-immorto Mdx-immorto C2 transfected 
Day 8 
Figure 4.3 Comparison of differentiation ability of stably 
transfected mdx-immorto cells with untreated controls 
C57BL/10-immorto myoblasts showing differentiation at day 3 and 
complete fusion by day 8. Mdx-immorto differentiation is slightly 
slower but cells are able to differentiate and fuse at day 8. Myoblast 
clones transfected with C2/∆H2-R19 construct fails to differentiate 
effectively. 10x magnification; scale bar 50 µm. 
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4.4 Establishment of an immortalised DMD human myoblast line 
 
In order to explore whether an alternative dystrophin-deficient cell line would 
provide a more suitable cell model for the in vitro experiments, an immortalised 
DMD human cell line with an extended life span was established. A muscle 
biopsy obtained in the course of a clinical trial from a Duchenne patient (aged 
10 years at biopsy) with a deletion in exon 52 had been processed in the MRC-
CNMD Biobank in Newcastle. The myoblasts were infected at ~30% confluence 
with a retrovirus expressing the E6E7 region from human papillomavirus type 
16 (Lochmuller et al., 1999) and the integration of the virus was confirmed by 
selection of colonies for G418 (Geneticin) resistance for at least 14 days. The 
G418-resistant clones were cultured for several weeks without significant 
change to their proliferative potential. The immortalisation was also performed 
on myoblasts from a healthy donor to serve as normal control. To determine the 
purity of the immortalised myoblasts, cells were stained with an antibody 
against the myoblast marker desmin. The staining showed a pure population of 
proliferative myoblasts as well as myotubes at day 4 after seeding (Figure 4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Desmin staining on immortalised DMD human cell line  
Mouse anti-desmin antibody and Alxa Fluor 488 goat anti-mouse antibody 
is used to test the purity of the immortalised DMD human myoblast line.  
Myoblats and myotubes are positive for desmin staining (green) and 
nuclei is stained with DAPI (blue). 20x magnification; scale bar 50 µm. 
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4.4.1 Comparison of transfection efficiency in mouse and human cell 
lines 
  
Efficiency of transfection was compared in several immortalised myoblasts cell 
lines available to define the optimal cell line for these experiments. Cells were 
grown to 70-90% confluence and transfected with a control GFP expressing 
construct using the Amaxa Nucleofector, followed by analysis by fluorescence 
microscopy and FACS. The aim was to determine the most suitable cell line for 
transfection. The mouse myoblast cell lines included C2C12, dystrophin-
deficient mdx-immorto and C57BL/10-immorto as a normal control. The human 
cells included the newly immortalised DMD human and the normal control 
myoblasts.  
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Normal Human  
DMD Human  
Figure 4.5 Comparison of transfection efficiency in 
different myoblast lines  
Mouse cell lines (C2C12, C57/BL10-immorto and mdx-
immorto) and human cell lines (immortalised DMD and 
normal human myoblasts) transfected with a control GFP 
construct. Cell culture images at 5x magnification; scale bar 
50 µm.  
Mouse cell lines Human cell lines 
Mdx-immorto 
C2C12 
C57BL/10 
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4.4.2 FACS analysis of transfection in different cell lines 
 
To obtain quantitative results on the transfection efficiency in myoblasts, FACS 
analysis 24 hours following transfection was undertaken. Only surviving, 
adherent myoblasts were collected. The detached and dead cells were not 
considered. In each group 20,000 cells were counted (except the mdx-immorto 
cell line, as only 4058 cells could be harvested in total). The transfection rate 
was 35.7% in C2C12, 37.7% in C57/BL10-immorto, 37.2% in mdx-immorto, 
69.2% in immortalised, normal human myoblasts and 61.4% in immortalised 
DMD human myoblasts (Figure 4.6). 
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Mouse myoblasts 
Human myoblasts 
C57BL/10-immorto 
myoblasts 
(37.7%) 
 
mdx-immorto 
myoblasts 
(37.2%) 
 
Normal human  
myoblasts 
(69.2%) 
 
DMD human  
myoblasts 
(61.4%) 
Figure 4.6 Flow cytometric results of mouse and human myoblasts 
transfected with a GFP control construct following Amaxa 
nucleofection  
(A) Scatter plots showing GFP positive cells (green) after transfection.  
(B) Bar chart presents the percentage rate of GFP positive cells for each 
cell type. Human myoblast lines show higher transfection efficiency than 
mouse myoblasts. 
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4.4.3 Choice of the best transfection method and transfectants 
 
In order to evaluate and compare the transfection efficacy of several lipofection 
reagents to that of the nucleofection system, immortalised DMD human 
myoblasts were transfected with a GFP plasmid using several different available 
lipofection reagents including Lipofectamine 2000, NanoJuice and FuGene HD 
and compared to nucleofection using the Amaxa system. Nucleofection proved 
to be less toxic and more efficient at delivering DNA into the cells as determined 
by cell viability that was estimated by observations of attached GFP positive 
cells in cell culture. Lipofectamine 2000, NanoJuice and FuGene were 
essentially equivalent in terms of toxicity and very low in efficiency. In general, 
the Amaxa nucleofection system seems to be superior to lipofection systems for 
this cell line (Figure 4.7). 
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GFP/Amaxa electroporation 
GFP/Lipofectamine 
GFP/NonoJuice 
GFP/FuGene 
DAPI 
DAPI 
DAPI 
DAPI 
Figure 4.7 Comparison of transfection efficiency of several lipofection 
reagents with nucleofection on DMD human myoblasts in cell culture 
Fluorescence microscope images of immortalised human DMD myoblast 
line transfected with a GFP control plasmid using various lipofection 
reagents or nucleofection. The highest efficiency was achieved using 
Amaxa nucleofection, as judged by attched cells. 5x magnification; scale 
bar 50 µm. 
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4.5 Immunofluorescence results 
 
4.5.1 Transient transfection of DMD human myoblasts 
  
Transfection of immortalised DMD human myoblasts was carried out with mini-
dystrophin constructs and GFP plasmid as a control, using the Amaxa 
nucleofection procedure, in order to define the localisation of dystrophin in the 
muscle fibre membrane after staining with anti-dystrophin antibodies. Following 
straining with Mandra1 (abcam), which has an epitope in the C-terminal region 
of dystrophin, fluorescence microscopy was used to identify transfected cells.  
Despite repeated attempts only low levels of transfection were observed, a level 
comparable to that obtained for the mouse myoblasts. Since, the GFP 
transfection had shown (Figure 4.7) a high transfection efficiency of 
approximately 60%, consistent with the previously described FACS analysis, it 
was concluded that the transfection efficiency was largely dependent on the 
construct used and not necessarily on the cell line (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMD/untransfected  
DMD/C1 DMD/C2 
Figure 4.8 DMD human myoblasts 
after transfection and staining with 
anti-dystrophin antibody Mandra1  
Untransfected immortalised DMD 
human myoblast line transfected with 
C1/∆R3-R13 and C2/∆H2-R19 and 
stained with mouse anti-dystrophin 
antibody Mandra1 and Alexa Fluor 
594 goat anti-mouse antibody. 20x 
magnification; scale bar 50 µm.  
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4.6 Improving gene transfer efficiency using viral transduction 
 
4.6.1 Introduction to design of replication incompetent lentiviral vectors 
 
In order to provide a more efficient and reliable mini-dystrophin transfection 
protocol, the mini-dystrophin constructs were first inserted into viral vector 
backbones to allow the use of lentiviral vectors (LVs) for expressing mini-
dystrophin constructs in muscle cells.  
 
Lentiviral vectors can transduce both dividing and non-dividing cells and have a 
relatively large transgene carrying capacity, and are therefore highly attractive 
as a gene delivery system (Talbot et al., 2010). The third generation lentiviral 
vectors are based on HIV-1 and carry an almost complete deletion in the U3 
region of the HIV 3' LTR which contains viral enhancer and promoter in addition 
to removal of all essential packaging and replication genes, improving biosafety 
(Follenzi and Naldini, 2002) (Figure 4.9). The constructs used for lentivirus 
production are maintained in the form of bacterial plasmids and can be 
transfected into mammalian cells to produce replication-defective viral stocks.  
 
 
 
 
 
 
 
 
 
 
 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV-1 A 
Figure 4.9 Schematic drawing of the four constructs required to generate VSV-pseudotyped third generation HIV-1 
derived lentiviral vectors 
(A) HIV-1 virus including structural (gag, pol and env), regulatory (tat and rev) and accessory (nef, vif, vpr and vpu) viral elements 
(B) The conditional packaging construct expressing the gag and pol genes driven by the CMV promoter. (C) Construct RSV-REV, 
expressing the REV cDNA from the RSV promoter. (D) The self-inactivating (SIN) transfer construct containing HIV cis-acting 
sequences and inactivating LTR in the transfer vector to prevent the virus from activating, containing an expression cassette for 
the transgene (in this case GFP), which can be replaced with the gene of interest and is driven by an internal promoter. (E) A 
construct encoding a heterologous envelope to pseudotype the vector, coding for the protein G of the vesicular stomatitis virus 
under the control of CMV promoter to replace the envelope protein of the virus. Illustration adapted from Follenzi and Naldini 2002. 
Abbreviations: gag: group antigen; pol: reverse transcriptase; env: envelope protein; LTR: long terminal repeat; tat: transcriptional 
transactivator; rev: RNA-binding protein; nef: negative factor. 
B 
C 
D 
E 
Packaging construct 
Transfer vector 
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4.7 Lentiviral transduction 
 
4.7.1 Subcloning of selected constructs into a lentiviral vector 
 
In order to produce viral particles for transduction, two of the mini-dystrophins 
were cloned into the pCCL.sin.PPT.prom.EGFP.EWpre lentiviral vector 
backbone to provide packaging signals which direct the construct into the 
packaged virus particles. The four previously described plasmids (Figure 4.9) 
(Follenzi and Naldini, 2002) and a plasmid (~7.7 kb) containing a desmin 
promoter (kindly provided by Professor Jenny Morgan, Dubowitz 
Neuromuscular Centre, Institute of Child Health, UCL, London) were used to 
investigate the behaviour of a muscle specific promoter in the new vector 
system. The construct C1/∆R3-R13 (~7.4 kb) and the C2/∆H2-R19 (~6.0 kb) 
were selected for this experiment in order to compare the transduction 
efficiency of lentivirus using two constructs of different sizes. I addition, these 
constructs offered a comparison for nNOS restoration between a constructs that 
contain the rod domain nNOS-binding site (C1/∆R3-R13) and a construct that is 
deleted for this region (C2/∆H2-R19).  
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4.7.2 Generation of lentivirus containing mini-dystrophin constructs 
driven by desmin promoter 
 
Three different vectors were used for this approach in multiple cloning steps. 
The lentiviral transfer vector pCCL.sin.PPT.prom.EGFP.EWpre, a vector 
carrying the desmin promoter (MA 884) and the expression vector  
PCMV-Tag2/C1/∆R3-R13 or pCMV-Tag2/C2/∆H2-R19, carrying the constructs. 
In the first step the vector was digested with ClaI and SalI to remove the GFP 
and the CMV promoter, whereby the NotI site in the multiple cloning site, 
located next to the SalI site was removed as part of the deleted sequence. In 
this step 1348 bp were deleted from the vector. A polylinker containing ClaI, 
XbaI, EagI and SalI was cloned into the digested lentiviral transfer vector to 
allow cloning of the desmin promoter and the mini-dystrophin constructs in 
multiple cloning steps (Figure 4.10). 
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Figure 4.10 First cloning step for generation of lentiviral vector 
containing mini-dystrophin constructs driven by desmin promoter 
(A) Map of pCCL.sin.PPT.prom.EGFP.EWpre LV vector. (B)  Agaose gel 
of  pCCL.sin.PPT.prom.EGFP.EWpre; lane 1: ladder [1 kb]; lane 2: 
linearised vector digested with ClaI (7425 bp); lane 3: ClaI digestion of the 
vector after removal of the CMV promoter and the GFP sequence and 
cloning of the polylinker (1348 bp are deleted), resulting in a vector size of 
6077 bp. (C) The sequence of the polylinker designed with restriction sites 
required for the cloning of a desmin promoter and mini-dystrophin 
constructs. 
C 
Polylinker 
CGATTCTAGACGGCCGG  
  TAAGATCTGCCGGCCAGCT 
   ClaIXbaIEagISalI 
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The resulting plasmids were then cut with NotI and treated with S1-Nuclease, 
an enzyme that removes single stranded tails from DNA to create blunt-ended 
molecules. This step resulted in the removal of the NotI recognition site from the 
vector backbone. The vector was then self-ligated and purified for the next 
cloning step. The removal of both NotI sites was confirmed after digestion with 
NotI and EagI. Plasmids without NotI sites remained undigested but linearised 
with EagI which was cloned into the vector as part of the polylinker (Figure 4.11; 
lanes 8 and 9). 
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Figure 4.11 Second cloning step for generation of lentiviral vector 
containing mini-dystrophin constructs driven by desmin promoter 
Agarose gel of pCCL.sin.PPT.prom.EGFP.EWpre vector containing a 
polylinker following digestion with S1-Nuclease and religation. This step 
removes the NotI site from the vector backbone which was confirmed 
after digestion with NotI and EagI. Left panel shows digestion with NotI. 
Only clones 8 and 9 are successful and not digested by the enzyme, 
because the NotI site has been removed from the vector. Right panel is 
digestion with EagI, resulting in linearised vectors. The unique EagI site is 
cloned into the vector as part of the polyllinker in the first cloning step. 
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In the third step the self-ligated vector (~6.1 kb) and the desmin plasmid (~7.7 
kb) were digested with ClaI and XbaI to allow the cloning of the desmin 
promoter in the vector (~1.8 kb) (Figure 4.12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Third cloning step for generation of lentiviral vector 
containing mini-dystrophin constructs driven by desmin promoter 
(A) Agarose gel of the self-ligated vector (~6.1 kb), digested with EagI  
(B) The desmin plasmid (~7.7 kb) digetsed with ClaI and XbaI to allow the 
cloning of the desmin promoter (~1.8 kb; lower band). (C) Digestion of 
different clones of the recombinant LV vectors (~7.9 kb) with EagI.  
 
       LV+ desmin promoter 
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A B 
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promoter 
~1.8 kb 
 
↓
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The recombinant lentiviral vector containing the desmin promoter (~7.9 kb) was 
then digested with EagI and SalI (Figure 4.13A) to facilitate the cloning of the 
constructs with unique NotI and SalI recognition sites at the 5’ and 3’ ends of 
the mini-gene constructs (Figure 4.13B). The resulting plasmids were digested 
with NotI and SalI for verification of the insert. The final lentiviral vectors 
containing mini-dystrophins were sequenced for verification of the desmin 
sequence and the cloning sites. 
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Figure 4.13 Fourth cloning step for generation of lentiviral vector 
containing mini-dystrophin constructs driven by desmin promoter 
(A) The recombinant lentiviral vector carrying the desmin promoter (~7.9 kb) 
digested with EagI and SalI for cloning of the constructs with NotI and SalI 
recognition sites at the 5’ and 3’ ends of the mini-dystrophin constructs. (B 
Mini-dystrophin constructs C1/∆R3-R13 and the C2/∆H2-R19 digested with 
NotI and SalI. (C) Map of the C2/∆H2-R19 construct showing the cloning 
sites. (D) Digestion of plasmids with EagI and SalI after cloning. The white 
arrows show the recombinant  LV vectors (~7.9 kb) and the black arrows 
C1/∆R3-R13 inserts; other bands are empty vectors. (E) Miniprep DNA 
from the final cloning step with C2/∆H2-R19 insert, digested with EagI and 
SalI. The black arrow shows the recombinant LV vector (~7.9 kb) and the 
white arrow C2/∆H2-R19 insert; other lanes with single bands derive from 
empty vectors.  
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4.8 Production of VSV-G lentivirus 
 
Lentiviruses with a VSV-G envelope can infect most mammalian cells, therefore 
all work must be performed at containment level 2, according to local institution 
guidelines. The four plasmids (Figure 4.9) were transfected into the packaging 
cell line HEK-293T to create the infectious viral particles (Figure 4.14). The 
transfer constructs carried the mini-dystrophins C1/∆R3-R13 and C2/∆H2-R19, 
driven by the desmin promoter or the GFP construct under control of the same 
promoter; the latter was used as a control. The virus supernatant was collected 
20, 30 and 48 hours after transduction.  
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Figure 4.14 Diagram of the viral production procedure  
(A) The plasmids containing the viral genome components and the transfer 
vector, carrying the transgene required for transfection into the packaging 
cell line to create the infectious viral particles. The image shows GFP 
expression in HEK-293T cells 24 hours after transfection of the four 
plasmids required for production of  the viral particles. 10x magnification; 
scale bar 50 µm. (B) Time line and procedure of viral production.  
 Final 
product 
        Supernatant collection: 
20 hours post transfection 
30 hours post transfection 
48    hours post transfection 
 
Days 2 & 3  
Supernatant filtration using low  
protein binding syringe filter 
Viral stock production 
    
HEK-293T transfection 
Day 1  
Transduced HEK-293T cells expressing  
GFP 24 hours post transduction 
Transfection  
A B 
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4.9 Myoblasts transduction  
 
4.9.1 GFP transduction and expression results 
 
Human DMD myoblasts were grown to ~50% confluence and transduced with 
the virus expressing GFP. Fluorescence microscopy images were taken 24 
hours later, showing GFP expression and the infection of the vast majority of 
the myoblasts (>99%) (Figure 4.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.9.2 Staining results of DMD human myoblasts after transduction with 
viral particles carrying mini-dystrophins 
 
DMD human myoblasts were grown at ~50% confluence and transduced with 
viruses carrying the mini-dystrophins C1/∆R3-R13 and C2/∆H2-R19. Cells were 
stained with anti-dystrophin antibody Mandra1, 72 hours after transduction. The 
results showed the infection of nearly all cells. A large proportion of the staining 
displayed membrane localisation of the dystrophin to the sarcolemma in the 
infected cells (Figure 4.16). 
 
Figure 4.15 Myoblast transduction using lentivirus 
Fluorescence microscope image of myoblasts transduced with 
the virus stock expressing GFP 24 hours after transduction. 20x 
magnification; scale bar 50 µm. 
96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.16 Immunofluorescence following transduction of DMD human myoblasts with lentivirus carrying mini-dystrophins   
(A, D) untransduced DMD myoblasts, (B, C) DMD myoblasts transduced with lentivirus carrying C1/∆R13-R13. (E, F) DMD human 
myoblasts transduced with lentivirus carrying C2/∆H2-R19. The staining was performed using mouse anti-dystrophin antibody 
Mandra1 and Alexa Fluor 594 goat anti-mouse. White arrows indicate membrane localisation of the mini-dystrophins. 20x  
magnification; scale bar 50 µm. 
E D F 
B A C 
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4.10 Discussion 
 
In contrast to mini-dystrophin expression in HeLa cells in chapter 3, myoblast 
transfection with mini-dystrophins proved to be challenging. One limiting factor 
was low transfection efficiency and insufficient expression of mini-dystrophins in 
transfected dystrophin-deficient myoblasts. Only seven of the 140 stably 
transfected mdx-immorto clones expressed dystrophin by Western blot, 
although only those cells which had integrated the resistance gene of the vector 
should be able to survive selection. These results indicate inefficient integration 
of the mini-dystrophins carrying plasmids in cells, probably due to loss of the 
transgene during cell replication. Some results showed smaller bands in 
Western blot than expected, indicating that the constructs had rearranged 
during integration, deleting the mini-dystrophins. Transfected nucleic acids in 
cells can be lost through different processes such as cell division, and 
transfection efficiency and sustainable expression largely depends on cell 
type (Kim and Eberwine, 2010).  
 
It has been reported that mdx-immorto cells were successfully transfected in 
order to express micro-dystrophins in vitro (Jorgensen et al., 2009), suggesting 
that this cell type may be efficiently used for integration of small micro-
dystrophins but did not allow the integration of the larger constructs that were 
generated in this project. One factor influencing DNA transfection efficiency is 
the size of the plasmids (Campeau et al., 2001; Molnar et al., 2004) and 
efficient transfection of large plasmid DNA may only be possible using viral 
vectors (Campeau et al., 2001). 
 
Another hurdle that limited the use of functional assays in vitro was lack of 
differentiation ability of the few stably transfected and isolated cell lines relative 
to untransfected mdx-immorto myoblasts. Ideally, a cell model for dystrophin 
restoration studies should not only offer a high transfection rate but also 
possess the ability to form myotubes, since dystrophin is only expressed in 
differentiated myotubes (Denetclaw et al., 1993). In addition, many in vitro 
experiments using myoblasts and transfection of a therapeutic gene require the 
formation of mature myotubes to evaluate and quantify the impact of transfected 
genes on late onset proteins. For instance assessment of CK activity after 
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induced stress is dependent on a high and reproducible differentiation state of 
the cells which is consistent between the experimental and control lines, since 
CK is an enzyme that is produced only in mature myofibres (Valdes and Jortani, 
1999; Tai et al., 2011). Comparing CK release in myotube cultures which are 
not at the same stage of differentiation could produce strongly biased results 
simply due to the different levels of CK expression between the myotubes.  
 
It was hoped that the use of immortalised myoblasts from a DMD patient might 
lead to sufficient amounts and proper subsarcolemmal localisation of dystrophin 
to offer an alternative cell model. Transient transfection of immortalised human 
myoblasts using a GFP plasmid presented up to two-fold transfection efficiency 
relative to mouse cell lines, suggesting that the dystrophin-deficient DMD 
human myoblast cell model had more favourable transfection characteristics. 
However no significant dystrophin expression was observed after staining and 
efficient transfection of the mini-dystrophin plasmids was not achieved in this 
cell line. FACS analysis data showed transfection efficiency of approximately 
60% with GFP plasmid in DMD human myoblasts, suggesting that that the GFP 
transfection data did not correlate with the transfection of cells with mini-
dystrophins and the transfection efficiency was largely dependent on the 
construct used. One possible explanation is that the constructs were too large 
to be expressed sufficiently in any of the myoblast lines. These data confirm 
that transfection efficiency of plasmid cDNA is proportional to the size of 
transfected DNA molecule (Campeau et al., 2001), and suggest that the large 
size of mini-dystrophin plasmids could be the dominant factor resulting in the 
low transfection efficiency in both mouse and human cell lines.  
 
Although transfection is generally a powerful tool for study of transgenes in cells, 
each transfection method has its disadvantages, can be harmful, toxic and 
affect nucleic acid delivery to cells depending on the cell type (Kim and 
Eberwine, 2010). These findings suggest that transfection itself might have 
caused damage to myoblasts and impaired their differentiation potential. 
Furthermore, stable transfection could not be considered for DMD human 
myoblasts, since this cell line was already transformed and selected with G418 
during the immortalisation procedure. In addition, DMD human cells had only 
extended lifespan and may not have survived during the long procedure of 
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stable transfection. It was concluded that transfection of myoblasts using 
plasmid constructs, either transient or stable, was difficult to achieve and that a 
different strategy was necessary to obtain localisation data on the constructs in 
cell culture. 
 
To address the low transfection capability of the constructs, lentiviral vectors 
were used to explore their feasibility to efficiently introducing DNA constructs 
into myoblasts. Several studies have shown that viral vectors increase 
transfection in a variety of cells and tissues (Odom et al., 2007; Macsai et al., 
2012; Sun et al., 2012). Lentiviral vectors were chosen since these vectors have 
a large packaging capacity and are suitable for the large constructs generated 
in this work. In addition, lentivirus can infect both dividing and non-dividing cells, 
independently of their proliferation status (Follenzi and Naldini, 2002), 
suggesting that differentiated myotubes could be used for transduction in future 
functional assays to circumvent the low differentiation potential of myoblasts 
after transfection.    
 
A pilot study with viral transduction by cloning two of the constructs into lentiviral 
vectors was initiated. Upon transduction a rapid uptake of GFP control in HEK-
293T and transduction of the same transgene in myoblasts after 48 hours was 
observed. The immunofluorescence results of dystrophin expression in 
myoblasts showed this method to be successful and have potential for future in 
vitro experiments. However, the expression showed not only subsarcolemmal 
but also cytoplasmic localisation of dystrophin. Studies have shown that 
dystrophin in skeletal muscle is detected in the cytoplasm at early stages which 
during maturation increasingly localises to the sarcolemma (Kobayashi et al., 
1995). It has also been reported that during transfection the majority of DNA is 
introduced to the nucleus during mitosis and reformation of nuclear membrane 
(Campeau et al., 2001). This could explain the incomplete migration of 
dystrophin to the sarcolemma (Figure 4.16) due to the short period between 
transduction and analysis. The preliminary viral work described in this chapter 
provides a basis for the efficient transfer of large plasmids into human 
myoblasts to facilitate in vitro studies as a precursor to using these constructs in 
gene therapy experiments. 
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Future work will involve differentiation and transduction of DMD human 
myotubes with lentivirus carrying mini-dystrophin constructs and evaluation of 
their ability to restore membrane stability by measuring CK release and cell 
survival after osmotic shock treatment of transfected cells. If successful, this 
experiment could be used as a standard method for in vitro characterisation of 
future micro- and mini-dystrophin constructs. 
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Chapter 5 Expression of mini-dystrophin constructs in 
mdx mouse muscle 
 
5.1 Introduction 
 
Viral vector mediated gene delivery as a therapy for Duchenne muscular 
dystrophy requires functional mini-genes that can express and restore 
dystrophin in dystrophic muscle. However, the functional nature of different 
mini-genes remains to be defined. DMD is primarily caused by the loss of 
dystrophin protein (Hoffman et al., 1987a) which forms a link between 
cytoskeletal elements and extracellular matrix that protects muscle from 
contraction-induced injury (Ervasti and Sonnemann, 2008). Clearly, there is a 
direct relationship between dystrophin expression and disease severity in DMD 
(Nicholson et al., 1993). Most DMD patients show very little or no dystrophin 
protein in muscle fibres, whereas patients with BMD have reduced but partially 
functional dystrophin (Monaco et al., 1988; Hrdlicka et al., 2002). Clinical 
correlations in DMD and BMD patients indicate that internally deleted dystrophin 
has the potential to convey clinical benefits in DMD patients (Anthony et al., 
2011). In order to determine the functionality of truncated dystrophin constructs 
and their therapeutic potential to ameliorate disease severity in DMD, it is 
essential to characterise the consequences of internal deletions in animal 
models. The mdx mouse is the most frequently used animal models for DMD 
preclinical studies. A wide range of physiological and histological parameters 
have been used to assess the therapeutic interventions in mdx mouse 
(Willmann et al., 2012). For characterisation of the mini-dystrophins that were 
generated in this study, direct injection of plasmid DNA in adult mdx muscles 
followed by electroporation was used (Molnar et al., 2004). This chapter will 
focus particularly on the effect of construct expression in the tibialis anterior (TA) 
muscle of dystrophic mdx mice and aims to quantify the outcome with respect to 
pathology-relevant morphometric parameters including expression intensity, 
number of internal nuclei, muscle fibre diameter and size distribution. A detailed 
comparison of cryosectioned injected muscles was performed to explore the 
extent to which different parts of the dystrophin molecule are required or 
dispensable for function. This initial assessment will determine the overall 
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suitability of different constructs for cloning into lentiviral vectors and gene 
delivery to skeletal muscle. 
 
5.2 Aims 
 
To examine whether the mini-dystrophins are able to restore dystrophin 
expression after injection and electroporation of naked plasmids into mdx 
mouse muscles.  
 
To test whether mini-dystrophin expression would lead to recruitment of other 
DGC proteins such as the sarcoglycan complex to the sarcolemma. 
 
To assess the relative expression levels of different constructs in the context of 
dystrophic muscle. 
 
To evaluate the relative change in morphometric parameters of fibres 
transfected with different constructs including measurement of muscle fibre 
diameter and analysis of the size distribution. 
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5.3 Intramuscular injection and electroporation of mini-dystrophins into 
mdx mouse muscle 
 
To evaluate the functional characteristics of the mini-dystrophin constructs in 
vivo, the newly generated mini-dystrophin plasmids were injected and 
immediately electroporated into 12 week old TA muscle of mdx mice (n=8) 
(Figure 5.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C D 
A B 
Figure 5.1 Transcutaneous electroporation of skeletal muscle 
after injection of mini-dystrophin constructs   
(A) BTX ECM 830 electroporator used for electroporation with 8x 20 
ms pulses of 200 V/cm at intervals of 250 ms applied through two 1.5 
cm2 stainless steel plate electrodes. (B) In vivo electroporation through 
the skin after the injection of 50 µg of plasmid into the TA muscle. (C) 
Dissection procedure of injected and electroporated TA muscle of mdx 
mouse 14 days post transfection. (D) Harvested TA muscle for 
embedding and cryosectioning. 
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5.4 Analysis of mini-dystrophin expression and localisation in 
electroporated mdx muscles 
 
In these experiments 14 week old male wild type and untreated male mdx mice 
were used as controls (n=4 in each group). Dystrophin expression after 
electroporation of mini-dystrophin constructs was detected on serial sections 
using the NCL-DYS2 dystrophin antibody and compared to control mice.  
In wild type mice, there was an equal and uniform dystrophin expression in 
nearly all fibres (Figure 5.2). In order to calculate the number of revertant fibres, 
a systematic study of the revertant fibres in age-matched mdx mice was 
required to estimate the number of such fibres in muscles transfected with mini-
dystrophin constructs. This was because the dystrophin antibody (NCL-DYS2) 
that were used for dystrophin detection, recognised revertant fibres. Revertant 
fibres occur in 50% of DMD patients (Hoffman et al., 1990; Nicholson et al., 
1990; Fanin et al., 1992) as well as in the mdx mouse (Koenig et al., 1987; 
Grounds et al., 2008) and in the golden retriever dystrophic dog (Schatzberg et 
al., 1998). Revertant fibres are thought to be the result of spontaneous 
alternative splicing or exon skipping leading to expression of internally deleted 
smaller isoforms (Schatzberg et al., 1998). A clear interpretation of these pre-
existing fibres in treated muscle is required for dystrophin quantification and 
evaluation of the efficiency of therapeutic interventions. The number of revertant 
fibres in mdx TA muscles varied between 2 and 12 per section.  All four 
constructs that were used for the experiment produced dystrophin and were 
localised at the muscle fibre membrane, confirming the expression of mini-
dystrophins at the correct cellular localisation in mdx muscle (Figure 5.2). 
However the number of transfected myofibres ranged from 35-198 per section 
(Figure 5.3). The use of dual immunohistochemistry staining for dystrophin and 
laminin allowed dystrophin quantification relative to laminin, providing an 
internal control across different samples and experiments (Figure 5.3). To 
assess expression levels of mini-dystrophins, the number of dystrophin positive 
fibres was first counted. Between 7 and 8 TA muscles were analysed in each 
group and 1560-2580 muscle fibres per section were used to calculate the 
percentage of positive fibres relative to the entire muscle cross section  
(Figure 5.3; Table 5.1).  
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Figure 5.2 Dystrophin expression in mdx mouse muscles electroporated with mini-dystrophin constructs  
Typical immunofluorescence images of mouse muscle sections stained with anti-dystrophin mouse antibody NCL-DYS2 and direct 
labelling using Zenon Alexa Fluor 488. (A) Control C57BL/10; (B, C) non-electroporated mdx mouse muscle; (D, E, F) mdx mouse 
muscle electroporated with construct C1/∆R3-R13; (G, H, I) mdx mouse muscle electroporated with construct C2/∆H2-R19; (J, K, L) 
mdx mouse muscle electroporated with construct C7/∆H2-R23; (M, N, O); mdx mouse muscle electroporated with construct C9/∆R1-
R10. 20x magnification; scale bar 50 µm. 
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Figure 5.3 Statistical analysis of dystrophin positive fibres 
(A) Representative immunostaining image for dystrophin (in green) and laminin (in red). 
(B, C) Screenshot images of each step in the ImageJ analysis process, green channel for 
dystrophin and red channel for laminin. (D) The median percentage of positive fibres in 
each section (n=8); box represents the inter-quartile range and the tick marks the 
minimum and maximum values. (E) Cross-comparison of the positive fibre distribution 
using an ANOVA multiple comparison analysis. ****P< 0.0001; ***P< 0.001; **P< 0.01;  
*P< 0.05; not significant (ns). 20x magnification; scale bar 50 µm. 
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Dys + fibres 
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5.5 Analysis of dystrophin expression intensity 
 
In view of relatively low percentage of dystrophin positive fibres, it was not 
possible to perform a semi-quantitative analysis using Western blot to quantify 
the amount of dystrophin in electroporated muscles. In order to get an idea of 
how much dystrophin was expressed, the intensity of immunofluorescence 
staining on cryosections was measured. Images of muscle sections were 
opened in ImageJ, the channels split into green, stained for dystrophin and red, 
stained for laminin as a control. Background was reduced (Figure 5.4) and the 
green channel was used to identify dystrophin positive fibres. A threshold was 
selected to create a mask, in order to measure the region of the selected area 
(dystrophin expressing fibres). The red channel was used to measure the 
intensity of the same selected region to normalise the dystrophin value relative 
to laminin which should be constant between fibres and experiments. Several 
parameters were measured for each section including area, min/max intensity, 
mean, standard deviation and median. The median value was chosen to reflect 
the average dystrophin expression intensity per selection. For comparison of 
sections with different numbers of dystrophin positive fibres and consideration 
of unavoidable technical variations (antibody batches, sample preparation and  
microscope light properties) in staining intensities, a ratio of dystrophin and 
laminin staining was calculated (median intensity green divided by median 
intensity red) and presented in box plots (Figure 5.5). No significant differences 
between constructs, or between constructs and revertant fibres, or positive 
controls was observed. However, the range of dystrophin expression from the 
constructs showed wider variability. 
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Figure 5.4 Semi-quantitative measurement of dystrophin 
expression intensity 
(A) Representative immunofluorescence image of an untreated 
muscle with a revertant fibre opened in ImageJ analysis process.  
(B) The image is split into channels for dystrophin and (C) for laminin 
staining. (D, E) Background staining is reduced and subtracted for 
both channels. (F) The green channel is used to identify dystrophin 
positive fibre and a threshold is adjusted to create a mask. (G) The 
red channel is used to measure the intensity of the same selected 
area as the normalisation value. (H) Screenshot of the parameters 
that were taken for calculation of the intensity. 
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Figure 5.5 Statistical 
analysis of dystrophin 
expression intensity 
(A) Ratios of median intensity 
values (n=8) of dystrophin 
normalised to laminin.  
(B) Cross-comparison of the 
median intensity ratios of 
dystrophin and laminin, using 
an ANOVA multiple 
comparison analysis. (C) 
Ratios of median RawIntDen 
values of dystrophin 
normalised to laminin. (D) 
ANOVA multiple comparison of 
median RawIntDen ratios of 
dystrophin and laminin. ****P< 
0.0001; ***P< 0.001; **P< 0.01; 
*P< 0.05; not significant (ns).  
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5.6 Correlation between dystrophin expression, internal nuclei and 
myofibre size 
 
One of the pathologic changes in dystrophic muscle is ongoing cycles of 
degeneration and regeneration of muscle fibres. This process is characterised 
by an increased rate of internally located nuclei and an abnormal distribution of 
myofibre size, with a large proportion of small regenerating fibres (Carnwath 
and Shotton, 1987; Coulton et al., 1988; Pastoret and Sebille, 1995). A 
decreased number of internal nuclei and a mitigation of the heterogeneity in 
myofibre size are considered as improvements in dystrophic muscle and 
proposed as standard targets for experimental readouts (Cavalcanti et al., 
2011). In order to compare the relative functionality of different mini-dystrophin 
constructs on these outcome measures, quantitative assessment of muscle 
fibre size variation and distribution of internal nuclei in mini-dystrophin 
expressing fibres was undertaken. Different protocols have been developed  
and published for standardised assessment of functional and histological 
parameters (Briguet et al., 2004; Grounds et al., 2008; Taylor et al., 2012). In 
this study, procedures in accordance with Treat-NMD protocols (Willmann et al., 
2012), available at http://www.treat-nmd.eu/research/preclinical/dmd-sops/ with 
some modifications such as the choice and use of the software were adapted. 
 
5.6.1 Evaluation of internal nuclei 
 
For determination of the proportion of internal nuclei in control muscles, 
overlapping images of H&E stained muscle at 10x magnification were acquired 
and assembled into one picture, allowing the analysis of 1800-4400 muscle 
fibres (Figure 5.6). Fibres containing internal nuclei were counted manually and 
expressed as the percentage of the nuclei in control muscles (Table 5.1).
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Figure 5.6 Analysis of internalised nuclei in muscle fibres 
Images of H&E stained TA muscle sections for evaluation of the 
proportion of internal nuclei using ImageJ. Overlapping images from 
the entire muscle section are analysed. The fibres containing 
internally located nuclei are labelled as 8, those without internal 
nuclei as 3 (arbitary numbers). (A) Wild type control C57BL/10;   
(B) mdx control.  
A 
C57BL/10 
B 
mdx 
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Proportions of internally located nuclei in muscle fibres expressing mini-
dystrophins were compared to those of dystrophin negative fibres on the same 
muscle sections (Figure 5.7). Dual immunostaining for dystrophin and laminin 
was also performed to distinguish between positive and negative fibres. At least 
50 images for each construct were analysed. Each image encompassed 
between 25 and 120 fibres and each analysis used a total of between 1800 and 
4400 muscle fibres. The number of internal nuclei in mini-dystrophin positive 
mdx muscles was reduced compared to untreated mdx muscles. It was also 
observed that dystrophin negative fibres with peripheral nuclei occurred more 
frequently where surrounded by dystrophin positive fibres compared with those 
ones without direct contact with dystrophin positive fibres. Dystrophin negative 
fibres in the injected muscles also showed a reduction in internal nuclei in 
comparison to uninjected mdx. However, dystrophin positive fibres showed 
considerably less internal nuclei compared to dystrophin negative fibres (Figure 
5.8A). In C1/∆R3-R13 the fibres with internal nuclei was reduced to ~48% (55% 
in negative fibres), in C2/∆H2-R19 to ~57% (68% in negative fibres), in C7/∆H2-
R23 to ~49% (49% in negative fibres) and in C9/∆R1-R10 to 51% (58% in 
negative fibres) (Table 5.1).  
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strain construct dystrophin 
positive fibres 
(%) 
internal nuclei in 
dystrophin 
positive fibres 
(%) 
internal nuclei in 
dystrophin 
negative fibres 
(%) 
     
BL/10 (n=4) ---- 100 1.7 N/A 
mdx (n=4) ---- 0.7 79 85 
mdx (n=8) C1 4.3 48 56 
mdx (n=8) C2 3.5 57 68 
mdx (n=8) C7 6.1 49 49 
mdx (n=8) C9 2.9 51 58 
Table 5.1 Median percentage of dystrophin positive fibres and proportion 
of internal nuclei in electroporated muscles 
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Figure 5.7 Determination of internal nuclei in mini-dystrophin 
expressing fibres 
Dual immunostaining of dystrophin and laminin showing the localisation 
of nuclei in fibres that show dystrophin expression and localisation and 
those without sarcolemmal dystrophin expression on the sections of 
electroporated muscle. (A) The merged image of dystrophin, laminin and 
nuclear staining (green for dystrophin, red for laminin and blue for nuclei 
stained with DAPI). (B) Image opened in ImageJ; (C, D) different 
channels are split to distinguish between positive and negative fibres. 
Fibres with internal nuclei are highlighted with yellow (8) and those 
without internal nuclei with green (3) (arbitary numbers). (E, F) The 
original channels are used for confirmation. 20x magnification; scale bar 
50 µm. 
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Figure 5.8 Distribution of internal nuclei in mini-dystrophin positive 
electroporated fibres  
(A) Each dot represents the percentage of internal nuclei in muscle fibres 
from one image containing 25-120 fibres. (B) Statistical analysis of 
internalised nuclei distribution by ANOVA. ****P< 0.0001; ***P< 0.001; 
**P< 0.01; *P< 0.05; not significant (ns).  
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5.6.2 Quantitative determination of myofibre size 
 
To provide baseline values for the quantitative measurement of muscle fibre 
size and variability in mini-dystrophin expressing muscle fibres the muscle fibre 
size distribution of C57BL/10 wild type mice and mdx TA muscles was 
assessed. 1250 muscle fibres were measured for wild type and mdx control and 
between 2300 and 4400 muscle fibres for mini-dystrophin electroporated 
muscles. For evaluation of myofibre size, sections were stained for dystrophin 
and laminin (section 2.6.5). Pixel values were converted into µm2 using a 
scaling factor determined from the microscope before measurement. Using 
ImageJ different channels were split and the boundaries of individual muscle 
fibres were identified and selected semi-automatically then manually checked. 
After identification of regions of interest two geometric parameters for muscle 
fibre size determination were calculated including the entire cross-sectional 
area and the minimal Feret’s diameter. Linear correlation performed with the 
paired observations indicated strong relationship between the two parameters 
(Figure 5.9). Therefore only one parameter (area) was used for quantification 
and statistical analysis.  
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Area BL/10 vs. mdx (n=4) Area BL/10 (n=4)  Area mdx (n=4) 
C D E 
Figure 5.9 Correlation between 
muscle fibre geometric parameters  
Geometric parameters of muscle fibre 
size, (A) the cross-sectional area and 
(B) minimal Feret’s diameter. (C-E) 
Plots of muscle cross-sectional area 
against minimal Feret’s diameter 
showing positive correlation between 
these variables in wild type; (C) wild 
type (R2 = 0.8146); (D) non- 
electroporated mdx (R2 = 0.9489);  
(E)  both combined, C57BL/10 in blue 
and mdx in red. 
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Analysis of muscle fibre morphometrics showed an abnormal distribution and 
higher variability of mdx muscle fibre size distribution when compared to wild 
type mouse muscle. In mini-dystrophin expressing fibres a high number of both 
small and extremely large fibres was found, as observed in untreated mdx fibres. 
However the median values of transfected fibres showed a tendency towards 
wild type values when compared to mdx (Figure 5.9; Figure 5.10). The median 
values for the wild type muscles showed a range between 218 and 8174 µm2, in 
the mdx muscle between 3 and 9336 µm2, in C1/∆R3-R13 transfected muscles 
between 26 and 13827 µm2, in C2/∆H2-R19 between 23 and 8553 µm2, in 
C7/∆H2-R23 between 21 and 8200 µm2 and in C9/∆R1-R10 between 35 and 
8937 µm2 (Table 5.2). These results suggest that the mini-dystrophin 
expression leads to improvement of morphological parameters which 
characterise the pathology of mdx dystrophic muscle. Fibre size distribution was 
illustrated as percentage of muscle fibre cross-sectional area in histograms 
(Figure 5.11). Muscle fibres were grouped in 100 µm
2 
intervals by relative 
frequency. Mdx cross-sectional area showed variable proportions of small and 
large muscle fibres with a shift towards the smaller fibre sizes compared to wild 
type C57BL/10. The electroporated muscles with mini-dystrophin constructs 
seemed to retain the shift to smaller fibres as in untreated mdx, but also showed 
larger fibres within fibre size range in control muscle C57BL/10. 
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Figure 5.10 Morphometric quantification of 
muscle fibre size and statistical analysis of 
transfected fibres  
Illustration of muscle fibre size measurement in (A) 
wild type muscle C57BL/10, (B) mdx and (C) 
electroporated muscle. 20x magnification; scale bar 
50 µm. (D) Graphic presentation of the muscle fiber 
size distribution. (E) Size distribution data assessed 
for statistical significance using ANOVA multiple 
comparison between mini-dystrophin electroporated 
mdx and wild type mouse muscle. ****P< 0.0001; 
***P< 0.001; **P< 0.01; *P< 0.05; not significant (ns).  
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Area                                            BL/10 Mdx C1 
neg 
C1 
pos 
C2 
neg 
C2 
pos 
C7 
neg 
C7 
pos 
C9 
neg 
C9 
pos 
Vector 
only 
Number of values 1250 1250 2328 511 2523 417 3292 813 1775 458 312 
            
Median 1467 608 1359 1982 1160 1568 1238 1631 1327 1975 465 
Minimum 218 3 5 26 7 23 18 21 14 35 2 
25% Percentile 1036 238 579 1065 506 842 590 765 588 931 84 
75% Percentile 2209 1150 2488 3508 2037 2900 2105 2839 2403 3508 1124 
Maximum 8174 9336 12178 13827 10428 8553 13268 8200 11716 8937 4482 
            
Mean 1663 934 1790 2486 1470 2019 1558 1972 1712 2403 753 
Standard deviation 813 1103 1608 1991 1294 1619 1344 1555 1498 1847 827 
Table 5.2 Descriptive statistics of muscle fibre size distribution (area)  
This table shows the values of the cross-sectional area measurements. All values are given in µm2. 
Measurements are performed in dystrophin positive as well as in dystrophin negative fibres from mini-
dystrophin electroporated mouse muscles.  
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Table 5.3 Descriptive statistics of muscle fibre size distribution (minimal Feret) 
This table shows the values of the cross-sectional minimal Feret’s diameter. All values are given in µm. 
Measurements were performed in dystrophin positive as well as in dystrophin negative fibres from mini-
dystrophin electroporated mouse muscles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Minimal Feret                                            BL/10  Mdx C1
neg 
C1 
pos 
C2 
neg 
C2 
pos 
C7 
neg 
C7 
pos 
C9 
neg 
C9 
pos 
Vector 
only 
Number of values 1250 1250 2328 511 2523 417 3292 813 1775 458 312 
            
Median 38 24 35 32 35 34 34 38 35 42 19 
Minimum 14 0.7 1.5 5 0.3 3.5 3.8 5 4 7 0.3 
25% Percentile 32 15 23 30 21 26 23 26 23 27 6 
75% Percentile 46 33 48 56 43 49 44 49 47 56 32 
Maximum 87 107 335 337 106 94 125 87 335 337 65 
            
Mean 40 26 37 44 33 39 36 38 36 43 21 
Standard deviation 11 15 19 23 17 18 15 17 19 24 16 
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Figure 5.11 Frequency distribution of muscle fibre size using cross-sectional area 
Muscle fibre cross-sectional areas in 100 µm2 intervals by relative frequency. (A) Muscle fibre size 
distribution of mdx (red) and BL/10 wild type (blue). (B-I) Mdx (red), BL/10 (blue) and electroporated 
fibres (green) with different constructs as labelled on individual histograms.  
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5.7 Effect of mini-dystrophin constructs on DGC proteins 
 
5.7.1 Gamma-sarcoglycan restoration 
 
In the absence of dystrophin, DGC proteins are reduced and therefore 
restoration of these proteins is a requirement for a mini-dystrophin to be 
considered functional (Turk et al., 2005). In order to examine the localisation of 
the mini-dystrophin constructs and their effect on sarcoglycan complex 
restoration, dual immunofluorescence staining was used with antibodies 
directed against mini-dystrophin C-terminus and γ-sarcoglycan. In wild type 
fibres, dystrophin and γ-sarcoglycan were detected at the correct location in all 
fibres, whereas in mdx muscles both antibodies were only found in the myofibre 
membrane of revertant fibres. All four constructs showed co-localisation of  
γ-sarcoglycan at the sarcolemma of dystrophin expressing fibres in muscles 
(Figure 5.12). These data suggest that the mini-dystrophins are capable of 
restoring the link between dystrophin and the DGC. 
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Figure 5.12 Dystrophin and γ-sarcoglycan expression in 
electroporated muscle  
Immunofluorescence analysis of TA muscles from mice electroporated with 
mini-dystrophins compared to control sections of wild type muscles and 
untreated mdx. Samples were stained for dystrophin with mouse anti-
dystrophin NCL-DYS2 and direct labelling with Zenon Alexa Fluor 488 
(green) and for γ-sarcoglycan with rabbit anti-γ-sarcoglycan and rat anti-
rabbit (red). 20x magnification; scale bar 50 µm. 
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5.7.2 nNOS stabilisation at the sarcolemma 
 
Studies have shown that dystrophin rod repeats 16 and 17 are capable of 
stabilising nNOS at the sarcolemma (Lai et al., 2009a; Lai et al., 2013). The 
following experiment was performed to test the hypothesis that mini-dystrophin 
molecules containing the rod domain nNOS-binding site (C1/∆R3-R13 and 
C9/∆R1-R10) would enhance nNOS localisation to the sarcolemma, compared 
to the mini-dystrophin constructs lacking these regions (C2/∆H2-R19 and  
C7/∆H2-R23). Dual immunostaining on muscle sections with antibodies directed 
against the dystrophin C-terminus and nNOS was performed. Both proteins 
were expressed at the muscle fibre membrane in wild type control and in 
revertant fibres of mdx sections. The majority of fibres in electroporated 
muscles expressing mini-dystrophins C1/∆R3-R13 and C9/∆R1-R10 increased 
nNOS expression at the sarcolemma whereas fibres of muscles electroporated 
with C2/∆H2-R19 and C7/∆H2-R23 were negative for nNOS staining (Figure 
5.13).  
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Figure 5.13 Dystrophin and nNOS expression in electroporated muscle 
Representative images of dystrophin and nNOS co-expression in muscle  
electroporated with different constructs. TA muscle sections were stained 
with mouse anti-dystrophin NCL-DYS2 directed against the dystrophin C-
terminus and direct labelling with Zenon Alexa Fluor 488 (green) and against 
nNOS with rabbit anti-nNOS and rat anti-rabbit Alexa Fluor 594 (red), 
predominantly observed in C1/∆R3-R13 and C9/∆R1-R10 carrying rod 
domain nNOS-binding site. Both proteins were expressed at the muscle fibre 
membrane in wild type control and in revertant fibres of mdx sections. 20x 
magnification; scale bar 50 µm. 
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5.8 Discussion  
 
With several potential therapeutic approaches aiming at dystrophin restoration 
and finding the best treatment option for DMD patients, there is a continuous 
need for optimisation and standardisation of the current research strategies. In 
this chapter functional analysis of the mini-dystrophin constructs was conducted 
in order to test their ability to express dystrophin and restore dystrophin- 
associated proteins such as sarcoglycans to the sarcolemma. 
 
Four mini-dystrophin constructs were successfully tested and expressed in 
dystrophic mdx muscle using injection and electroporation. Although not all 
fibres displayed dystrophin expression (as expected for this method), the  
mini-dystrophin expression resulted in some morphological benefits. Studies on 
dystrophin restoration therapies suggest a certain level (30%) of induced 
dystrophin expression is required to achieve clinical benefits (Neri et al., 2007). 
However recent studies describe that even low levels of dystrophin expression 
can lead to slower disease progression in the dko mouse model (Li et al., 2010a; 
van Putten et al., 2011; van Putten et al., 2013). It has been shown that mice 
that expressed <4% of wild type dystrophin levels had prolonged life span and 
improved functional performance. Dystrophin levels between 4-15% improved 
functional performance and survival (van Putten et al., 2011). One reason for 
the low level of dystrophin could be due to the fact that naked plasmid delivery 
using local injection results in low uptake of plasmid, since the most injected 
plasmid remains extracellular (Cappelletti et al., 2003). Although, 
electroporation-associated gene transfer was a useful tool for studying 
histopathological changes after mini-dystrophin expression in mdx muscle, the 
method displayed significant discrepancies between experiments even if the 
same conditions were applied using the same plasmid DNA. For instance, the 
number of positive fibres or the number of replicates needed to achieve 
acceptable results showed enormous variability. Furthermore the number of 
positive fibres varied considerably in muscles expressing different constructs, 
possibly depending on their size. C7/∆H2-R23, the smallest construct showed 
the highest number of transfected fibres and the lowest repeated attempts of 
injection and electroporation, whereas the largest construct C9/∆R1-R10 
showed sufficient results only through repeated experiments. These results are 
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consistent with those observed in studies on myoblasts which have shown that 
size of constructs significantly influences the transfection efficiency and reduces 
the transgene expression in vitro (Campeau et al., 2001; Yin et al., 2005). A 
different group that investigated factors affecting plasmid-based gene transfer 
combined with electroporation in vivo, have also provided data on low 
transfection ability of large plasmids of ~9 kb when compared with smaller 
constructs of ~3.5 kb (Molnar et al., 2004). Nonetheless, all examined sections 
showed significant levels of expression compared to untreated mdx and the 
number of mini-dystrophin expressing fibres was substantially greater than 
revertant fibres. 
 
Confirmed expression levels of C7/∆H2-R23 were also consistent with high 
level dystrophin expression in HeLa cells as shown in chapter 3, indicating that 
the lack of 3’ UTR does not affect the mini-dystrophin expression in vivo. This is 
an important finding, since removal of the 3’ UTR from larger constructs would 
reduce the size without affecting gene expression which yet again may improve 
dystrophin expression for future studies.  
 
Most studies consider internal nucleation as an endpoint to evaluate correlation 
between dystrophin expression and pathological improvements. In this study, 
morphological analysis on numbers of internal nuclei showed mdx mice were 
clearly distinguishable from wild type (79% compared to 1.7%). Despite the 
invasive electroporation method and massive muscle damage as a 
consequence of application of electric pulses to the injected muscles, mini-
dystrophin expressing fibres showed reduced numbers of internal nuclei, while 
dystrophin negative fibres displayed a higher percentage of internally located 
nuclei, indicating that this feature of dystrophic pathology was decreased in 
electroporated muscles, possibly by fewer cycles of degeneration and 
regeneration. Another reason could be due to incomplete detection of low levels 
of dystrophin in treated muscles or loss of expression in fibres that might have 
triggered this protective effect. These data suggest that positive fibres may 
provide additional stability for negative fibres and protect muscle against 
myofibre degeneration and regeneration assuming that internal nucleation is a 
measure of past regenerative activity. Statistical analysis showed that all 
constructs were significantly different from untreated mdx (P< 0.0001) but also 
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from wild type control (P< 0.0001), suggesting that they had almost the same 
effect as in wild type using internal nuclei as an indicator for dystrophic 
pathology, yet far from the values observed in the wild type control. Since the 
onset of the dystrophic changes in mdx muscle starts at ~3 weeks age 
(Grounds et al., 2008), it would probably be more favourable to start the 
treatment in younger mice to assess the pathological changes  and the efficacy 
of treatment, before the onset of degenerative and regenerative cycles.  
 
Dystrophic muscle is marked by prevalence of small fibres in the course of the 
disease (Massa et al., 1997). Animals in treated groups showed to some extent 
an increase in muscle fibre size compared to untreated mdx with a tendency 
toward the size range observed in wild type controls. Morphometric analyses of 
muscles in different groups suggest that C7/∆H2-R23 had a more pronounced 
effect on the myofibre diameter. Remarkably, there was an increase in myofibre 
size of some electroporated fibres of the treated groups in excess of that 
observed in wild type and mdx controls, perhaps manifesting muscle fibre 
hypertrophy as a side effect of electroporation. In wild type the median value of 
myofibres was 1467/µm2, a value that was almost double that in mdx animals 
which showed a cross-sectional area of 608/µm2 (Figure 5.10; Figure 5.11). In 
addition muscle fibre measurements per unit area demonstrated a reduction in 
the number of small fibres in all treated groups compared to mdx animals, 
reflecting a decrease in muscle fibre degeneration and fewer smaller myofibres, 
probably representing regenerating fibres (Table 5.2). Muscle fibre size in 
muscles electroporated with empty vector revealed smaller fibres compared to 
untreated mdx indicating that the electroporation had negative consequences in 
the absence of dystrophin delivery (Figure 5.9), suggesting that restoration of 
fibre sizes in the positive fibres was associated with expression of mini-
dystrophins. 
 
As for internal nuclei, muscle fibre size of electroporated muscles displayed 
significant differences when compared to untreated mdx (P< 0.0001), however 
comparing the P-values with the wild type control, variable levels of  
significance were observed (C1/∆R3-R13, P< 0.05; C9/∆R1-R10, P< 0.01). 
Only constructs C2/∆H2-R19 and C7/∆H2-R23 showed no significance 
compared to fibre size range of normal control, suggesting that these construct 
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may have more prominent effects on muscle fibre size, unless this occurrence 
is a coincidence. However this assumption is debatable, since these data are 
from only a few hundreds positive fibres, which may not be enough for a 
credible and convincing assessment.  
 
Expression intensity measurements of mini-dystrophins on immunofluorescence 
cryosections with different constructs showed some differences when compared 
with one another, but these were not statistically significant from each other or 
from mdx revertant fibres. The ratios of median intensity values (dystrophin to 
laminin) (Figure 5.5A) were taken as the average amount of dystrophin within 
the selection, or as the sum of the grey values (RawIntDen) reflecting the total 
amount of dystrophin within the selection (Figure 5.5C), respectively. These 
measurements were also used in a different group to show the close 
relationship between both parameters (Taylor et al., 2012). The dystrophin 
expression amount in untreated mdx mice was significantly different, compared 
to wild type mice. Muscle sections of untreated mdx mice expressing revertant 
fibres were assessed as a separate group which clearly demonstrated that 
dystrophin expression in revertant fibres was similar to the wild type group. 
Dystrophin expression levels from different constructs displayed a high variance, 
however dystrophin expression was consistently higher than untreated mdx 
mice and in the range of values obtained in wild type controls. These variations 
could also be observed in other publications (Arechavala-Gomeza et al., 2010; 
Anthony et al., 2011; Taylor et al., 2012). Initially,  Arechavala-Gomeza et al. 
demonstrated a difference in dystrophin expression between DMD, BMD and 
female carriers by selection of ten random areas on a cryosection using the 
maximum value (at the sarcolemma) minus a minimum value (representing 
regions within the cytoplasm as background). A ratio was calculated using 
dystrophin levels on control sections. In addition, they used α-sarcoglycan, β-
dystroglycan and utrophin staining and measured the intensity of these proteins. 
In contrast to our work, no internal standard was used. To compare the 
expression intensity in sections of female carriers, they selected 100 regions of 
interest in strong and weak labelled fibres. All pixels within the selected region 
(dystrophin positive fibres) were measured to get values of dystrophin 
expression in areas where dystrophin at different levels was expressed. The 
same procedure for intensity measurement was used by Anthony et al. for 
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quantitative assessment of dystrophin levels in BMD patients that were grouped 
by deletions. In addition they used Western blot analysis in BMD patients with 
different dystrophin mutations and found comparable expression levels using 
both techniques. Expression intensity values were quantified in control muscles 
and normalised to β-spectrin expression (Anthony et al., 2011). Taylor et al. 
used a similar method as that in our study using spectrin and dystrophin co-
staining as an internal control. As in our study, they also used a mask for 
identification of regions of interest with the difference that they selected the 
entire section. The use of immunofluorescence intensity measurements, may 
help to understand the relationship between low dystrophin expression levels 
and clinical benefit in gene therapy strategies, however whether dystrophin 
expression just over the lowest expression ranges correlates to improvement in 
muscle function remains to be elucidated (Taylor et al., 2012). Therefore, 
immunofluorescence intensity on cryosections of skeletal muscle for dystrophin 
quantification should be approached with caution, since the method is at best 
only semi-quantitative and should not be used as an absolute outcome measure 
for gene therapy experiments and diagnostic procedures (Taylor et al., 2012). 
 
In addition to histopathological assessment, the ability of mini-dystrophins to 
restore other members of DGC to the sarcolemma was examined. Our data 
provided evidence for γ-sarcoglycan restoration in treated mice using different 
mini-dystrophin constructs. γ-sarcoglycan co-expression at the muscle fibre 
membrane was observed in almost all fibres that were positive for dystrophin 
which remained consistent throughout repeated experiments using different 
constructs indicating that the mini-dystrophins are equally capable of interacting 
with other muscle proteins and restore function of the DGC. It is known that 
dystrophin absence in the dystrophic muscles leads to abnormal localisation 
and reduced levels of several other DGC proteins at the sarcolemma (Turk et 
al., 2005). Immunohistochemistry on sarcoglycans is being used as an standard 
outcome measure in a variety of DMD preclinical studies in animal models as 
well as a diagnostic marker in clinical trials (Cirak et al., 2011; Cirak et al., 2012). 
Recruitment of sarcoglycan subunits is considered as evidence for DGC 
restoration. However, one should bear in mind that DGC restoration is not 
necessarily an indication for dystrophin functionality, since studies on transgenic 
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Dp71 expressing mice have been shown to result in DGC restoration but fails to 
prevent muscle dystrophy (Cox et al., 1994; Greenberg et al., 1994).  
 
Immunohistochemistry on nNOS resulted in nNOS restoration and the ability of 
two constructs to restore nNOS to the sarcolemma. In previous studies, it was 
thought that the dystrophin C-terminal domain is responsible for nNOS 
expression at the sarcolemma (Brenman et al., 1996; Tochio et al., 1999; 
Adams et al., 2001), suggesting that truncated versions of dystrophin with an 
intact C-terminal domain should restore sarcolemmal nNOS expression. 
However none of the miniaturised dystrophins with large internal rod domain 
deletions that were used in experimental studies seemed to be able to recruit 
nNOS expression to the sarcolemma (Chao et al., 1996; Crawford et al., 2000; 
Wells et al., 2003). It was hypothesised that the constructs C1/∆R3-R13 and 
C9/∆R1-R10 carrying the rod domain nNOS binding-site should recruit nNOS to 
the sarcolemma, while the constructs missing these regions were not supposed 
to display subcellular localisation of this protein in dystrophin positive fibres. 
This prediction was confirmed in repeated experiments, however nNOS 
expression was occasionally observed in fibres that were treated with 
constructs lacking this region, probably due to presence of revertant fibres. It 
has been suggested that the use of mdx52 knockout mouse could be 
considered as an alternative option to overcome this issue, since no revertant 
fibres are present in this strain, due to loss of other shorter isoforms (Araki et al., 
1997; Grounds et al., 2008). 
 
No correlation between nNOS restoration and any of the other parameters was 
found, since percentage of internal nuclei and increase in muscle fibre size 
were statistically equivalent using any of the constructs. It would be interesting 
to monitor nNOS expression in long-term studies and compare the expression 
pattern in different time points after injection to assess the effect of mini-
dystrophins on nNOS expression over a longer time period. Although C9/∆R1-
R10 nNOS expression was also confirmed by immunostaining, but this 
construct required multiple injection attempts, indicating that it was much more 
difficult to be stably expressed in vivo. In addition, the feasibility of 
accommodating this construct in a suitable viral vector might be more 
challenging due to its larger size of ~7.7 kb. The role of the ABD2 in this 
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construct has not been explored yet and future physiological studies may 
address the importance of this region.  
 
In the present study it was only possible to demonstrate expression and 
localisation of mini-dystrophins. A range of additional functional tests have been 
reported to monitor dystrophin restoration and assess the impact of 
interventions on the disease progression in the mdx mouse, including the 
degree of fibrotic, necrotic (Briguet et al., 2004) and leaky myofibres using dyes 
or proteins that can enter or exit muscle fibres through damaged sarcolemma 
(Straub et al., 1997), measurement of blood biomarkers such as muscle 
creatine kinase (Zatz et al., 1991), immunological testing (Yokota et al., 2006), 
whole body imaging (MRI) (Pasquesi et al., 2006), In vivo measurement of 
whole body function and muscle strength in mouse (van Putten et al., 2011; van 
Putten et al., 2012; van Putten et al., 2013; van Putten et al., 2014). However, 
each of these quantification methods would require a whole body administration 
of mini-dystrophins to be able to overcome the limitations of local injection and 
to circumvent the adverse effect of electroporation. Nevertheless, the use of 
electroporation as a screening tool has several advantages including large 
insert capacity, relative cost-effectiveness, lack of viral vector-mediated toxicity 
and the possibility for testing candidate genes before use of viral vectors. 
Furthermore, repeated administration is possible without concerns about 
immunological reaction, which is a major issue when using viral vectors 
(McMahon et al., 2001; Molnar et al., 2004).  
 
Another important factor is the choice of the most appropriate promoter which 
could sustain high transgene expression with long-term efficiency. It has been 
shown that use of the muscle specific desmin promoter produced significantly 
greater expression compared to other muscle specific promoters such as MCK 
(Talbot et al., 2010). 
 
Due to lack of physiological studies and low dystrophin expression it is too early 
to assess which construct is the optimal mini-dystrophin construct. Although 
morphological analyses on different constructs displayed some significant 
differences when they were compared to untreated mdx muscles, a major 
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divergence was not demonstrated when compared with one another. 
Undoubtedly, each construct has its advantages and disadvantages. 
  
Construct C1/∆R3-R13 has been designed to maintain the most functional part 
of the dystrophin including the rod domain nNOS-binding site and part of the 
ABD2 (repeats 14 and 15), while maintaining a size within the packaging 
capacity of lentiviral vectors. This construct represents a novel mini-dystrophin 
and could be the most favourable construct, since it restores both  
γ-sarcoglycan and nNOS expression, and showed also sarcolemmal 
localisation in DMD myoblasts.  
 
The C2/∆H2-R19 construct carries the major functional domain of dystrophin 
including the N-terminal actin-binding part, cysteine rich domain and C-terminal 
region. Repeats 16 and 17 were deleted to be able to create a useful 
comparison between this mini-gene and the constructs that carry this region. 
Moreover this construct resembles a Becker-like deletion from mildly affected 
BMD patients (England et al., 1990). Other groups have also developed and 
tested a similar construct using dual AAV vectors (Lai et al., 2005; Odom et al., 
2011) or generated transgenic mouse lines expressing this mini-gene, indicating 
full functionality of the transgene and overall improvement in phenotype (Harper 
et al., 2002; Banks et al., 2007). A major advantage of this construct is its 
smaller size (~6.0 kb) when compared to C1/∆R3-R13 and C9/ ∆R1-R10 in this 
study, keeping in mind that the nNOS-binding site is missing due to the large 
deletion in central rod domain. Taken together this construct could be used as a 
control to monitor the ability of the other constructs with a well-established mini-
dystrophin which also displays a mild Becker muscular dystrophy deletion.  
 
Construct C7/∆H2-R23 could be considered as a potential candidate for AAV-
mediated gene therapy. This construct appeared to be more advantageous in 
terms of higher expression levels in vitro and in vivo. However, since the 
construct is deleted for most of the rod domain, it will not restore nNOS to the 
sarcolemma. 
 
On the basis of these observations the construct C1/∆R3-R13 seems to be 
superior compared to other mini-dystrophins in this project, therefore this 
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construct is predicted to be the optimal mini-dystrophin construct at this stage. 
Future studies will use this mini-gene, alongside two other constructs C10/∆R3-
R13-∆CT and C11/∆R3-R13-∆CT-synt (recently generated; Table 3.1) to 
evaluate whether or not reduced size of this construct is beneficial. Apart from 
lentiviral vectors, the use of dual AAV vectors could be an alternative option for 
gene delivery of these mini-genes in dystrophic muscle. In a recent study, it has 
been shown that intravenous injection of dual AAV vectors expressing a mini-
dystrophin of ~6.0 kb resulted in 30-50% dystrophin positive fibres leading to 
improvement of histopathology and increased muscle force (Zhang et al., 2013). 
Many hurdles remain, such as wide spread delivery of the constructs, yet this 
study provided reliable data on some functional benefits of novel mini-
dystrophin constructs for preclinical studies. 
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Chapter 6 General discussion and future directions  
 
Since identification of the dystrophin protein and its molecular sequence, 
numerous genetic strategies have been developed showing encouraging results 
in animal models with potential to treat Duchenne muscular dystrophy patients. 
A variety of approaches have been moving from basic studies in animal models 
to early phase clinical trials and show great promise to defeat DMD; however 
none of these therapeutic options have reached the level of treatment and cure. 
Therefore, optimisation and refinement of the individual methods and ongoing 
research remains one of the most important efforts to achieve long-term 
therapeutic benefits.  
 
The work presented in this thesis has been conducted to contribute to DMD 
gene replacement therapy with the main focus on constructs designed to take 
the maximum advantage of the cloning capacity of lentiviral vectors. So far, 
most studies have been restricted to characterisation and study of smaller  
micro-dystrophin genes due to consideration of the limited packaging capacity 
of AAV vectors (<5 kb). Studying and characterisation of larger constructs that 
are as close as possible to the full-length dystrophin is useful for future gene 
replacement studies. 
 
Currently, several genetic therapeutic approaches are in development, aiming 
at dystrophin restoration, including stop codon readthrough, exon skipping and 
gene replacement therapy using truncated versions of dystrophin (Fairclough et 
al., 2013). Exon skipping using AONs is the most promising strategy for 
treatment of DMD and has shown great promise in preclinical studies. Most 
mutations found in DMD patients are frame-shifting deletions of one or several 
exons that alter the translational reading frame and therefore fail to express 
dystrophin in muscle (Monaco et al., 1988; Muntoni et al., 2003). Skipping of 
one or more exons by binding a short synthetic RNA sequence (AON) to block 
sequences promoting splicing results in a shorter but partially functional 
dystrophin (Nowak and Davies, 2004). Although this method is not applicable to 
all DMD patients due to the heterogeneity of DMD mutations and would need to 
be a personalised therapy, the majority of patients (~80%) would theoretically 
benefit from this treatment and skipping of exon 51 (currently in clinical trials) 
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could be applied to ~13% of DMD patients (Aartsma-Rus et al., 2009). 
Therapeutic efficacy of AONs has been demonstrated in various experimental 
studies in animal models including mdx and cxmd (canine X-linked muscular 
dystrophy) (Yokota et al., 2009; Aartsma-Rus et al., 2010; Tanganyika-de 
Winter et al., 2012; Yokota et al., 2012). However some of the recent clinical 
trials using AONs failed to demonstrate significant improvement in the 6-minute 
walk test (6MWT) outcome measure compared to placebo, while some studies 
reported a high level of dystrophin expression (Mendell et al., 2013; Flanigan et 
al., 2014). In addition, in the drisapersen trial low platelets and kidney toxicity 
was found in some patients (Flanigan et al., 2014). These results have raised 
doubts whether the 6MWT is a reliable outcome measure as a clinical endpoint 
and as to whether or not the clinical efficacy of treatments is directly linked with 
dystrophin expression (Lu et al., 2014). Nonetheless, the correlation between 
dystrophin expression and clinical condition cannot be ignored since the lack of 
dystrophin results in DMD and reduced expression to the milder BMD (Wilton et 
al., 2014). Extensive studies are required to optimise exon skipping strategy 
and demonstrate clinical benefits for DMD patients.  
 
Another approach for DMD gene therapy is delivery of a functional copy of 
dystrophin to dystrophic muscle (Chamberlain, 2002; Blankinship et al., 2006). 
Adeno-associated virus (AAV)-based vectors are the most commonly used 
vectors (Athanasopoulos et al., 2011) and have facilitated gene transfer of 
micro-dystrophins showing safe and long-term dystrophin expression with 
significant functional improvement in animal models. The potential advantage of 
gene replacement therapy over exon skipping is that the same treatment can 
theoretically be applied to all patients, irrespective of their mutation (Tremblay 
and Frederickson, 2011). Advantages of using rAAV-based vectors include their 
non-pathogenic nature (Sun et al., 2003; Okada and Takeda, 2013), their 
production at high titres (Wright, 2008) and long-term expression in animal 
models (Schultz and Chamberlain, 2008). However these vectors have several 
drawbacks including the inability to integrate into the host genome resulting in 
the lack of heritable characteristics that can be passed on and repopulate newly 
formed muscle (Chamberlain, 2002; Blankinship et al., 2006) and the small size 
of gene that can be inserted (<5 kb) (Lai et al., 2010; Yuan et al., 2011). To date 
engineered micro-dystrophins that have been used in experimental models 
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have deletions in a large portion of the rod domain but contain the minimal 
essential regions of the dystrophin molecule (Phelps et al., 1995; Cadenas et al., 
2002; Fabb et al., 2002; Watchko et al., 2002; Foster et al., 2007; Jorgensen et 
al., 2009; Wang et al., 2009a; Koo et al., 2011) to bypass the packaging 
limitations of AAV vectors (<5 kb) (Lai et al., 2010; Yuan et al., 2011) which has 
restricted the application of larger and possibly more favourable constructs that 
could carry additional regions of the dystrophin molecule.  
 
With advanced viral technology and increasing knowledge about the functional 
domains in dystrophin, researchers have realised that the concept of rod 
domain dispensability needs to be reconsidered due to data that have been 
published on spectrin-like repeats interacting with other cell components, 
including signalling molecules (Afanasiev et al., 2009; Lai et al., 2013), 
membrane lipids and other cytoskeletal elements (Sarkis et al., 2011). Mini-
dystrophins in this project have been designed to be packaged into lentiviral 
vectors. Lentiviral vectors carry a considerably larger DNA insert (~10 kb) (Xiao 
et al., 2000; Kumar et al., 2001) compared to AAV vectors and have been 
considered as the potential delivery system for this project to allow use of less 
highly truncated mini-dystrophins, given our eventual aim of correcting 
dystrophin deficiency in stem cells.  
 
Lentiviral vectors can efficiently infect dividing and non-dividing cells including 
satellite cells and stem cells (Kimura et al., 2010), can integrate into the host 
genome and provide long-term, heritable gene expression. Lentiviral vectors 
have been shown to transduce myogenic stem cells as well as myofibres in 
dystrophic muscle and successfully express micro-dystrophins. Expression was 
maintained  for at least  two years and supported by stable transduced satellite 
cells that were able to regenerate dystrophin expressing myofibres in vivo 
(Kimura et al., 2010). Drawbacks with lentiviral vectors include possible gene 
silencing or mutagenesis due to the site at which the virus inserts into the host 
genome (Ciuffi, 2008). However, the development of third generation 
lentiviruses and advances in vector design with physiological promoters and 
cell-specific envelope proteins (Follenzi and Naldini, 2002) and incorporation of 
non-viral regulatory elements are likely to address these shortcomings to a 
significant extent (Bonci et al., 2003).  
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The first clinical trial for gene replacement therapy using intramuscular 
injections of an AAV recombinant vector carrying a mini-dystrophin into the 
biceps of six DMD patients at the Nationwide Children's Hospital Ohio did not 
result in clinical benefits due to mini-dystrophin specific T-cell immune response 
(Mendell et al., 2010) which poses new challenges for dystrophin gene therapy. 
More importantly, none of the patients displayed significant levels of mini-
dystrophin expression (∆D3990; encoding the N- terminus, cysteine-rich domain, 
H1, H3, H4, 5 spectrin-like repeats including R1-R2 and R22-R24 (Mendell et 
al., 2010). This leads to the question whether the therapeutic transgene was 
capable of restoring dystrophin in patients and did not lack some functional 
parts of dystrophin. 
 
To answer this question, one could speculate that one of the reasons for 
insufficient dystrophin expression in this clinical trial might have been due to 
removal of the C-terminus of the mini-dystrophin, given that the truncated C-
terminus ∆D3990 (exon 70-79) has never been reported in a BMD patient 
(http://www.dmd.nl/). Truncated dystrophins with deletion of the C-terminus 
have been shown to be functional in animal models (Phelps et al., 1995; 
Gregorevic et al., 2006; Yue et al., 2006), but this does not necessarily mean 
that this part is dispensable for a functional protein in man. In addition, repeats 
20 and 21 were deleted in the mini-gene ∆D3990 and H3 directly joined to 
repeat 22, a composition that is not similar to natural structure of dystrophin 
molecule. Harper et al. studied the dystrophin structural domains and identified 
several factors important for function of the truncated dystrophin molecule 
including the phasing of the rod domain repeats. Organisation of the rod domain 
spectrin-like repeats plays a critical role in supporting dystrophin function and 
the repeats should be arranged in a way that do not differ from the natural 
dystrophin organisation (Harper et al., 2002). Mini-dystrophins that were 
generated in this study have addressed several limitations of the mini-gene 
∆D3990. In addition to an intact C-terminus, they all carry only one internal 
deletion and maintain consecutive repeats without disruption, and precisely 
follow the native composition as in full-length dystrophin. Studies on BMD 
patients have shown that deletions of different parts of the rod domain are 
associated with different levels of dystrophin expression. For instance, 
dystrophin expression levels in patients with a deletion of exon 51 endpoint are 
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higher than patients ending with exon 53 deletions (Anthony et al., 2011), 
suggesting that dystrophin expression depends on the extent and location of the 
deleted region and resulting disruption in the functional domains, such as 
spectrin-like repeats, could be important factors that have not been identified as 
yet (Wilton et al., 2014). Based on the data from the gene therapy clinical trial, 
these considerations might be critical for mini-dystrophin functionality. At least 
one construct (C7/∆H2-R23; ~4.3 kb) with a similar size to the mini-dystrophin 
that was used for the clinical trial (∆D3990) could be more advantageous, since 
it has only one internal deletion, phased repeats and additionally retains the 
entire C-terminal region which is preserved in most mildly affected BMD 
patients. Due to its smaller size compared to other mini-dystrophins, this 
construct could be considered as a potential candidate for AAV-mediated gene 
therapy. 
 
In addition to considerations for design and construction of optimised and 
functional dystrophin proteins, some of which have been addressed in this 
project, it is critical to provide data on the outcome measures for evaluation of 
therapeutic efficacy. There are several challenges for dystrophin quantification 
which are common to all genetic therapeutic strategies, including the low 
amount of dystrophin protein which accounts for only 0.002% of total muscle 
protein (Hoffman et al., 1987), its large size of 427 kDa (Watkins et al., 1988) 
and the presence of revertant fibres in DMD patients and the mdx mouse 
(Crawford et al., 2001; Pigozzo et al., 2013). In recent years several studies 
have been published reporting techniques for dystrophin quantification in 
treated DMD patients and the mdx mouse. Semi-quantitative methods to detect 
dystrophin include Western blot (Anderson and Davison, 1999) and 
immunohistochemistry (Arechavala-Gomeza et al., 2010a; Anthony et al., 2011; 
Taylor et al., 2012; Pertl et al., 2013), whereas alternative methods such as 
mass spectrometry (Brown et al., 2012), reverse protein arrays (Escher et al., 
2010) and ELISA (Ishikawa et al., 1996) allow absolute quantification of the 
protein.  
 
Most studies measure morphological changes in biopsies from patients or 
treated animals. For interpretation of morphological changes, it was crucial to 
include age-matched controls which allowed a reliable comparison of dystrophin 
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expressing fibres compared to untreated controls. Clearly, one of the main 
reasons for low levels of dystrophin expression in muscle was the local 
administration of the mini-dystrophins and therefore the limited distribution in 
dystrophic muscle. Because the number of dystrophin expressing fibres was not 
as high as hoped, the presence of revertant fibres was strictly defined in control 
muscles, in order to avoid any possibility that revertant fibres could lead to 
misinterpretation of the frequency of dystrophin positivity. Since dystrophin 
restoration is the end point for most therapeutic approaches (Arechavala-
Gomeza et al., 2010b; Lu et al., 2014), a pre-assessment of the frequency of 
revertant fibres prior to treatment is absolutely crucial. Since the onset of the 
dystrophic changes in mdx muscle starts at ~3 weeks age (Grounds et al., 
2008), it would probably be more favourable to start the treatment in younger 
mice to assess the pathological changes and the efficacy of treatment, before 
the onset of degenerative and regenerative cycles; however one should bear in 
mind that this does not reflect the human situation as treatment may not be 
feasible before the onset of degeneration. 
 
The pathological mechanism in dystrophin-deficient muscle is characterised by 
myofibres that have gone through rounds of degeneration and regeneration. 
Internally located nuclei and variability in muscle fibre size are two characteristic 
features diagnostic for this process (Willmann et al., 2012) and can provide 
evidence for disease progression or efficacy of therapeutic approaches if 
resulting in improvement of muscle pathology. In this study, despite the low 
level of dystrophin expression in treated animals, there was a significant 
reduction of internally located nuclei in treated muscles, more pronounced in 
dystrophin-positive, but also apparent in dystrophin-negative muscle fibres. 
However, this should be taken with caution since the low number of dystrophin 
positive fibres may not have been substantial enough for an unequivocal 
interpretation of these parameters. Nonetheless, dystrophin negative fibres in 
treated muscles showed reduction of internally located nuclei, perhaps a 
bystander effect from the positive effect of mini-dystrophins in injected muscles 
which may be due to general reduction in inflammation (Porter et al., 2002), 
slower cycles of necrosis and regeneration (Coulton et al., 1988) or the effect of 
dystrophin below the detection range in immunohistochemical analysis (Dunant 
et al., 2003). 
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Standard protocols and improvement of conventional detection methods are 
required for accurate evaluation of therapeutic interventions worldwide to avoid 
repeated efforts (Willmann et al., 2012). For instance, semi-quantitative 
expression intensity measurement has been developed in two different 
laboratories (Arechavala-Gomeza et al., 2010a; Taylor et al., 2012) and 
recognised as a standard protocol for assessment of muscle biopsies 
undergoing clinical trials (Kinali et al., 2009; Cirak et al., 2011; Finkel et al., 
2013). Expression intensity in combination with Western blot should be used for 
analysis of treated muscle to determine the correlation between the levels of 
expression intensities in both detection methods. However, dystrophin detection 
using Western blot would require a minimum expression of 10% in treated 
muscle (Lu et al., 2014). Drawbacks of this methods include requirement for a 
muscle biopsy from patient during treatment and ideally prior to treatment in 
order to compare the effectiveness of therapeutic interventions on a “per-
patient” level rather than cumulatively for the entire cohort (Lu et al., 2014). 
Repeated muscle biopsies are invasive for patients, especially because most 
patients are at young ages. For these reasons alternative quantification 
methods should be considered to reflect the therapeutic outcome including 
serum biomarkers which provide a useful tool for monitoring disease 
progression ('t Hoen et al., 2011; Martin et al., 2014). However the potential of 
such biomarkers as alternative markers for dystrophin or disease progression 
has not been validated yet. Furthermore, it is questionable whether these 
biomarkers can distinguish between endogenous and therapeutic dystrophin 
(Wilton et al., 2014).  
 
A major issue for all DMD gene therapy approaches is that the treatment 
efficacy depends on the degree of disease progression, fibrotic tissue 
replacement and the number of intact fibres (Chamberlain, 1997; Meregalli et al., 
2008). In a recent exon skipping study it was shown that the treatment 
significantly improved the phenotype in young dko mice and extended life span, 
however even a high level of dystrophin expression failed to prevent disease 
progression in older, more disease progressed mice (Wu et al., 2014), 
suggesting that a successful therapy requires regenerating, myogenic muscle 
mass not lost prior to treatment. Although regeneration in DMD patients and 
dystrophin-deficient animal models is supported by activation of satellite cells, 
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this self-repair capacity is limited resulting in loss of muscle strength over time 
(Collins et al., 2005; Sacco et al., 2008). Moreover, these regenerated muscle 
fibres are still dystrophin-deficient in DMD patients and therefore continue to 
degenerate (Luz et al., 2002). A possible treatment option is transplantation of 
stem cells to introduce the missing dystrophin gene to muscle fibres (Wang et 
al., 2009b). Transplants from a healthy donor to repair and regenerate muscle 
fibres would result in dystrophin protein production. However, the use of 
heterologous stem cells would need lifelong immunosuppression of the treated 
patient (Benchaouir et al., 2008; Chamberlain, 2013).  
 
A potential therapy is a combination of autologous stem cells and viral vectors 
to introduce the missing dystrophin gene and the lost muscle mass to muscle 
fibres (Wang et al., 2009b). This approach may have more efficacy for patients 
in later stages of the disease (Seto et al., 2014). Genetic correction of 
autologous stem cells has been successfully demonstrated as a therapeutic 
option in animal models (Davies and Grounds, 2007; Benchaouir et al., 2008; 
Wang et al., 2009a). This approach would need the choice of the best stem cell 
that has both myogenic potential and can give rise to the muscle fibres (Parker 
et al., 2009; Meng et al., 2014). Although satellite cells can functionally 
reconstitute the satellite cell pool, they have only a very local effect after direct 
intramuscular injection and lose their regenerative capacity following expansion 
in tissue culture, limiting their practicality (Montarras et al., 2005). Alternative 
stem cells include muscle-derived stem cells including CD133+ bone marrow 
and blood cells, vessel cells such as pericytes and their progeny 
mesoangioblasts (Skuk et al., 2014), and patient-derived iPSC (Dick et al., 
2013).  
 
Mini-dystrophins that were produced in this study have already been used in a 
combined gene- and cell therapy research within a collaborative project with 
encouraging results (Morgan and Muntoni, unpublished data). In this project, 
lentivirally-transduced stem cells (pericytes), carrying mini-dystrophins C1/∆R3-
13, C2/∆H2-R19 and C7/∆H2-R23 were injected into dystrophin-deficient mice. 
First, GFP tagged mini-dystrophins were transduced into DMD pericytes and 
dystrophin expressing cells were sorted and transplanted into dystrophin-
deficient mice. One month after transplantation human DMD pericytes 
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expressing spectrin and dystrophin fibres were formed. Cells were able to 
successfully differentiate and fuse with existing fibres. These encouraging 
results may help to pave the way for future preclinical studies using mini-
dystrophins. Challenges when using this method include a potential risk for an 
immune response against viral proteins expressed by the vectors required for 
genetic correction, activation of oncogenes and insertional mutagenesis and 
administration route to obtain dystrophin restoration in all muscles fibres 
including heart (Okada and Takeda, 2013). The latter is one of the major 
difficulties for any ex vivo treatment strategy. Accumulation of cells in non-
muscle tissues such as the lung which has been shown after treatment of 
dystrophic dog with mesoangioblasts could also be a serious issue (Sampaolesi 
et al., 2006).  
 
It is encouraging that studies in DMD gene therapy may also be useful in 
treatment of other diseases. A recent publication suggested that dystrophin may 
have anti-metastatic features in cancer and act as a tumour suppressor 
suggesting that molecular therapies that are in development for muscular 
dystrophies may also have relevance in the treatment of cancer (Wang et al., 
2014). 
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Future directions 
 
The long-term goal of this study is to contribute to the development of a clinical 
trial using autologous stem cells encoding a functional mini-dystrophin. 
Although expression of mini-dystrophins has shown improvements in 
histopathology of the mdx mouse, it is still unclear how they will affect disease 
pathology when administered systemically.  
 
Prospective studies will involve measurable outcomes from physiological 
studies, utilising lentiviral vectors and systemic delivery, which would be 
expected to result in higher and long-term transgene expression. Monitoring 
dystrophin expression over time may provide data on expression stability and 
additional histopathology-relevant parameters, including evaluation of 
macrophage infiltrations, fibrosis and necrotic area and would enable us to 
assess their long-term potential to improve muscle function and delay disease 
progression. The investigation could be extended to a combined gene- and cell 
therapy approach. 
 
Meanwhile, collaborative studies have harnessed the mini-dystrophins in 
combination with stem cell and lentiviral technology to transplant dystrophin 
expressing human cells in the mdx dystrophic mouse. It has been proposed to 
use mini-dystrophin expressing stem cells for treatment of a small hand muscle 
in a selected cohort of older DMD patients by local delivery to provide proof-of-
principle for safety and functionality. This will enable us to determine whether or 
not the mini-dystrophins could be used as potential candidates for human 
clinical trials (Professor Francesco Muntoni; personal communication).  
 
Future studies will particularly focus on studying the long-term expression of  
mini-dystrophins and the mechanism of nNOS relocalisation in dystrophic 
pathogenesis. In addition, it is important to focus on optimising a vector system 
that can package larger dystrophin transgenes rather than shortening the 
dystrophin molecule. Finally, in order to compare efficacy in these preclinical 
studies, it is essential to put efforts in implementation of standardised operating 
procedures for dystrophin quantification based on collaborations worldwide.  
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Sequences of the oligonucleotides used for cDNA synthesis and PCR  
The nomenclature refers to the cDNA sequence position of oligonucleotides; 
adapted from Rinninsland et al., 1992 
Appendix A   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fragment Primer name Primer sequence (5’-3’) Product size 
1.1 1 F ACTCAGA TCTGGGAGGC AATTA  nt. 64 -1032  969 bp 
  1.1 R TCTTTAGTCACTTTAGGTGGCC    
1.2 1.2 F GATGTTGATACCACCTATCCAG  nt. 893- 1445  bp 553   
  1.2 R GTAGAATATTACCAACCCGGCCC    
2.1 2 F TGTAAAACGACGGCCAGTATGGAT
TTGACAGCCC  
nt. 1393- 1952  bp 549   
  2.1 R GGCACTGTTCTTCAGTAAGACG    
2.2 2.2 F AGGTATTGGGAGATCGATGG  nt. 1845- 2347  bp 503 
  2.2 R CTCTTGAGCATGCTTTACCAG    
3.1 3 F CAGCCATCACTAACACAGAC  nt. 2261- 2886  bp 626 
  3.1 R GATAGCCGGTTGACTTCATC    
3.2 3.2 F TGAAAATCCAACCCACCACC nt. 2802- 3522  bp 721 
  3.2 R AGTCTGCACTGTTTCAGCTGC    
3.3 3.3 F TTTCTGAAGGAGGAATGGCC  nt. 3452- 4155  bp 704 
  3.3 R TCAGAGTTTCCTCAGCTCCG    
4.1 4 F GGAGAAAGCAAACAAGTGGC  nt. 4069- 5019  bp 951 
  4.1 R ATATCTGTAGCTGCCAGCC    
5.1 5 F GAAATTGTCCCGTAAGATGCG nt. 4954- 5319  bp 366 
  5.1 R GTGATGTGGTCCACATTCTGG   
5.2 5.2 F GGAATACCAGAAACACATGG nt. 5269- 5780  bp 512 
  5.2 R CCTCTCTCTTTCTCTCATCTG   
5.3 5.3 F GGGTGAATCTGAAAGAGGAAG nt. 5655- 6615  bp 961 
  5.3 R TCAGCTTCTGTTAGCCACTG   
6.1 6 F AAATGTACAAGGACCGACAAGG nt. 6513- 6778  bp 266 
  6.1 R GGCATCTGTTTTTGAGGATTGC   
6.2 6.2 F TCCTGAGAATTGGGAACATGCT nt. 6640- 7598  bp 959 
  6.2 R TAGTAACCACAGGTTGTGTCAC   
6.3 6.3 F GGACTGACCACTATTGGAG nt. 7532- 8380  bp 849 
  6.3 R GGCAGTTGTTTCAGCTTCTGTA   
7.1 7 F GGCTGCTTTGGAAGAAACTC nt. 8287- 9061  bp 834 
  7.1 R GATCCCTTGATCACCTCAGCTTGG   
7.2 7.2 F AATGTCACTCGGCTTCTACGAAA nt. 8939- 9821  bp 883 
  7.2 R TCCCTGTTCGTCCCGTATC   
8.1 8 F CAATTTGGTCAACGTCCCTC nt. 9742- 10636  bp 895 
  8.1 R GCTCTCATTAGGAGAGATGC   
8.2 8.2 F TTCTGGCCAGTAGATTCTGC nt. 10487- 11357  bp 871 
  8.2 R GATACTAAGGACTCCATCGC   
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Primers for mini-dystrophin constructs and vectors 
 
Appendix B  
 
 Primer 
name 
Sequence (5’-3’) Restriction  
site 
Application 
C1/C2-F1-
ClaI 
ATTGGGAGATCGATGGGCAAACATCTGTA ClaI Construct 
C1-R1 CATCATCGTTTCTTCACGGACAGTGTGAAT 
ATCCACAGTAATCTGCCTCTTCTTTTGGG 
- Construct 
C1-F2 CCCAAAAGAAGAGGCAGATTACTGTGGAT 
ATTCACACTGTCCGTGAAGAAACGATGATG 
- Construct 
C1/C2-R2-
NgoMIV 
GTGCCTGCCGGCTTAATTCATCATCTTT NgoMIV Construct 
C2-R1 CGGTTGTTTAGCTTGAACTGCTATTTCAGTTTC 
CTGTGCTGTACTCTTTTCAAGTTTTTGGACTAAATTAT 
- Construct 
C2-F2 ATAATTTAGTCCAAAAACTTGAAAAGAGTACAGC 
ACAGGAAACTGAAATAGCAGTTCAAGCTAAACAACG 
- Construct 
C7 Left-R TCCGTGGCCTCTTGAAGTTCCTGGAGTCTTTCAAGGGTC
TGTGCTGTACTCTTTTCAAGTTTTTGGACTAAATTAT 
- Construct 
C7 right-R ATAATTTAGTCCAAAAACTTGAAAAGAGTACAGCACAGAC
CCTTGAAAGACTCCAGGAACTTCAAGAGGCCACGGA 
- Construct 
C9-F1-KasI   GGATGGGAGGCGCCTCCTAGACCTCCTC KasI   Construct 
C9-R1   TTGTAGACGCTGCTCAAAATTGGCTGGCTCCATCAATGA
ACTGCCAAATGACTTGTCT  
- Construct 
C9-F2 AGACAAGTCATTTGGCAGTTCATTGATGGAGCCAGCCAA
TTTTGAGCAGCGTCTACAA 
- Construct 
C9-R2-ClaI   CTGCAAATCGATGGTTGAGCTCTGAGATTT ClaI Construct 
8.3F AGGACACAAGCACAGGGTTAGA - Dystrophin  
cDNA primer 
1.0R CTTAGAAAATTGTGCATTTACC - Dystrophin  
cDNA primer 
T7 TAATACGACTCACTATAGGG - Universal  
primer 
DysT1-4/2  
F-vec 
AGAGGCCAAA GTGAATGGCA CAAC - RSV-Vector 
DysT1-4/2  
R-vec 
GGTTCTCAAT ATGCTGCTTC CCAAA - RSV-Vector 
Dys-
Forward 3’ 
CCACCACACCAAATGACTACTACACA - RSV-Vector 
Dys-
Reverse 5’ 
ATACGCAGGAAAGAACATGTGAGCA - RSV-Vector 
3rd-Dys-
Forward 
CCACACAGGCATAGAGTGTCTGCTA - RSV-Vector 
3rd-Dys-
Rev 
GGCACCTATCTCAGCGATCTGTCTA - RSV-Vector 
4th-Dys-
Forward 
TATCCAAAACAGCCTTGTGGTCAGT - RSV-Vector 
4th-Dys-
Reverse 
GTGAGCAAAAACAGGAAGGCAAAAT - RSV-Vector 
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Antibodies used in this project 
 
Appendix C  
 
Antibody Name Description Application 
In this study 
Target Source Order information 
Anti-dystrophin Mandra1 Mouse monolonal WB, ICC AA 3558-3684 (C-terminus) abcam Ab7164 
Anti-dystrophin Ab15277 Rabbit polyclonal IHC Rod domain residues 1400 and 1505 abcam ab15277 
Anti-dystrophin NCL-DYS1 Mouse monolonal WB AA 1181-1388 (rod domain)     Leica biosysyems DYS1-CE-S 
Anti-dystrophin NCL-DYS2 Mouse monolonal IHC AA 3669- 3685 (C-terminus) Leica biosysyems DYS2-CE-S 
Anti-dystrophin NCL-DYS3 Mouse monolonal IHC AA 321-494 (N- terminus) Leica biosysyems DYS3-CE-S 
Anti-actin  Anti-Actin Rabbit polyclonal WB ---- Sigma-Aldrich A2066 
Anti-laminin Anti-Laminin Rat monoclonal WB ---- Sigma-Aldrich L0663 
Anti-desmin  Anti-Desmin Mouse monolonal ICC ---- Dako M0760 
Anti-nNOS  nNOS Rabbit Antibody Rabbit polyclonal IHC ---- Life technologies 617000 
Anti-gamma sarcoglycan  Anti-GSGC Rabbit polyclonal IHC ---- Proteintech Europe 18102-1-AP 
Anti-laminin  Anti-Laminin Rabbit polyclonal IHC ---- Sigma-Aldrich L9393 
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Appendix D  
The entire coding sequence from C2/∆H2-R19 as an example (5952 bp) 
 
1         ATGCTTTGGTGGGAAGAAGTAGAGGACTGTTATGAAAGAGAAGATGTTCAAAAGAAAACA 
1          M  L  W  W  E  E  V  E  D  C  Y  E  R  E  D  V  Q  K  K  T   
 
61        TTCACAAAATGGGTAAATGCACAATTTTCTAAGTTTGGGAAGCAGCATATTGAGAACCTC 
21         F  T  K  W  V  N  A  Q  F  S  K  F  G  K  Q  H  I  E  N  L   
 
121       TTCAGTGACCTACAGGATGGGAGGCGCCTCCTAGACCTCCTCGAAGGCCTGACAGGGCAA 
41         F  S  D  L  Q  D  G  R  R  L  L  D  L  L  E  G  L  T  G  Q   
 
181       AAACTGCCAAAAGAAAAAGGATCCACAAGAGTTCATGCCCTGAACAATGTCAACAAGGCA 
61         K  L  P  K  E  K  G  S  T  R  V  H  A  L  N  N  V  N  K  A   
 
241       CTGCGGGTTTTGCAGAACAATAATGTTGATTTAGTGAATATTGGAAGTACTGACATCGTA 
81         L  R  V  L  Q  N  N  N  V  D  L  V  N  I  G  S  T  D  I  V   
 
301       GATGGAAATCATAAACTGACTCTTGGTTTGATTTGGAATATAATCCTCCACTGGCAGGTC 
101        D  G  N  H  K  L  T  L  G  L  I  W  N  I  I  L  H  W  Q  V   
 
361       AAAAATGTAATGAAAAATATCATGGCTGGATTGCAACAAACCAACAGTGAAAAGATTCTC 
121        K  N  V  M  K  N  I  M  A  G  L  Q  Q  T  N  S  E  K  I  L   
 
421       CTGAGCTGGGTCCGACAATCAACTCGTAATTATCCACAGGTTAATGTAATCAACTTCACC 
141        L  S  W  V  R  Q  S  T  R  N  Y  P  Q  V  N  V  I  N  F  T   
 
481       ACCAGCTGGTCTGATGGCCTGGCTTTGAATGCTCTCATCCATAGTCATAGGCCAGACCTA 
161        T  S  W  S  D  G  L  A  L  N  A  L  I  H  S  H  R  P  D  L   
 
541       TTTGACTGGAATAGTGTGGTTTGCCAGCAGTCAGCCACACAACGACTGGAACATGCATTC 
181        F  D  W  N  S  V  V  C  Q  Q  S  A  T  Q  R  L  E  H  A  F   
 
601       AACATCGCCAGATATCAATTAGGCATAGAGAAACTACTCGATCCTGAAGATGTTGATACC 
201        N  I  A  R  Y  Q  L  G  I  E  K  L  L  D  P  E  D  V  D  T   
 
661       ACCTATCCAGATAAGAAGTCCATCTTAATGTACATCACATCACTCTTCCAAGTTTTGCCT 
221        T  Y  P  D  K  K  S  I  L  M  Y  I  T  S  L  F  Q  V  L  P   
 
721       CAACAAGTGAGCATTGAAGCCATCCAGGAAGTGGAAATGTTGCCAAGGCCACCTAAAGTG 
241        Q  Q  V  S  I  E  A  I  Q  E  V  E  M  L  P  R  P  P  K  V   
 
781       ACTAAAGAAGAACATTTTCAGTTACATCATCAAATGCACTATTCTCAACAGATCACGGTC 
261        T  K  E  E  H  F  Q  L  H  H  Q  M  H  Y  S  Q  Q  I  T  V   
 
841       AGTCTAGCACAGGGATATGAGAGAACTTCTTCCCCTAAGCCTCGATTCAAGAGCTATGCC 
281        S  L  A  Q  G  Y  E  R  T  S  S  P  K  P  R  F  K  S  Y  A   
 
901       TACACACAGGCTGCTTATGTCACCACCTCTGACCCTACACGGAGCCCATTTCCTTCACAG 
301        Y  T  Q  A  A  Y  V  T  T  S  D  P  T  R  S  P  F  P  S  Q   
 
961       CATTTGGAAGCTCCTGAAGACAAGTCATTTGGCAGTTCATTGATGGAGAGTGAAGTAAAC 
321        H  L  E  A  P  E  D  K  S  F  G  S  S  L  M  E  S  E  V  N   
 
1021      CTGGACCGTTATCAAACAGCTTTAGAAGAAGTATTATCGTGGCTTCTTTCTGCTGAGGAC 
341        L  D  R  Y  Q  T  A  L  E  E  V  L  S  W  L  L  S  A  E  D   
 
1081      ACATTGCAAGCACAAGGAGAGATTTCTAATGATGTGGAAGTGGTGAAAGACCAGTTTCAT 
361        T  L  Q  A  Q  G  E  I  S  N  D  V  E  V  V  K  D  Q  F  H   
 
1141      ACTCATGAGGGGTACATGATGGATTTGACAGCCCATCAGGGCCGGGTTGGTAATATTCTA 
381        T  H  E  G  Y  M  M  D  L  T  A  H  Q  G  R  V  G  N  I  L   
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1201      CAATTGGGAAGTAAGCTGATTGGAACAGGAAAATTATCAGAAGATGAAGAAACTGAAGTA 
401        Q  L  G  S  K  L  I  G  T  G  K  L  S  E  D  E  E  T  E  V   
 
1261      CAAGAGCAGATGAATCTCCTAAATTCAAGATGGGAATGCCTCAGGGTAGCTAGCATGGAA 
421        Q  E  Q  M  N  L  L  N  S  R  W  E  C  L  R  V  A  S  M  E   
 
1321      AAACAAAGCAATTTACATAGAGTTTTAATGGATCTCCAGAATCAGAAACTGAAAGAGTTG 
441        K  Q  S  N  L  H  R  V  L  M  D  L  Q  N  Q  K  L  K  E  L   
 
1381      AATGACTGGCTAACAAAAACAGAAGAAAGAACAAGGAAAATGGAGGAAGAGCCTCTTGGA 
461        N  D  W  L  T  K  T  E  E  R  T  R  K  M  E  E  E  P  L  G   
 
1441      CCTGATCTTGAAGACCTAAAACGCCAAGTACAACAACATAAGGTGCTTCAAGAAGATCTA 
481        P  D  L  E  D  L  K  R  Q  V  Q  Q  H  K  V  L  Q  E  D  L   
 
1501      GAACAAGAACAAGTCAGGGTCAATTCTCTCACTCACATGGTGGTGGTAGTTGATGAATCT 
501        E  Q  E  Q  V  R  V  N  S  L  T  H  M  V  V  V  V  D  E  S   
 
1561      AGTGGAGATCACGCAACTGCTGCTTTGGAAGAACAACTTAAGGTATTGGGAGATCGATGG 
521        S  G  D  H  A  T  A  A  L  E  E  Q  L  K  V  L  G  D  R  W   
 
1621      GCAAACATCTGTAGATGGACAGAAGACCGCTGGGTTCTTTTACAAGACATCCTTCTCAAA 
541        A  N  I  C  R  W  T  E  D  R  W  V  L  L  Q  D  I  L  L  K   
 
1681      TGGCAACGTCTTACTGAAGAACAGTGCCTTTTTAGTGCATGGCTTTCAGAAAAAGAAGAT 
561        W  Q  R  L  T  E  E  Q  C  L  F  S  A  W  L  S  E  K  E  D   
 
1741      GCAGTGAACAAGATTCACACAACTGGCTTTAAAGATCAAAATGAAATGTTATCAAGTCTT 
581        A  V  N  K  I  H  T  T  G  F  K  D  Q  N  E  M  L  S  S  L   
 
1801      CAAAAACTGGCCGTTTTAAAAGCGGATCTAGAAAAGAAAAAGCAATCCATGGGCAAACTG 
601        Q  K  L  A  V  L  K  A  D  L  E  K  K  K  Q  S  M  G  K  L   
 
1861      TATTCACTCAAACAAGATCTTCTTTCAACACTGAAGAATAAGTCAGTGACCCAGAAGACG 
621        Y  S  L  K  Q  D  L  L  S  T  L  K  N  K  S  V  T  Q  K  T   
 
1921      GAAGCATGGCTGGATAACTTTGCCCGGTGTTGGGATAATTTAGTCCAAAAACTTGAAAAG 
641        E  A  W  L  D  N  F  A  R  C  W  D  N  L  V  Q  K  L  E  K   
                  (Deletion) 
1981      AGTACAGCACAGGAAACTGAAATAGCAGTTCAAGCTAAACAACCGGATGTGGAAGAGATT 
661        S  T  A  Q  E  T  E  I  A  V  Q  A  K  Q  P  D  V  E  E  I   
                  Left Right 
2041      TTGTCTAAAGGGCAGCATTTGTACAAGGAAAAACCAGCCACTCAGCCAGTGAAGAGGAAG 
681        L  S  K  G  Q  H  L  Y  K  E  K  P  A  T  Q  P  V  K  R  K   
 
2101      TTAGAAGATCTGAGCTCTGAGTGGAAGGCGGTAAACCGTTTACTTCAAGAGCTGAGGGCA 
701        L  E  D  L  S  S  E  W  K  A  V  N  R  L  L  Q  E  L  R  A   
 
2161      AAGCAGCCTGACCTAGCTCCTGGACTGACCACTATTGGAGCCTCTCCTACTCAGACTGTT 
721        K  Q  P  D  L  A  P  G  L  T  T  I  G  A  S  P  T  Q  T  V   
 
2221      ACTCTGGTGACACAACCTGTGGTTACTAAGGAAACTGCCATCTCCAAACTAGAAATGCCA 
741        T  L  V  T  Q  P  V  V  T  K  E  T  A  I  S  K  L  E  M  P   
 
2281      TCTTCCTTGATGTTGGAGGTACCTGCTCTGGCAGATTTCAACCGGGCTTGGACAGAACTT 
761        S  S  L  M  L  E  V  P  A  L  A  D  F  N  R  A  W  T  E  L   
 
2341      ACCGACTGGCTTTCTCTGCTTGATCAAGTTATAAAATCACAGAGGGTGATGGTGGGTGAC 
781        T  D  W  L  S  L  L  D  Q  V  I  K  S  Q  R  V  M  V  G  D   
 
2401      CTTGAGGATATCAACGAGATGATCATCAAGCAGAAGGCAACAATGCAGGATTTGGAACAG 
801        L  E  D  I  N  E  M  I  I  K  Q  K  A  T  M  Q  D  L  E  Q   
 
151 
2461      AGGCGTCCCCAGTTGGAAGAACTCATTACCGCTGCCCAAAATTTGAAAAACAAGACCAGC 
821        R  R  P  Q  L  E  E  L  I  T  A  A  Q  N  L  K  N  K  T  S   
 
2521      AATCAAGAGGCTAGAACAATCATTACGGATCGAATTGAAAGAATTCAGAATCAGTGGGAT 
841        N  Q  E  A  R  T  I  I  T  D  R  I  E  R  I  Q  N  Q  W  D   
 
2581      GAAGTACAAGAACACCTTCAGAACCGGAGGCAACAGTTGAATGAAATGTTAAAGGATTCA 
861        E  V  Q  E  H  L  Q  N  R  R  Q  Q  L  N  E  M  L  K  D  S   
 
2641      ACACAATGGCTGGAAGCTAAGGAAGAAGCTGAGCAGGTCTTAGGACAGGCCAGAGCCAAG 
881        T  Q  W  L  E  A  K  E  E  A  E  Q  V  L  G  Q  A  R  A  K   
 
2701      CTTGAGTCATGGAAGGAGGGTCCCTATACAGTAGATGCAATCCAAAAGAAAATCACAGAA 
901        L  E  S  W  K  E  G  P  Y  T  V  D  A  I  Q  K  K  I  T  E   
 
2761      ACCAAGCAGTTGGCCAAAGACCTCCGCCAGTGGCAGACAAATGTAGATGTGGCAAATGAC 
921        T  K  Q  L  A  K  D  L  R  Q  W  Q  T  N  V  D  V  A  N  D   
 
2821      TTGGCCCTGAAACTTCTCCGGGATTATTCTGCAGATGATACCAGAAAAGTCCACATGATA 
941        L  A  L  K  L  L  R  D  Y  S  A  D  D  T  R  K  V  H  M  I   
 
2881      ACAGAGAATATCAATGCCTCTTGGAGAAGCATTCATAAAAGGGTGAGTGAGCGAGAGGCT 
961        T  E  N  I  N  A  S  W  R  S  I  H  K  R  V  S  E  R  E  A   
 
2941      GCTTTGGAAGAAACTCATAGATTACTGCAACAGTTCCCCCTGGACCTGGAAAAGTTTCTT 
981        A  L  E  E  T  H  R  L  L  Q  Q  F  P  L  D  L  E  K  F  L   
 
3001      GCCTGGCTTACAGAAGCTGAAACAACTGCCAATGTCCTACAGGATGCTACCCGTAAGGAA 
1001       A  W  L  T  E  A  E  T  T  A  N  V  L  Q  D  A  T  R  K  E   
 
3061      AGGCTCCTAGAAGACTCCAAGGGAGTAAAAGAGCTGATGAAACAATGGCAAGACCTCCAA 
1021       R  L  L  E  D  S  K  G  V  K  E  L  M  K  Q  W  Q  D  L  Q   
 
3121      GGTGAAATTGAAGCTCACACAGATGTTTATCACAACCTGGATGAAAACAGCCAAAAAATC 
1041       G  E  I  E  A  H  T  D  V  Y  H  N  L  D  E  N  S  Q  K  I   
 
3181      CTGAGATCCCTGGAAGGTTCCGATGATGCAGTCCTGTTACAAAGACGTTTGGATAACATG 
1061       L  R  S  L  E  G  S  D  D  A  V  L  L  Q  R  R  L  D  N  M   
 
3241      AACTTCAAGTGGAGTGAACTTCGGAAAAAGTCTCTCAACATTAGGTCCCGTTTGGAAGCC 
1081       N  F  K  W  S  E  L  R  K  K  S  L  N  I  R  S  R  L  E  A   
 
3301      AGTTCTGACCAGTGGAAGCGTCTGCACCTTTCTCTGCAGGAACTTCTGGTGTGGCTACAG 
1101       S  S  D  Q  W  K  R  L  H  L  S  L  Q  E  L  L  V  W  L  Q   
 
3361      CTGAAAGAGGATGAATTAAGCCGGCAGGCACCTATTGGAGGCGACTTTCCAGCAGTTCAG 
1121       L  K  E  D  E  L  S  R  Q  A  P  I  G  G  D  F  P  A  V  Q   
 
3421      AAGCAGAACGATGTACATAGGGCCTTCAAGAGGGAATTGAAAACTAAAGAACCTGTAATC 
1141       K  Q  N  D  V  H  R  A  F  K  R  E  L  K  T  K  E  P  V  I   
 
3481      ATGAGTACTCTTGAGACTGTACGAATATTTCTGACAGAGCAGCCTTTGGAAGGACTAGAG 
1161       M  S  T  L  E  T  V  R  I  F  L  T  E  Q  P  L  E  G  L  E   
 
3541      AAACTCTACCAGGAGCCCAGAGAGCTGCCTCCTGAGGAGAGAGCCCAGAATGTCACTCGG 
1181       K  L  Y  Q  E  P  R  E  L  P  P  E  E  R  A  Q  N  V  T  R   
 
3601      CTTCTACGAAAGCAGGCTGAGGAGGTCAATACTGAGTGGGAAAAATTGAACCTGCACTCC 
1201       L  L  R  K  Q  A  E  E  V  N  T  E  W  E  K  L  N  L  H  S   
 
3661      GCTGACTGGCAGAGAAAAATAGATGAGACCCTTGAAAGACTCCAGGAACTTCAAGAGGCC 
1221       A  D  W  Q  R  K  I  D  E  T  L  E  R  L  Q  E  L  Q  E  A   
 
3721      ACGGATGAGCTGGACCTCAAGCTGCGCCAAGCTGAGGTGATCAAGGGATCCTGGCAGCCC 
152 
1241       T  D  E  L  D  L  K  L  R  Q  A  E  V  I  K  G  S  W  Q  P   
 
3781      GTGGGCGATCTCCTCATTGACTCTCTCCAAGATCACCTCGAGAAAGTCAAGGCACTTCGA 
1261       V  G  D  L  L  I  D  S  L  Q  D  H  L  E  K  V  K  A  L  R   
 
3841      GGAGAAATTGCGCCTCTGAAAGAGAACGTGAGCCACGTCAATGACCTTGCTCGCCAGCTT 
1281       G  E  I  A  P  L  K  E  N  V  S  H  V  N  D  L  A  R  Q  L   
 
3901      ACCACTTTGGGCATTCAGCTCTCACCGTATAACCTCAGCACTCTGGAAGACCTGAACACC 
1301       T  T  L  G  I  Q  L  S  P  Y  N  L  S  T  L  E  D  L  N  T   
 
3961      AGATGGAAGCTTCTGCAGGTGGCCGTCGAGGACCGAGTCAGGCAGCTGCATGAAGCCCAC 
1321       R  W  K  L  L  Q  V  A  V  E  D  R  V  R  Q  L  H  E  A  H   
 
4021      AGGGACTTTGGTCCAGCATCTCAGCACTTTCTTTCCACGTCTGTCCAGGGTCCCTGGGAG 
1341       R  D  F  G  P  A  S  Q  H  F  L  S  T  S  V  Q  G  P  W  E   
 
4081      AGAGCCATCTCGCCAAACAAAGTGCCCTACTATATCAACCACGAGACTCAAACAACTTGC 
1361       R  A  I  S  P  N  K  V  P  Y  Y  I  N  H  E  T  Q  T  T  C   
 
4141      TGGGACCATCCCAAAATGACAGAGCTCTACCAGTCTTTAGCTGACCTGAATAATGTCAGA 
1381       W  D  H  P  K  M  T  E  L  Y  Q  S  L  A  D  L  N  N  V  R   
 
4201      TTCTCAGCTTATAGGACTGCCATGAAACTCCGAAGACTGCAGAAGGCCCTTTGCTTGGAT 
1401       F  S  A  Y  R  T  A  M  K  L  R  R  L  Q  K  A  L  C  L  D   
 
4261      CTCTTGAGCCTGTCAGCTGCATGTGATGCCTTGGACCAGCACAACCTCAAGCAAAATGAC 
1421       L  L  S  L  S  A  A  C  D  A  L  D  Q  H  N  L  K  Q  N  D   
 
4321      CAGCCCATGGATATCCTGCAGATTATTAATTGTTTGACCACTATTTATGACCGCCTGGAG 
1441       Q  P  M  D  I  L  Q  I  I  N  C  L  T  T  I  Y  D  R  L  E   
 
4381      CAAGAGCACAACAATTTGGTCAACGTCCCTCTCTGCGTGGATATGTGTCTGAACTGGCTG 
1461       Q  E  H  N  N  L  V  N  V  P  L  C  V  D  M  C  L  N  W  L   
 
4441      CTGAATGTTTATGATACGGGACGAACAGGGAGGATCCGTGTCCTGTCTTTTAAAACTGGC 
1481       L  N  V  Y  D  T  G  R  T  G  R  I  R  V  L  S  F  K  T  G   
 
4501      ATCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATACCTTTTCAAGCAAGTG 
1501       I  I  S  L  C  K  A  H  L  E  D  K  Y  R  Y  L  F  K  Q  V   
 
4561      GCAAGTTCAACAGGATTTTGTGACCAGCGCAGGCTGGGCCTCCTTCTGCATGATTCTATC 
1521       A  S  S  T  G  F  C  D  Q  R  R  L  G  L  L  L  H  D  S  I   
 
4621      CAAATTCCAAGACAGTTGGGTGAAGTTGCATCCTTTGGGGGCAGTAACATTGAGCCAAGT 
1541       Q  I  P  R  Q  L  G  E  V  A  S  F  G  G  S  N  I  E  P  S   
 
4681      GTCCGGAGCTGCTTCCAATTTGCTAATAATAAGCCAGAGATCGAAGCGGCCCTCTTCCTA 
1561       V  R  S  C  F  Q  F  A  N  N  K  P  E  I  E  A  A  L  F  L   
 
4741      GACTGGATGAGACTGGAACCCCAGTCCATGGTGTGGCTGCCCGTCCTGCACAGAGTGGCT 
1581       D  W  M  R  L  E  P  Q  S  M  V  W  L  P  V  L  H  R  V  A   
 
4801      GCTGCAGAAACTGCCAAGCATCAGGCCAAATGTAACATCTGCAAAGAGTGTCCAATCATT 
1601       A  A  E  T  A  K  H  Q  A  K  C  N  I  C  K  E  C  P  I  I   
 
4861      GGATTCAGGTACAGGAGTCTAAAGCACTTTAATTATGACATCTGCCAAAGCTGCTTTTTT 
1621       G  F  R  Y  R  S  L  K  H  F  N  Y  D  I  C  Q  S  C  F  F   
 
4921      TCTGGTCGAGTTGCAAAAGGCCATAAAATGCACTATCCCATGGTGGAATATTGCACTCCG 
1641       S  G  R  V  A  K  G  H  K  M  H  Y  P  M  V  E  Y  C  T  P   
 
4981      ACTACATCAGGAGAAGATGTTCGAGACTTTGCCAAGGTACTAAAAAACAAATTTCGAACC 
 
153 
1661       T  T  S  G  E  D  V  R  D  F  A  K  V  L  K  N  K  F  R  T   
 
5041      AAAAGGTATTTTGCGAAGCATCCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAG 
1681       K  R  Y  F  A  K  H  P  R  M  G  Y  L  P  V  Q  T  V  L  E   
 
5101      GGGGACAACATGGAAACTCCCGTTACTCTGATCAACTTCTGGCCAGTAGATTCTGCGCCT 
1701       G  D  N  M  E  T  P  V  T  L  I  N  F  W  P  V  D  S  A  P   
 
5161      GCCTCGTCCCCTCAGCTTTCACACGATGATACTCATTCACGCATTGAACATTATGCTAGC 
1721       A  S  S  P  Q  L  S  H  D  D  T  H  S  R  I  E  H  Y  A  S   
 
5221      AGGCTAGCAGAAATGGAAAACAGCAATGGATCTTATCTAAATGATAGCATCTCTCCTAAT 
1741       R  L  A  E  M  E  N  S  N  G  S  Y  L  N  D  S  I  S  P  N   
 
5281      GAGAGCATAGATGATGAACATTTGTTAATCCAGCATTACTGCCAAAGTTTGAACCAGGAC 
1761       E  S  I  D  D  E  H  L  L  I  Q  H  Y  C  Q  S  L  N  Q  D   
 
5341      TCCCCCCTGAGCCAGCCTCGTAGTCCTGCCCAGATCTTGATTTCCTTAGAGAGTGAGGAA 
1781       S  P  L  S  Q  P  R  S  P  A  Q  I  L  I  S  L  E  S  E  E   
 
5401      AGAGGGGAGCTAGAGAGAATCCTAGCAGATCTTGAGGAAGAAAACAGGAATCTGCAAGCA 
1801       R  G  E  L  E  R  I  L  A  D  L  E  E  E  N  R  N  L  Q  A   
 
5461      GAATATGACCGTCTAAAGCAGCAGCACGAACATAAAGGCCTGTCCCCACTGCCGTCCCCT 
1821       E  Y  D  R  L  K  Q  Q  H  E  H  K  G  L  S  P  L  P  S  P   
 
5521      CCTGAAATGATGCCCACCTCTCCCCAGAGTCCCCGGGATGCTGAGCTCATTGCTGAGGCC 
1841       P  E  M  M  P  T  S  P  Q  S  P  R  D  A  E  L  I  A  E  A   
 
5581      AAGCTACTGCGTCAACACAAAGGCCGCCTGGAAGCCAGGATGCAAATCCTGGAAGACCAC 
1861       K  L  L  R  Q  H  K  G  R  L  E  A  R  M  Q  I  L  E  D  H   
 
5641      AATAAACAGCTGGAGTCACAGTTACACAGGCTAAGGCAGCTGCTGGAGCAACCCCAGGCA 
1881       N  K  Q  L  E  S  Q  L  H  R  L  R  Q  L  L  E  Q  P  Q  A   
 
5701      GAGGCCAAAGTGAATGGCACAACGGTGTCCTCTCCTTCTACCTCTCTACAGAGGTCCGAC 
1901       E  A  K  V  N  G  T  T  V  S  S  P  S  T  S  L  Q  R  S  D   
 
5761      AGCAGTCAGCCTATGCTGCTCCGAGTGGTTGGCAGTCAAACTTCGGACTCCATGGGTGAG 
1921       S  S  Q  P  M  L  L  R  V  V  G  S  Q  T  S  D  S  M  G  E   
 
5821      GAAGATCTTCTCAGTCCTCCCCAGGACACAAGCACAGGGTTAGAGGAGGTGATGGAGCAA 
1941       E  D  L  L  S  P  P  Q  D  T  S  T  G  L  E  E  V  M  E  Q   
 
5881      CTCAACAACTCCTTCCCTAGTTCAAGAGGAAGAAATACCCCTGGAAAGCCAATGAGAGAG 
1961       L  N  N  S  F  P  S  S  R  G  R  N  T  P  G  K  P  M  R  E   
 
5941      GACACAATGTAG 
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